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Abstract 
The process of soft tissue injury repair at the cellular lew I can be decomposed into three 
phases: acute inflammation including coagulation, proliferation and remodelling. While tht> 
later phases are well undl'rstood the early phase is less so. We produce a series of new math-
ematical models for the early phases coagulation and inflammation. The modt'ls product'd 
are relevant not only to soft tissue injury rt'pair but also to the many disease states in which 
coagulation and inflammation playa role. 
The coagulation cascade and the subst>quent formation of the enzyme thrombin are central to 
the creation of blood clots. By focusing on a subset of reactions that occur within the coagu-
lation cascade, we develop a modt'l that exhibits a rich asymptotic structure. Using singular-
perturbation theory we produce a sequence of simpler time-dependent mod(,\s which enable us 
to elucidate the physical mechanisms that underlie the cascade and the formation of thrombin. 
Tht're is considerable interest in identifying new therapt'utic targets within tht> coagulation cas-
cade, as currt'nt drugs for treating pathological coagulation (thrombosis) targd multiple factors 
and cause the unwelcome side effect of exct'ssive bleeding. Factor XI is thought to be a poten-
tial therapeutic target, as it is implicated in pathological coagulation but not in haemostasis (the 
stopping of blt'eding), but its mt'chanism of activation is controv{>rsial. By extending our previ-
ous model of the coagulation cascade to include the whole cascade (albeit in a simplistic way) 
we use numerical methods to simulate experimental data of the coagulation cascade under nor-
mal as welI as specific-factor-deficient conditions. We then provide simulations supporting the 
hypothesis that thrombin activates factor XI. 
The interest in inflammation is now increasing due to it being implicated in such diverse condi-
tions as Alzmeimer's disease, cancer and heart disease. Inflammation can either resolve or set-
tle into a self-perpetuating condition which in the context of soft tissue repair is termed chronic 
inflammation. Inflammation has traditionally been thought gradualIy to subside but new bi-
ological interest centres on the anti-inflammatory processes (rt'lating to macrophages) that are 
thought to promote resolution and the pro-inflammatory role that neutrophils can provide by 
causing damage to healthy tissue. We develop a new ordinary differential equation model of 
the inflammatory process that accounts for populations of neutrophils and macrophages. We 
use numerical techniques and bifurcation theory to characterise and elucidate the physiological 
mechanisms that are dominant during the inflammatory phase and the roles they play in the 
healing process. There is therapeutic interest in modifying the rate of neutrophil apoptosis but 
we find that increased apoptosis is dependent on macrophage removal to be anti-inflammatory. 
We develop a simplified version of the model of inflammation reducing a system of nine or-
dinary equations to six while retaining the physical processes of neutrophil apoptosis and 
macrophage driven anti-inflammatory mechanisms. The simplified model reproduces the key 
outcomes that we relate to resolution or chronic inflammation. We then present preliminary 
work on the inclusion of the spatial effects of chemotaxis and diffusion. 
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CHAPTER 1 
Introduction 
The overall sequence of events that soft tissue is believed to follow after various typt·s of in-
jury is remarkably preserved. Thus a burn, wound, sprain or even a heart attack eli('it the 
same interrelated phases of events (Gurtnl'T I'f al., 20(8). This thesis is in part sponsored by the 
Health and Safety Laboratory who are intt'restt'd in soft tissue injury f(:'pair in relationship to 
work-related musculoskeletal disorders (WRMSDs). Musculoskelt>tal disordt'rs encompass a 
wide range of conditions from acute onset with short duration to Iifl'long disorders including 
such clinical conditions as osteoarthritis, sciatica and epicondylitis, as Wl'll as less specific con-
ditions such as low back pain (Punnett & Wegman, 2(04). They affect many areas of soft tissue 
including muscles, tendons, ligaments and cartilage. 
WRMSDs are caused mainly by factors associated with the work place such as working too 
long without breaks, awkward working positions and manual handling and are usually dUl' to 
the nature of a person's work rather than as a result of some hazard (Pheasant & Haslegrave, 
1996). The disorders are often multi-factorial, so that thPre is not a one-to-one correspondl·nce 
between specific ergonomic exposures and particular MSDs (Forde t.'t al., 2(02) such as tht're is 
in occupational disorders (e.g. farmer's lung caused by inhalation of spores from mouldy hay). 
They can have contributory factors such as pre-existing medical conditions and events such as 
activities outside of the work place, such as sport. They are "work related", not occupational, 
i.e. they do not have a single identifiable cause. The factors that give rise to WRMSDs can be 
found in virtually every workplace and it is estimated that 12.3 million days a year are lost 
in the UK through WRMSDs (H.S.E., 2003). They are the most common work related ailment 
affecting the general popUlation in Great Britain and they account for more than half of all self 
reported occupational ill health (H.S.E., 2002). 
1.1 Soft tissue healing 
In simplistic terms the response of soft tissue to injury has to resolve three problems: dam-
aged vessels, destroyed tissue and bacterial infection. This is achieved through a series of 
overlapping events, shown in Figure 1.1, that serve to repair any vascular leakages, remove 
any bacteria and cellular damage and reconstitute damaged tissue. The fastest acting of these 
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Figure 1.1: Illustrative time-course of regeneration of injured tissue including the major events 
of haemostasis (coagulation), inflammation, proliferation and remodelling, showing their rela-
tionships to the cell types typical of each major event. Haemostasis (coagulation) is the fastest 
acting event, plugging any local vascular leakages and providing a structure for cellular infil-
tration. Inflammation is where bacteria and damaged tissue are removed . It is characterised by 
the infiltration of white blood cells (neutrophils and macrophages). Neutrophils arrive first, be-
ing smaller and faster acting, and they are followed by the larger macrophages, which help set 
in motion the subsequent healing phases of proliferation and remodelling in which damaged 
tissue is replaced. The dominant cells of these later phases are fibroblasts, which produce the 
collagen required to replace damaged tissue. 
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events is coagulation (the formation of fibrin blood clots) which plugs local vascular leakages, 
acts to wall-off the surrounding areas in an attempt to prevent further damage, holds damaged 
tissue together and provides a provisional matrix for the recruitment of cells into the injured 
area (Guyton, 1992). The acute inflammatory phase serves to rid the organism of bacteria and 
cellular damage, it is closely intertwined and stimulates the reparative phases that it stimulates. 
Inflammation is characterised by an influx of white blood cells that attempt to kill any bacteria 
and remove any damaged tissue and cells by the process of phagocytosis. Chemicals that trig-
ger the subsequent healing phases are then released. These reparative processes reconstitute 
the site of damage, either by resolution (where damaged cells are replaced by cells of a simi-
lar type) or by fibrosis (where the damaged area is replaced by newly-synthesised connective 
tissue). Usually repair involves a combination of the two. 
1.2 Thesis structure 
As soft tissue repair is so complex we have confined our modelling to the two early phases 
of coagulation and inflammation. Their resolution is critical if the healing phases are to be 
initiated. Coagulation and inflammation are both highly complex systems. There is a wide and 
detailed knowledge of coagulation, probably as a consequence of blood being such a readily 
available tissue for experimentation and because the diseases associated with deficiencies in 
its constituents are easily recognisable (Mann, 2003). Data about the inflammatory phase are 
difficult to obtain, in part due to the short duration of the phase, the difficulty of removing tissue 
from individuals and the lack of presentation in a clinical setting (patients tend to wait for an 
injury to tum chronic). These features contribute to a lack of data and detailed understanding 
of the biology in this area, presenting us with different challenges in terms of modelling. 
The thesis splits into two parts: part I, which comprises chapters 2, 3 and 4, relates to coagu-
lation while part II comprises chapters 5, 6, and 7 and relates to inflammation. Chapter eight 
provides a summary of our major acheivements, a discussion of the insights they provide and 
an outline for future work in this area. 
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Part I 
Coagulation 
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Figure 2.1: M.e. Escher, Metamorphosis. The formation of blood clots (coagulation) 
occurs over multiple timescales; we can use mathematics to generate a series of simplified 
models representing the reactions occurring at each timescale. Rather like the picture we move 
from one scale to the next. All M.e. Escher works (c) 2010 The M.e. Escher Company - the 
Netherlands. All rights reserved. Used by permission. www.mcescher.com 
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CHAPTER 2 
Coagulation Background 
This chapter is divided into two main parts. We first present a description of the biological 
principles of coagulation and follow this, in Section 2.2, with a review of the current mathemat-
icalliterature relevant to the coagulation cascade and the formation of blood clots. We refer the 
reader to Colman et al. (2000) for a more detailed description of the biology of coagulation. 
2.1 Biological background 
Haemostasis (the halting of bleeding) is nature's fastest reaction to tissue damage. Its function 
is to maintain blood in a fluid state under normal conditions and to plug any leaks when the 
vasculature is damaged. This is achieved by coagulation, a process that converts blood to a 
solid mass (fibrin blood clots) in a localised area while leaving it fluid in surrounding areas 
(Majno & loris, 2004). Generating a blood clot in the correct place and at the correct time re-
quires precise coordination: the clots must form quickly, be easily broken down and should not 
be stimulated inappropriately. 
Fibrin blood clots are formed by the aggregation (clumping together) of platelets and the for-
mation of a fibrin mesh which stabilises and provides strength to the clot. The fibrin monomers 
that form the mesh are the end product of the coagulation cascade, which is activated at almost 
the same time as platelets are activated (see Figure 2.2). Thrombin, one of the main components 
of platelet aggregation (Gurbel et al., 2007) is also responsible for the converting of fibrinogen 
to fibrin: therefore thrombin is a key enzyme in the formation of a fibrin blood clot. 
2.1.1 Coagulation cascade 
The coagulation cascade is a network of sequentially activated factors (proteins) that coordinate 
the production of thrombin. The factors within the cascade are numbered from I to XIII, in 
their order of discovery rather than function; an 'a' suffix is traditionally added to denote an 
activated factor (Majno & loris, 2004). Various reactions within the cascade are assembled on 
specific cell surfaces, referred to as phospholipids. The limitation of such sites, such as to those 
exposed on the surfaces of activated platelets, helps to prevent the clot spreading throughout 
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Figure 2.2: Overview of haemostasis. A fibrin blot clot is formed from the dual processes of 
platelet aggregation and the coagulation cascade. The coagulation cascade produces the fibrin 
monomers that provide stability to the clot. (Key: ADP, adenosine diphosphate.) Adapted from 
Colman et al. (2000) 
6 
the vascular system (Hoffman, 2004). There are also various feedback loops that either inhibit 
or accelerate the reaction (Majno & Joris, 2004), with thrombin enhancing its own formation by 
activating factors V, VIII and XI. Anticoagulants which act to contain the clot include the protein 
C/protein 5 inhibitory system, antithrombin III (whose speed of action is greatly enhanced by 
heparin (Porth, 2005» and tissue factor inhibitor. 
Figure 2.3 shows the dynamics of the various factors within the coagulation cascade. It has 
been traditional to divide it into an extrinsic (that begins with tissue damage) and intrinsic 
(that begins in the blood) pathway. These pathways converge at the level of factor X activation 
into a common set of reactions (named the common pathway). 
2.1.1.1 Extrinsic pathway 
Under normal circumstances (haemostasis) the coagulation cascade is thought to be initiated 
through the extrinsic pathway and the expression of tissue factor (TF) on the surface of dam-
aged cells (Colman et al., 2000). TF is a receptor normally absent from all cells in direct contact 
with blood, but is present on damaged cells or on a variety of cells outside the vasculature. 
When TF does come into contact with blood it binds to plasma factors VII and VIla (trace 
levels are present in plasma), TF:VII is subsequently activated by TF:VIla (autoactivation). The 
TF:VIla complex is termed the extrinsic tenase and subsequently activates factor X (Tucker et ai., 
2009; Colman et ai., 2000), a factor common to both pathways. 
In a clinical setting, tests for coagulating potential are used when someone has unexplained 
bleeding or bruising and before surgery. Plasma is drawn from the patient and mixed with 
activators of the relevant pathway in the presence of high levels of calcium and phospholipids 
and clot formation time is recorded. The prothrombin time (PT) assay (activated by tissue 
factor) is such a test that detects deficiencies in factors within the extrinsic pathway. 
2.1.1.2 Intrinsic pathway 
When blood is brought into contact with negatively charged surfaces (including non-
physiological substances such as glass) it results in activation of factor XII, prekallikrein, high 
molecular weight kininogen and, subsequently, factor XI. This is known as contact activation 
(its position in the coagulation cascade is shown in Figure 2.3). The lack of abnormal bleeding 
associated with congenital factor XII deficiency indicates that it may not be important for coag-
ulation in vivo (Renne et ai., 2006; Gailani & Renne, 2007a). Factor Xla converts factor IX to IXa 
which complexes with factor VIla to form the intrinsic tenase (a factor X activator). The clini-
cal test for the intrinsic pathway is the activated partial thromboplastin time (aPTT) in which 
plasma is activated via a material such as silica and the time until a clot is formed is measured. 
In such tests, plasma that is deficient in a factor of the intrinsic pathway (such as the congenital 
deficiencies of hemophilia A (clotting factor VIII deficiency) and hemophilia B (clotting factor 
IX deficiency» clots slowly (Gailani & Renne, 2007a). 
7 
Contact 
Activation 
_ XII. 
Injury 
XI IX 
-- + I XI. TFPI 
t t I X X - ~ ~
I I 
I I 
I I 
I 
I 
I 
APC 
I I 
, - - ~ ~... y l!I.! _1 
+ 
VIII 
TFPI 
X 
- - - - - - - - - - - - - - - - - - ~ ~
Extrinsic Pathway 
Intrinsic Pathway 
Common Pathway 
Feedback 
Cumple).e5 , ' 
"- --' 
Inhlbilion I 
I 
I 
, 
------------ ______ 1 
Prothrombin 
" I 
i ~ X . . : : : ; ; : I ~ ; o ~ ~ I I ~ S ~ ~ - '0--. _. 
APC : ,---------- ATIII 
, , 
V V. 
+ I 
I 
I, I 
I, \ \ 
... - - - - - - - - - ' ~ ~ - - - - - - - - - - - - - - - - - - - - - - - - - - - '- - - - - - - - - - - - - - - - - - - - - - - Thrombin 
Fibrinogen ------<_ Fibrin 
Figure 2.3: Diagram showing the major reactions involved in the coagulation cascade. Under 
normal conditions initiation of the cascade is considered to involve tissue factor (a receptor on 
damaged cell surfaces) wruch acts with factor VIla (found in blood) to conv rt factor IX to fac-
tor IXa and factor X to factor Xa (the extTinsic pathway, shown by green arrows). The intrinsic 
pathway (blue arrows) includes contact activation through factor XlIa wruch activates factor 
Xla . Factor Xla converts factor IX to IXa. Factor IXa forms a complex with factor VIla that con-
verts factor X to factor Xa. Factor Xa onwards is sometimes referred to as the common pathway 
(red arrows). Factor Xa can convert prothrombin to thrombin but, as prothrombinase in com-
plex with factor Va, does trus at a markedly increased rate. Thrombin feeds back (interrupted 
lines) to activate factors V and VU!, wruch accelerates its own formation and is also thought 
to trigger the intrinsic pathway by activating factor Xl. Thrombin dampens its own activity by 
activating protein C (not shown) which degrades factors Va and VIIIa. Natural inltibitors r -
tard clotting: tissue factor pathway inltibitor (TFPI) blocks factor VIIa/TF and antithrombin III 
(ATIJI) blocks factors IXa, Xa and thrombin. (Arrow, activated factors; filled rectangles, sites of 
inhibitor action; dashed lines, feedback reactions; dashed rectangles, complex assembled on a cell 
surface). Adapted from Colman et al. (2000) . 
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2.1.1.3 Common pathway 
The two pathways converge at factor X and, regardless of how factor Xa is formed (either 
through the extrinsic or the intrinsic tenase), it can convert prothrombin to thrombin. Fac-
tor Xa in complex with factor Va (as prothrombinase) does this at a markedly increased rate 
(Colman et al., 2000). It is thrombin that cleaves fibrinogen to generate the fibrin monomers 
needed to form a clot. 
2.1.1.4 Cell based model 
The contemporary view of haemostasis includes some key revisions to the cascade theory. The 
intrinsic and extrinsic pathways, while not redundant, are seen to have their reactions oper-
ate at different locations: in plasma or on the cell surfaces of platelets, extravascular cells or 
endothelium. Blood platelets are thought to playa role in supporting procoagulant reactions, 
and endothelial cells are thought to help maintain the anticoagulant properties of the vascu-
lature (Hoffman, 2003). This leads to the view that, in a time-dependent manner, haemostasis 
occurs in three overlapping phases. During the initiation phase, with sufficient stimulus, small 
amounts of thrombin are formed on TF-bearing cells. Thrombin activates platelets, exposing 
receptors and binding sites. During the amplification phase the small amount of thrombin 
already produced activates factor V and VIII on activated platelet surfaces. In the final prop-
agation phase large numbers of platelets are activated, providing surfaces for large scale acti-
vation of factor X by the intrinsic tenase (factor XIa/VIlla complex) that is responsible for the 
large scale burst of thrombin production leading to clot formation Hoffman (2004). The protein 
C system is thought to localise the generation of thrombin close to the injury by being much 
more efficient at inactivating factor Va on the surface of endothelial cells than on the surface 
of platelets, thereby preventing the generation of thrombin on nearby healthy cells (Hoffman, 
2003). 
2.1.1.5 Inhibition 
Inhibition within the coagulation cascade is acheived through antithrombin III (ATIII), the pro-
tein C subsystem and tissue factor pathway inhibitor (TFPI). 
Antithrombin III inhibits thrombin directly by forming an irreversible compound, and indi-
rectly by inhibiting other factors within the coagulation cascade such as factor XIa and factor 
IXa. It is present at high concentrations, over twice that of any procoagulant concentration 
(Mann et al., 2003; Colman et al., 2000). 
Thrombin participates in its own inhibition by activating protein C which, as part of the throm-
bomodulin/protein C/protein 5 system, regulates the activity of factor VIlla and Va, cleav-
ing them into inactive fragments, thereby dampening the activity of prothrombinase (Xa:Va) 
and the tenase complexes (VIIIa:IXa and VIIa:TF) (Dahlback & Villoutreix, 2005; Colman et al., 
2000). 
TFPI is the principal inhibitor of the extrinsic pathway, directly inhibiting factor Xa by the 
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formation of the Xa:TFPI complex. It also indirectly inhibits the extrinsic tenase (VIIa:TF) by 
the formation of the Xa:TFPI:VlIa:TF whereby TFPI forms part of a negative feedback loop 
with factor X, participating in its own inhibition (Broze, 1995). 
2.1.2 Therapeutic interventions 
Disruption in thrombin generation can have adverse effects on the host. For example, insuffi-
cient levels of thrombin lead to excessive bleeding (as observed in congenital deficiencies such 
as haemophilia) while excessive clotting, or clots in the wrong place, can cause a number of 
conditions including thrombosis (obstructive clot formation), which is the primary cause of 
heart attacks and stroke. Therapeutic drugs in common use for thrombosis, including war-
farin and heparin, target many factors within the coagulation cascade based on the assumption 
that thrombosis and normal blood clotting occur by the same pathway (Colman, 2006). Fig-
ure 2.4 shows the many factors which these drugs target. Consequently, although effective at 
limiting thrombus growth, these drugs cause the unwelcome side effect of excessive bleeding 
(Gailani & Renne, 2007b). There is interest in identifying new therapeutic targets which are less 
blunt, preventing thrombosis formation without promoting bleeding. 
Deficiency of either factor IX or its cofactor VIII is associated with severe bleeding disorders 
(hemophilia A and B respectively). This is in contrast to deficiencies of factor XI and factor XII. 
Factor XI deficiency is a much milder disorder (hemophilia C), even though it has a prolonged 
aPTT assay (see Section 2.1.1.2), and factor XII has no bleeding disorder associated with it. 
Several studies suggest that factor XII is required for thrombosis but not for normal clotting 
(Colman,2006). These differences in bleeding tendencies and knowledge of factor XII have 
stimulated interest in factor XI and factor XII as therapeutic targets (Gailani & Renne,2007a). 
2.1.3 Clinical tests and the thrombin generation curve 
Clinical tests routinely used for the evaluation of human coagulation include the PT and aPTT 
(described in Sections 2.1.1.1, 2.1.1.2 respectively). However, though widely used, these tests 
are non-physical (being activated at much higher levels of TF than occurs phycically, in the 
case of the PT test, or via the nonphysiological contact pathway for the aPTT test) and, as 
such, are insensitive to mild bleeding disorders and new therapeutic drugs (van Veen et al., 
2008). They ignore the whole of thrombin generation, being based on the time blood takes to 
clot. In-vitro blood clots, and fibrin formation, occur when thrombin concentration reaches five 
percent of its peak concentration. In-vivo clotting and fibrin formation occurs later in thrombins 
formation, this is thought to be due to thrombin diffusing, or being washed away, from the 
site of injury. Laboratory tests on plasma describing the complete thrombin generation curve 
have been possible but have been too laborious to use in a clinical setting (Baglin, 2005). New 
techniques are resulting in a more effective thrombin generation assay (TG) that may be more 
ameneable to clinical use. The assay produces a thrombin generation curve (see Figure 2.5) that 
shows thrombin generation lag time, maximum thrombin concentration and the time required 
to acheive maximum thrombin concentration.The TG assay, unlike the PT and aPTT assay, can 
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arin) are shown and their targeted coagulation factors (dashed blocking arrows). Heparin binds 
to antithrombin III, increasing its ability to inactivate thrombin and other clotting factors; war-
farin decreases prothrombin and other coagulation factors. Adapted from Mackman (2008). 
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detect deficiencies in both the intrinsic and extrinsic pathway (van Veen et al., 2008). Initiation 
is at physiological levels of tissue factor (much lower than the aPTT is initiat d with) making 
it sensitive to deficiencies in either the intrinsic or extrinsic pathway and therefore correlate 
more closely with hyper and hypo-coagulable phenotypes than traditional tests (van Veen et al., 
2008). This is providing new insights on the function of pro and anti-coagulant proteins present 
in plasma (Salvagno et al., 2009). 
2.2 Mathematical background 
A complete model of coagulation would combine the biochemical reactions of the coagulation 
cascade (including its various inhibitory systems and its interaction with platelets), platelet 
aggregation, perhaps shear flow (that activates platelets) and the process of a clot breaking 
down (fibrinolysis). Mathematical models in this area have evolved from simple biochemical 
reaction models, through more comprehensive reaction pathways, to large detailed models that 
include blood flow, spatial effects and cell interactions such as the availability of cell surfaces 
(binding sites) for the formation of complexes. In this review we focus on mathematical models 
which are relevant to those developed in this thesis. We start by describing models of the 
coagulation cascade that are based on activation by the extrinsic pathway. In the following 
section we describe models that concentrate on the intrinsic pathway, with particular focus 
placed upon factor XI activation. 
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A more comprehensive review of mathematical models of coagulation and the formation of 
blood clots is provided by Ataullakhanov & Panteleev (2005), who have developed a number of 
spatial models (Zamitsina et ai., 1996a; Zamista & Ataullakhanov, 2001; Panteleev et ai., 2006). 
2.2.1 The extrinsic pathway 
Most early mathematical models of thrombin generation concentrate on the extrinsic pathway 
since it is believed to be more relevant (than the intrinsic one) for haemostasis. One of the 
earliest mathematical models is a linear model due to Levine (1966) that focuses on enzyme ki-
netics. More detailed models were developed as the understanding of coagulation progressed. 
The first model to simulate the PI assay (the coagulation assay for the extrinsic pathway) was 
described by Willems et al. (1991). It is based on six reactions that include inhibition by an-
tithrombin III and protein C, with a feedback from thrombin to factor V. Initiation of the cas-
cade was modelled by a function representing tissue damage and the extrinsic pathway. The 
resulting simulations of thrombin were in good agreement with in-vitro experiments carried 
out by the same group. 
Mann and coworkers have produced a number of models in this area. Nesheim et al. (1984) 
investigated an individual reaction within the coagulation cascade, namely the formation of the 
complex prothrombinase which is responsible for activating thrombin, discussing it and other 
cell surface dependent complexes. In two further papers, the same group Gones & Mann, 1994; 
Lawson et ai., 1994) developed a model of thrombin generation in response to extrinsic pathway 
activation formulated as a system of eighteen ODEs which accounts for activation of factors IX, 
X, V, VIII, II and the assembly of the complexes VIIIa:lXa and Va:Xa on cell surfaces. They 
find that the level of the activator (the extrinsic tenase) affects the time lag between initiation 
of the system and thrombin generation more significantly than the maximum level of thrombin 
generated. The model was later extended (Hockin et ai., 2002) to incorporate the inhibitory 
action of TFPI and antithrombin III. The resulting model comprised thirty four ODEs and was 
successfully compared to laboratory experiments (van't Veer & Mann, 1997) of clot formation 
in plasma in the presence and absence of inhibitors. 
Khanin et al. produced two models that concentrate on the extrinsic pathway, the first be-
ing a nonlinear model with a positive feedback loop to account for thrombin activation of 
factor V (Khanin & Semenov, 1989). This model was then extended to describe the PT assay 
(Khanin et al., 1998) by incorporating three positive feedback loops (one for each of factor V 
and factor VIII activation by thrombin and for activation of TF-VII complex by factor Xa) and 
accounts for inhibitors antithrombin III and tissue factor pathway inhibitor (TFPI). A sensi-
tivity analysis of the second model revealed that only severe coagulation disorders associated 
with large reductions in the concentrations of coagulation factors could be identified using the 
model. 
Other models have focused on other aspects of the coagulation cascade. Beltrami & Jesty (1995) 
and Jesty et al. (2005) considered different long range positive feedback mechanisms within the 
cascade (such as the activation of factor VIII by thrombin) and showed how these affect the 
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peak concentration of thrombin produced. Fogelson & Kuharsky (1998) investigated the effect 
of the density of membrane binding sites on activation thresholds in enzyme reactions, both 
in a general setting and specifically within the coagulation cascade. Lu et al. (2004) studied the 
membrane dependent reaction for the formation of factors IXa and Xa in the presence of tissue 
factor pathway inhibitors and antithrombin III. 
Further models of coagulation that attempt to incorporate larger macroscopic effects have also 
been proposed. Alber et al. produced a number of multiscale models (Xu et al., 2008, 2009, 
2010) of thrombus development in blood, incorporating the microscale interactions of platelets 
through a discrete cellular Potts model and the macroscale interaction with blood flow through 
the Navier Stokes equations. The effects of platelets on blood coagulation and thrombus for-
mation have been studied by Fogelson et al. in a series of models for biochemical interac-
tions of platelets and plasma (Kuharsky & Fogelson, 2001), continuum models of platelet ag-
gregation (Fogelson, 1992; Fogelson & Guy, 2004) and thrombus formation under blood flow 
(Fogelson & Guy, 2004; Guy et al., 2007). Anand et al. incorporated the mechanical effect of 
shear stress activation of platelets, biochemical factors and blood flow in a series of models for 
the growth and lysis of clots (Anand et al., 2003, 2005, 2008). 
2.2.2 The intrinsic pathway and factor XI activation. 
Less work has been devoted to the intrinsic pathway and, although mathematical models exist 
for most parts of the pathway, few models account for thrombin activation of factor XI and 
its potential role as a therapeutic target (see Section 2.1.2). We start by describing models that 
include all, or part of, the intrinsic pathway but do not include thrombin's activation of fac-
tor XI. We then describe, in more detail, those models that account for factor XI activation by 
thrombin. 
2.2.2.1 The intrinsic pathway. 
The intrinsic pathway can be studied in vitro via the aP'IT assay (see Section 2.1.1.2). Kogan et al. 
(2001) developed a model to investigate the sensitivity of this screening test to its activation 
by factor XII. The impact of the extrinsic pathway and of thrombin activation of factor XI are 
neglected in the model. The authors concluded that trace amounts of activated factor XII (nor-
mally present in plasma) are sufficient to autoactivate factor XII. Prior to this (and in addi-
tion to their work on the extrinsic pathway) Khanin et al. (1991) studied how platelet activation 
(providing surfaces for reactions to occur on) affects thrombin generation through the intrinsic 
pathway. They concluded that the secretion of factor V by platelets is necessary for activation 
of the system only at low levels of stimulation. 
Materials placed in contact with blood are thought to induce coagulation through factor XII and 
contact activation of the intrinsic pathway (see Figure 2.3). This is of considerable interest since 
it is often necessary to place materials in contact with blood in vivo (such as stents) without 
inducing pathological coagulation (Zhuo et al., 2005). Guo et al. (2006) developed a model to 
investigate material-induced coagulation through factor XII activation. In their model they 
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Figure 2.6: The intrinsic pathway of blood coagulation as used by Zarnitsina et al. (1996a,b) in 
their spatial models of the intrinsic pathway. Only factors of the intrinsic and common pathway 
are included in their models reflecting the aPTf assay. Activation is via the contact pathway us-
ing the initial concentration of factor XIa as an indicator of the level of activation. [Solid arrows, 
sequential activation; dotted arrows complex formations; dashed arrows, feedback activations.] 
reduce the coagulation cascade to two ODEs, representing factor XII activation by a biomaterial 
and single enzyme/substrate representing the rest of the intrinsic pathway. They conduded 
that, in material-induced coagulation, the primary mechanism for activation of coagulation 
involves autoactivation of factor XII mediated by the inducing material. 
2.2.2.2 Factor XI activation. 
Ataullakhanov et al. presented one of the earliest models of the intrinsic pathway 
(Zarnitsina et al., 1996a) and extended this to include factor XI activation by thrombin 
(Zamitsina et al., 1996b) (see Figure 2.6). A one-dimensional spatial model for the evolution 
of factors IX, VIII, V, X, II and I and the complexes prothrombinase (VaXa) and the intrinsic 
tenase (VIIIaIXa) was presented by Zamitsina et al. (1996a). There are positive feedbacks from 
thrombin to factors V and VIII and inhibition via antithrombin III, and the protein C system is 
also included. Activation is via the intrinsic pathway. Parameter values are taken from the liter-
ature and diffusion is incorporated for all factors at the same rate. In the latter paper they solve 
the model numerically and demonstrate threshold behaviour for different initial conditions of 
factor Xla, with above-threshold levels producing explosive thrombus growth before decreas-
ing. The model is then modified to incorporate thrombin activation of factor XI. They investi-
gated varying the levels of thrombin activation in the range 0 _10-2 min-I, finding that levels 
greater than 10-6 min-I dramatically change the spatial pattern of dot growth with the dot 
now becoming infinite in size. Ataullakhanov et al. have developed further models, induding 
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a mathematical model of factor X activation by the intrinsic tenase (the complex of factors IXa 
and factor VIla) (Panteleev et al., 2004) which was incorporated into a spatial model of both the 
intrinsic and extrinsic pathways (Panteleev et al., 2006), demonstrating that the intrinsic tenase 
is important in clot propagation far from the activated site. Although these models assume that 
factor XI is activated via thrombin, this is not discussed further. 
Anand et al. have proposed several models that incorporate the intrinsic and extrinsic pathway 
and factor XI activation by thrombin. A detailed discussion of the requirements for a whole 
clot model was given by Anand et al. (2003, 2005), alongside an initial attempt at this in which 
the biochemical reactions presented in Zamitsina et al. (1996a,b) were extended to include the 
extrinsic pathway, blood flow and activated and resting platelets as sources of membrane bind-
ing sites for the assembly of prothrombinase and the intrinsic tenase. A model for the growth 
and lysis of clots in static plasma was given by Anand et al. (2008), who again incorporated the 
extrinsic and intrinsic pathway and factor XI activation by thrombin. They were able to corrob-
orate existing experimental data (Butenas et al., 1999) and discussed two anti-coagulant states 
antithrombin III and protein C deficiency, but not the implications of thrombins activation of 
factor XI. 
Kramoroff & Nigretto (2001) developed the only model which specifically addresses the acti-
vation of factor XI. The model only includes the factors of the intrinsic and common pathway; 
being designed to simulate the aPTf screening test; activation of factor XI by thrombin is in-
cluded (see Figure 2.7 for a network diagram of these reactions). Guided by model simulations, 
they concluded that factor XI autoactivation is more important than thrombin-mediated activa-
tion for the formation of thrombin. The model was evaluated by comparing model predictions 
with laboratory measurements conducted on normal plasma and plasma deficient in one of 
factors VIII, IX, XI and XIII. 
In avascular environments, such as synovial fluid and ovarian follicular fluid, protein compo-
nents are similar to blood, but there are no platelets. Therefore, complexes form on phospho-
lipid surfaces such as those provided by activated or ruptured endothelial cells. Bungay et al. 
(2003) presented a model of thrombin generation within such environments. The resulting 
system of seventy-three ODEs (see Figure 2.8 for a simplified network diagram of the reactions 
included) includes thrombin activation of factor XI, thrombin inhibition through protein C and 
antithrombin III and cell surfaces on which complexes may form. Activation is through the ex-
trinsic pathway and the VIla:TF complex. Numerical solutions of the model obtained by using 
parameter estimates from the literature were shown to be in good qualitative agreement with 
experiments reported by Butenas et al. (1999). By varying the availability of surfaces on which 
reactions could occur, they concluded that the availability of such surfaces regulates the time 
and peak level of thrombin generation. 
A modification of the above model (Bungay et al., 2oo6) was used to study thrombin genera-
tion in human ovarian follicular fluid, where an absence of feedback mechanisms is thought to 
account for the low amounts of thrombin produced. The original model was also used to in-
vestigate the effects of varying the initial values of the factors VIII, IX and XI (corresponding to 
haemophilia A, Band C respectively) and shown to yield results that were qualitatively similar 
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Figure 2.7: Intrinsic pathway of blood coagulation as used by Kramoroff & Nigretto (2001) in 
their model of the intrinsic pathway. Only factors of the intrinsic and common pathway are 
included and the system (reflecting the aPTf assay) is activated through initial conditions of 
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dashed arrows, feedback activations.] 
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Figure 2.8: A simplified schematic of the reactions included in the pathway of blood coagula-
tion used by Bungay et al. (2003); Bungay (2008). Factors of the extrinsic, intrinsic and common 
pathways are included with variables for their occurrence in fluid and as lipid bound factors. 
Activation is via VIIa:TF and the extrinsic pathway. [Positive feedback, dashed lines; PL, as-
sembly dependent on phospholipid surfaces.] 
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to what would be expected (Bungay, 2008). 
2.3 Discussion 
In this chapter we have provided a biological introduction to coagulation focussing on aspects 
that will be relevant to our mathematical models. We also reviewed existing relevant mathe-
matical models. Due to the incredible biochemical complexity of the coagulation cascade we 
start our modelling (chapter 3) with a reduced set of reactions that have previously been shown 
to produce the characteristic thrombin generation curve (Figure 2.5) and we aim to understand 
some of the underlying mechanisms of its production. In chapter 4 we extend this model to 
include the biochemical reactions of the extrinsic and intrinsic pathways and produce simu-
lations discussing, in particular, the activation of factor XI that is thought to be of interest for 
therapeutic intervention. 
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CHAPTER 3 
An asymptotic analysis of thrombin 
generation 
3.1 Introduction 
There are numerous mathematical models of coagulation and the formation of blood clots, 
including many that concentrate on thrombin generation; a review of these is given in the 
previous chapter. The coagulation cascade is traditionally thought of as being split into two 
pathways, the slower (intrinsic) one beginning in the blood and the faster (extrinsic) one be-
ing initiated by tissue trauma. The two converge into a common pathway at the formation of 
factor X (Porth, 2005). This pathway results in the generation of thrombin, which induces the 
conversion of fibrinogen to fibrin monomers. The contemporary view of haemostasis includes 
some key revisions: the intrinsic and extrinsic pathways are seen to occur at different loca-
tions and the two pathways are linked through such mechanisms as extrinsic tenase activation 
of factor X (Hoffman, 2004). Models exist for both the intrinsic (Bungay et a1., 2003; Guo et a1., 
2006) and the extrinsic (Kuharsky & Fogelson, 2001; Lawson et al., 1994; Jones & Mann, 1994; 
Khanin & Semenov, 1989) pathways, with the number of reactions included ranging from small 
subsets aones & Mann, 1994; Khanin & Semenov, 1989; Qiao et al., 2004; Jesty et al., 2005) to 
more comprehensive models (Hockin et a1., 2002; Anand et a1., 2008), reflecting how the under-
lying biology has increasingly succumbed to investigation. 
We base our model on a set of reactants from within the common pathway of the cascade 
activated via the extrinsic pathway and ending with the enzyme thrombin. These reactions 
have previously been shown to be able to simulate the observed rise and fall of thrombin lev-
els. Willems et a1. (1991) fully describe the reactions but not the equations derived from them. 
While we acknowledge that these reactions represent only a vastly reduced subset of what is an 
extremely complicated network, we contend that they capture many of its characteristic mech-
anisms, notably participation of thrombin in its own generation (through its activation of factor 
V) and two important anticoagulant pathways (protein C and antithrombin III inhibition). We 
analyse the step-by-step processes involved in the generation of thrombin through a process of 
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time-dependent asymptotic analysis (aided considerably by the availability from the literature 
of the required parameter values), which enables us to demonstrate the importance of various 
reactions for thrombin generation and to identify which components of the cascade are active 
on each timescale. We determine how the resultant series of simplified models over seven 
timescales corresponds physiologically to various interactions within the cascade, illustrating 
the usefulness of this technique when applied to such complex systems. 
3.2 Mathematical model 
3.2.1 Formulation 
The reactions and the kinetics used, from (Willems et al., 1991), are listed in Table 3.1 and 
illustrated in Figure 3.1. We give details of these six reactions below. While Willems et al. (1991) 
describe these reactions and show simulations produced from a mathematical model derived 
from them they do not describe the mathematical equations. The reactants (factors) within the 
coagulation cascade are numbered from one to thirteen using Roman numerals, the addition 
of 'a' denoting (as is traditional) an activated factor; moreover, we use an 'i' for inactivated 
downstream factors in their various forms. We note that the numerical value does not refer to 
the reactant's position within the cascade but rather to the historical sequence of discovery. We 
formulate a system of coupled ordinary differential equations (3.2.1a}-(3.2.3b) based on these 
reactions; see Tables 3.2 and 3.3 for definitions of the variables and parameters and Table 3.1 
for the reactions that we now describe. 
Reaction 1. Generation and inactivation of factor Xa. Injury to tissue leads to the activa-
tion of factor X through the recruitment of factor VII (found in blood) by tissue factor (TF), 
a cell-surface receptor, exposed on damaged cells normally found outside the vasculature, 
(Hoffman, 2004; Crawley et al., 2007). Recruitment of factor VII and factor VIla by TF leads to 
the assembly of the TF:VIIa complex, which in tum is responsible for the activation of factor X 
(Riewald & Ruf, 2003; Crawley et al., 2007). We follow Willems et al. (1991) and describe this ac-
tivation of factor X by the VIIa:TF complex (extrinsic tenase) by the function H(t) = k1a1'lae-'hat 
representing the variable production of factor Xa, where k1a is the total amount of factor Xa 
(concentration If) produced (while k1a1'la is in effect a measure of the severity of the injury), 
the rate constant 1'la is associated with the loss of the stimulant by its degradation and se-
questration into an inactive form and t is the time after injury; see (3.2.2a). We note that the 
exponential dependance is for definiteness, the precise functional form being of limited signif-
icance; it assumes in particular that the timescale over which Xa is produced by the trauma is 
much shorter than the timescale for its degradation (the activation of X ceases rapidly follow-
ing injury due to TFPI inhibition). Antithrombin III inhibits factor Xa by forming an irreversible 
complex (concentration f ~ ) ) with rate k1b see (3.2.2a, 3.2.3a). 
Reaction 2. Generation and inactivation of factor Va. The conversion of factor V (fTJ) into 
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Reaction Generation Inactivation 
No. Description No. Description 
Generation and inactivation la HlO, Xa lb Xa+ATIII -+ Xa:ATIII 
of factor Xa 
Generation and inactivation 2a V ~ V a a 2e Va APC, InactiveV 
of factor Va 2b V ~ V a a
Formation and inactivation 3a Va+Xa -+ Va:Xa 3b Va:Xa+ATIII -+ Va+Xa:ATIII 
of prothrombinase 3e Va:Xa APC,lnactiveV+Xa 
Generation and inactivation 4a II ~ ~ IIa 4e lIa+ATIII -+ lIa:ATIII 
of thrombin 4b II Va:Xa, IIa 
Protein C inhibition Sa C.!!; APC Sb APC -+ InactiveC 
Fibrinogen to fibrin 6 F'b . I1a F'b . I nnogen -+ I nn 
Table 3.1: The set of reactions for a reduced model of thrombin generation (Willems et al., 1991). 
Michaelis-Menten kinetics are adopted for enzymatic reactions 2a, 2b, 2e, 3e, 4a, 4b, while mass-
action kinetics are adopted for the remainder, with lb, 3b, 4e, Sa, 5b and 6 being of first-order 
(due to the abundance of ATIII, its concentration is assumed to be constant) and 3a (the binding 
of two proteins) of second order. Reactants (factors) within the cascade are normally denoted 
by Roman numerals (with the addition of 'a' indicating an activated factor); other terms used 
are prothrombinase for the complex formed from factor Xa and factor Va, prothrombin (factor 
II), thrombin (factor lIa), fibrinogen (factor I), fibrin (factor la), the inhibitors being protein C 
(APC in its activated form) and ATIII (antithrombin III). These reactions are shown graphically 
in Figure 3.1. 
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Figure 3.1: A schematic representing the model of thrombin generation based on the reactions shown in Table 3.1. The boxes correspond to the coagulation 
factors, with the lower case letters in brackets being used in the mathematical model to designate the concentrations. Red boxes (with superscript a) denote 
the active factors, yellow the procoagulants and green (with superscript i) the inactivated factors. Arrows pointing into boxes represent conversion from one 
species to another, while those directed at other Lines correspond to catalysis. 
Variable Description Variable Description 
bxa va Prothrombinase (VaXa) l i ~ ~ Thrombin, factor IIa 
C Protein C Ifi Inactivated thrombin 
ca Activated protein C (APC) Iv Factor V 
c; Inactive protein C Ig Activated factor V 
tr Fibrin It Inactivated factor V 
I; Fibrinogen I: Activated factor X 
Ii; Prothrombin, factor II I ~ ~ Inactivated factor X 
Table 3.2: Dependent variables; all concentrations having units of nMs. 
factor Va (concentration Ig) is mediated by factor Xa (rate constant k2b) and by thrombin (rate 
constant k2a) (Asselta et al., 2006; Segers et al., 2007) (equations (3.2.1b), (3.2.2b». The model 
takes into account the competition for factor Xa between factor V and prothrombin (fii) and 
for thrombin between factor V and fibrinogen (fi). The downregulation of factor Va activity is 
achieved by activated protein C (Asselta et al., 2006) at a rate k2c, (3.2.2b), (3.2.3a). 
Reaction 3. Formation and inactivation of prothrombinase. Prothrombinase is assembled 
from factor Va and factor Xa with rate constant k3a, (3.2.2a), (3.2.2b), (3.2.2c). This occurs on 
binding sites present on activated platelets or on negatively charged phospholipids that are 
exposed as a result of cell damage (Spronk et al., 2003), so the rate of assembly will vary with the 
availability of these sites. However, variation is not included in the model but could be explored 
by changing the rate constant k3a, with the assembly of the complex simply being considered 
to be a second order reaction between factors Va and Xa. Downregulation of prothrombinase is 
achieved in two distinct ways: the factor Xa complexed within it can be irreversibly inactivated 
by antithrombin III to produce factor Xi (rate k3b), releasing factor Va - see (3.2.2b), (3.2.2c), 
(3.2.3a) - or the cofactor Va can be inactivated by APC (with rate k3c) to form (irreversibly) an 
inactive factor (ft), releasing factor Xa - see (3.2.2a), (3.2.2c), (3.2.3a). 
Reaction 4. Generation and inactivation of thrombin. There are two pathways by which 
prothrombin can be activated to thrombin, via factor Xa with rate constant k4a (taking into 
account the competition for factor Xa between factor V and prothrombin) - see (3.2.1c), (3.2.2d) 
- or catalysed by prothrombinase with rate constant k4b - see (3.2.1c), (3.2.2d). Antithrombin III 
converts thrombin directly (rate k4c) to its inactivated form (f!i); see (3.2.2d), (3.2.3b). 
Reaction 5. Protein C system. The inhibitory protein C pathway is modelled as a first-order 
reaction with activation at rate kSa - see (3.2.1d), (3.2.2e) - and conversion to its inactivated form 
(Ci) at rate kSb - see (3.2.2e), (3.2.3b). 
Reaction 6. Conversion of fibrinogen to fibrin. The conversion of fibrinogen (fi) to fibrin 
(ff) (rate constant k6) is included to account for the reduction in the activation rate of fac-
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Parameter Value Parameter Value 
kla 20000nM k3c 24 min-I 
'rIa 1 min-1 k3cm 20nM 
kIb 0.25 min-I k4a 2.3 min-I 
k2a 14 min-1 k4am 58nM 
k2am nnM k4b 2000 min-l 
k2b 2.6 min-1 k4bm 210nM 
k2bm 10nM k4c 1.3 min-1 
k2c 24 min-I kSa 0.0014 min-1 
k2cm 20nM kSb 0.35 min-l 
k3a 10 nM-Imin-1 k6 2 X 103 min-I 
k3b 0.05 min-I k6m 2000nM 
Table 3.3: Dimensional parameter values, based on values from Willems et al. (1991), where a 
similar parameter set is used for the simulations - Willems et al. (1991) adopts a lower value for 
the initial stimulus (k1a = 20). The reasons for adjusting the parameter kla are given in Section 
3.2.3. The value of k6 is not listed by Willems et al. (1991) and we use a value of 2 x l o - ~ ~ min-1 
taken from Kogan et al. (2001); Higgins et al. (1983). 
tor V caused by the competition for thrombin between fibrinogen and factor V: (3.2.1b), (3.2.2b). 
The equations representing the procoagulants are thus: 
dli 
= -k6Ii' dt 
dlv 
= 
k 2 a / ~ ~ Iv 
dt Iv + k2am{1 + It.) 6m 
dlii k4al: Iii 
= dt Iii + k4am (1 + i::) 2bm 
dc 
-kSac, = dt 
with those for the activated factors being 
dl: = 
dt 
dl: 
dt 
_ kzcca t: _ k fa fa fa+k 3a XJvl Jv 2cm 
25 
kz"I:lv 
Iv + k2bm(1 + ~ ) ' '4Rm 
k bxa k 4b va " 
Iii + k4bm 
, 
(3.2.1a) 
(3.2.1b) 
(3.2.1c) 
(3.2.1d) 
(3.2.2a) 
(3.2.2b) 
d b ~ ~ ~Tt= 
d l i ~ ~
dt 
(3.2.2c) 
(3.2.2d) 
(3.2.2e) 
where H(t) = k1al1ae-1'lat represents the activation of factor X through tissue injury and the 
extrinsic pathway, k1a reflecting the severity of the injury with Jooo H(t')dt' = k1a and 11a being 
a representative timescale for the extrinsic pathway. Finally, the equations for the downstream 
inactivated factors and fibrin are 
d I ~ ~ _ k fa k bxa d It _ k2cCa Ig k3cCa b ~ ~ ~Tt - 1b x + 3b va' dt - Ig + k2cm + b ~ : : + k3cm' (3.2.3a) 
dlli =k4c1'1I dc
i 
=k5bCa dlr =k6/j. dt III' dt ' dt (3.2.3b) 
Initial conditions are taken from Willems et al. (1991), and describe the initial concentrations for 
procoagulants and regulatory proteins in plasma, it being assumed that no activated or inacti-
vated factors are present at t = 0 with the levels of the procoagulants taken to be liio = lOOOnM 
for prothrombin, Ivo = 300M for factor V, Co = 1000M for protein C, and liO = lOOOOoM for 
fibrinogen, i.e. we set 
at t = 0, Ii = liO, Iv = Ivo, Ijj = liiO, 
bxa - 0 {a - 0 ca - 0 fi - 0 I'i - 0 va - , J ii , , x - , J v - , 
C = CO, I: = 0, I: = 0, 
I'i 0 ci = 0, I',Q = O. Jii = , II 
We note that in this system we have conservation (in their various forms) of fibrinogen, pro-
thrombinase, protein C, factor V and factor X as expressed by 
tr + Ii = liO, Ijj + I ~ ~ + Ifi = liiO, C + ca + ci = Co, 
Iv + I: + I ~ ~ + b ~ : : = Ivo + b ~ : o ' ' I: + I ~ ~ + b ~ : : = lot H(t')dt' + b ~ ; o ' '
which follow from (3.2.1)-(3.2.3). 
3.2.2 Nondimensionalisation 
(3.2.4) 
We nondimensionalise the model, comprised of equations (3.2.1a)-(3.2.3b), with time scaled 
such that f = k4ct denotes nondimensional time, f =0(1) being an intermediate timescale that 
corresponds to the inactivation of thrombin by antithrombin III. The remaining variables are 
scaled to simplify the corresponding equations as much as possible and are 
r = k4cJ: 
x k3a' 
l- k4cl£ 
x - k3a ' 
I ~ ~ = k 2 c m ! ~ , , bxa k ;;xa va = 3cm va' 
~ i . . = k2cm k4clfi c= k2cmk4ct 
II k2am' k2c 
, 
Ii = k6mJ;, Ir = k6mlt, 
Iv = k2bm/ v, 
Iii = k4am/;;, 
CQ = 
k2cmk4cta 
k2c 
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(3.2.5) 
(3.2.6) 
(3.2.7) 
(3.2.8) 
Procoagulant Dimensional Nondim. 
value value 
Fibrinogen (JiO) 10pM }iO = 5 
Factor V (Jvo) 30nM Jvo =3 
Prothrombin (JiiO) 1pM JiiO = 17 
Protein C (co) 100nM Co = 92 
Table 3.4: Initial concentrations of the procoagulants in plasma, taken from Willems et al. (1991). 
It is assumed that no other factors are present at the start. 
where tildes denote the nondimensionless variables. The resulting dimensionless parameters 
are 
;;; 'YIa 
Ila = k4c' 
r k2b 
K2b = , 
k3ak2cm 
r k3c 
K3c = k2c' 
- k4bm k4bm = -k-' 
4am 
The dimensionless initial conditions are 
1. _ /iiO ,,_ k2cCO '1 /iD d 1 /vO 
J ilO - , LO - , J io = -k an J vo = -k-
k4am k2cmk4c 6m 2bm 
k2a = k2cm , 
k2bm 
i'I _ k2cm 
'73a - --, 
k3cm 
k4a 
q4a = k k ' 4am 3a 
l" kSb 
KSb = k4c' 
(3.2.9) 
(numerical values listed in Table 3.4), all other initial conditions being set to zero. 
Equations (3.2.1a)-(3.2.3b) transform to give a dimensionless system of fourteen ordinary dif-
ferential equations, which can be subdivided as follows (henceforth dropping the -s). The 
equations for fibrinogen and fibrin, 
d ~ · · df,a d/ = -k6/il lit = k6/i' 
are independent and are easily solved in the form 
I. - I. e-k6t la - I. (1 _ e-k6t) J 1 - J 10 ,,, - J 10 • 
The equations for protein C in all its forms also decouple 
dc dca dci 
dt = -ksac, Tt = kSac - kSbca, lit = kSbca, 
and can be solved to give 
c = coe-ks..t, ca = coksa (e-ks.. t _ e-ksbt) , 
kSb - kSa 
ci = k Co k (kSb - kSa + ksae-ksbt - ksbe-ks.. t) • 
Sb - Sa 
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(3.2.10) 
(3.2.11) 
(3.2.12) 
(3.2.13) 
dfv 
tit = 
dfjj = 
dt 
with the following equations, for downstream inactivated factors, decoupling 
d (i cQ (a k.,_ca bxa d (i ) v J v +.x va -1Ji. = /,11 tit = fg + 1 b ~ g g + 1 ' dt II' 
3.2.3 Parameter Values 
(3.2.14) 
(3.2.15) 
(3.2.16) 
(3.2.17) 
(3.2.18) 
(3.2.19) 
(3.2.20) 
Willems et al. (1991) take a parameter set from literature and then vary parameters to fit their 
simulated thrombin generation curve to experimental data from Pieters et al. (1988). Taking 
their initial parameter set (Table 3.3 except kla = 20) and adjusting k1a (representing the total 
amount of tissue factor expressed) up (k1a = 200(0) we find that numerical simulations of our 
model produce a maximum peak thrombin concenration of approximately six hundred nM 
after one minute, the same as data from Pieters et al. (1988). 
3.3 Numerical illustration 
We solve the full (dimensional) system (3.2.10)-(3.2.20) numerically using a Matlab ODE solver 
(ode15s) with the initial conditions given in Table 3.4 and the parameter values in Table 3.3. 
Such results (Figure 3.2) and the range of orders of magnitude of the dimensional parameters 
(Table 3.5) suggest that reactions occur on many different timescales. To understand these sim-
ulations more fully we next use a systematic asymptotic approach to separate the dynamics 
into a sequence of timescales to elucidate the underlying physical mechanisms. This results in 
a sequence of seven timescales in which initially only the fastest reactions feature, namely the 
conversion of fibrinogen to fibrin, with the slower reactions, such as the depletion of activated 
protein C, contributing on the longer timescales. In Section 3.7 we provide a discussion of all 
of these timescales and identify the relevant components within the cascade. The sea lings re-
quired for each variable on each timescale, in terms of the dimensionless variables defined in 
(3.2.5)-(3.2.8), are given in Table 3.6 and at the start of each subsection they are given relative 
to those on the previous timescale. If no scaling is given then the variable in question does not 
require rescaling on that particular timescale. On each timescale we in particular analyse the 
large-time behaviour of the reduced problem to ascertain the scalings for the next timescale. 
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Figure 3.2: Numerical simulations of the dimensional model for (from top to bottom) procoag-
ulants, activated factors and downstream factors. The dynamics of thrombin (fourth plot from 
left on second row) exhibit its characteristic time lag, explosive growth and decay. Parame-
ters are taken from Table 3.3 and initial conditions for the procoagulants from Table 3.4. Time is 
shown on a log scale to highlight the multiple timescales involved in the formation of thrombin. 
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Nondim. Nondim. Scaled nondim. Nondim. Nondim. Scaled nondim. 
paramo value paramo paramo value paramo 
k 1a 1.5 x lOs k1a = d 1a = 166 k3c 1.0 k3c = EOk3c = 1.0 
11a 0.77 11a = E011a = 0.77 k4a 0.12 k4a = E-1k4a = 115 
klb 0.19 k 1b = E-1klb = 180 q4a 0.0040 q4a = E-1q4a = 3.7 
k2a 2.0 k2a = EOk2a = 2.0 k4b 5.3 x 102 k4b = Ek4b = 0.57 
k2am 7.2 k2am = EOk2am = 7.2 k4bm 3.6 k4bm = EOk4bm = 3.6 
k2b 0.013 k2b = E-1k2b = 12 kSa 0.0011 kSa = E-1ksa = 1.0 
k3a 1.5 x 102 k3a = Ek:3a = 0.17 kSb 0.27 KSb = EOksb = 0.27 
q3a 1.0 q3a = EOq3a = 1.0 k6 1.5 x 103 k6 = Ek6 = 1.7 
k3b 0.038 k3b = E-1k3b = 35 
Table 3.5: Nondimensional parameters, the rescaled ones in the third and sixth columns being 
based on E = kSa = 1.1 x 10-3; the choice of how certain parameters are scaled with E is, 
as usual, somewhat arbitary. The nondimensional group ksa measures the ratio of protein C 
activation to antithrombin III inhibition of thrombin. ArIII attenuates thrombin activity quickly 
with protein C activating on a longer timescale after thrombin is generated (Mann et al., 2(03), 
we would therefore expect ksa to be a small parameter. 
30 
UJ 
...... 
Tune- Variable 
scale 
t f: f: bxa va f i ~ ~ c;Il 
1 ET - E2Fa E3Bxa E 2 F ~ ~ E2Ca v va 
" 
2 E2/ 3t E-1I3t a x E4/ 3t.a v E5/ 3nxa va E 4 / 3 t ~ ~
" 
E5/ 3Ca 
3 €1/2f €-1I2f a x d a v d'3 xa va € 1 I 2 f ~ ~1/ €3/2Ca 
4 ts +€1/2t €-l/2In (n t; €1I2 ( I n _ ( ~ ) ) )-1 tg El/2 Bxa 
- E3/2InJ ~ ) ) Ca va 
5 ts + € l / 2 l n J ~ ) ) yt €-l/2ln U} t: €1/2 (In ( ~ ) ) ) -1 tg €1I2ln ( ~ ~ ) Bxat - €3/2ln 0) CD c va 
6 1"* €-IF4 €F4 
- - Ed r v 
7 €-lyo €-lFaf €mf 
- -
Ed r Va a 
--- -- -- -- -- - - -
Table 3.6: Summary of the scalings required on each of the timescales, ,_, meaning that the variable does not require scaling. A, {3, 'Yand the timeshift Ts will be 
determined in Sections 3.5.3 and 3.5.4. ts = £1/2 In (1/£) Ts is the timeshift in terms of original scaling. 
3.4 Dimensionless problem restatement 
We introduce e = kSa = kSa/k4c = 1.1 x 10-3; this small nondimensional parameter expresses 
the ratio of the rate of activation of the slowly acting protein C inhibitory system to the fast act-
ing rate at which antithrombin III inhibits thrombin. We rescale the dimensionless parameters 
as indicated in Table 3.5. With the new scalings (Table 3.5), where the constants with bars are 
taken to be 0(1) and the initial values are given in Table 3.4 (from here on we drop the ·'s) we 
have 
(3.4.1) 
These expressions imply that there are at least three timescales (and there tum out to be four 
more). On the first of these, t = O(e), the procoagulant fibrinogen (ji) decays and is exponen-
tially small on all subsequent timescales. On the second, t = 0(1), APe (ca) increases. The last 
timescale in (3.4.1) has t = 0(1/e), over which both protein C (c) and APe decay, converting 
to inactivated protein C (Cj). The system (3.2.14)-(3.2.19) takes the rescaled form 
dfa 
e...L dt 
dfg 
dt 
d b ~ ~ ~
lit 
dff' 
e-" dt 
for the activated factors and 
dfv = 
dt 
edf;; = 
dt 
e2q4aJ: fii 
fv + 1 + fii 
£k2ak2bf: fv 
fv + 1 + fii' 
k4bfii b ~ : :
fii + k4bm' 
(3.4.2a) 
(3.4.2b) 
(3.4.2c) 
(3.4.2d) 
(3.4.2e) 
(3.4.2f) 
for the procoagulants. This is the system that we analyse, with fi and ca given by (3.4.1). 
To help guide the asymptotic analysis we first solve the nondimensional system (equations 
(3.2.10)-(3.2.20» with the nondimensional parameters set to unity to ensure no complications 
arise associated with small or large parameters that are nominally of 0(1). For example the 
rescaled parameter k4c = 115 is large but not as large as £-1, so for the initial validation we 
set it to unity and, as we see, the asymptotic approximation continues to give viable insight 
even for the original parameter set. We use this parameter set (unity) for all simulations in 
the asymptotic analysis (Section 3.5) and provide a comparison to the original parameter set in 
Section 3.6. Figure 3.3 shows plots for succesively smaller £ to helps us tease out the asymptotic 
structure. 
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Figure 3.3: umerical simulations of the nondimensional model (3.4.1),(3.4.2) with parameter 
values set to one and variable epsilon. The first plot on the bottom row is a blown up region of 
fg showing the initial peak in factor Va concentration. A decrease in produces a substantial 
increase in peak factor Xa concentration, a decrease in APC and a decrease in the injtial pea k of 
factor Va concentration. 
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3.5 Asymptotic analysis 
3.5.1 The first timescale, t =O(e) 
Initially we look at the short timescale that we obtain from equation (3.4.1), where fibrino-
gen decays (it turns out that this is the only variable showing non-trivial behaviour on this 
timescale). We introduce the scalings 
t T (a - 2Fa bxa - 3Bxa = e , Jv - e v' VII - eVil' 
and apply these to the system (3.4.1)-(3.4.2). For T =0(1) we can see from (3.4.1) that (at leading 
order, a qualification we shall subsequently often omit) 
C = Co, ea = kSaco T. 
The remaining system reads 
dl: 
= 
k "f e-'rlacT + e5k3ck3aca B ~ : : _ e2k x - e2k r Fa 
dT la la e3 B ~ : : + 1 Ib II 3a x v' (3.5.1a) 
dFg eBalv k2bl: Iv 3 k'Jb Bxa e3ea Fg 
- el: Fg, dT = (/;)+/< j,+e-va-pa 1 Iv + k2am 1 + i v + 1 + ii q3a v + (3.5.1b) 
d B ~ : : 3k ea Bxa r Fa 2k Bxa e 3cq'Ja va 
dT = q3a x v - e 3b va- e 3 B ~ : : + 1 , (3.5.1c) 
d F i ~ ~
= 
k4al: Iii + ek4ak4blii B ~ : : _ eFa. 
dT Iv + 1 + Iii q4a (fii + k4bm ) . II' (3.5.1d) 
dlv 
= 
e 3 k 2 a F ~ ~ Iv e2k2ak2bl: Iv 
dT Iv + k2am(1 + Ii) /11+1 + Iii , (3.5.1e) 
dk e2q4al: Iii 3k k Bxa II e 4b /I va 
= , dT Iv + 1 + Iii Iii + k4bm 
(3.5.1f) 
which, at leading order, reduces to 
dIll = 0 dlii = 0 dl: _ d F ~ ~ _ k4al: Iii 
dT 'dT 'dT - k11l"fla, dT - Iv + 1 + lu' 
dFg _ k2bl: Iv d B ~ : : _ fa Fa 
dT - Iv + 1 + Ii;' dT - q3a x V' (3.5.2) 
Solving this system sequentially gives 
( ( ( ( fa k T Fa. = k4akla"flaluo T2, 
JII = JVO' Jii = JiiO' x = la"fla, 1/ 2(( 1 () JVO + + JiiO 
Fa _ k2bkla"fla!vo T2 Bxa _ q 3 a k 2 b k ~ a a " f ~ a l v o o y4 
v - 2(fvo + 1 + l;iO) , va - 8(fvo + 1 + liiO) . (3.5.3) 
Fibrinogen (fi), the precursor of fibrin monomers, is included in the model as it competes with 
factor V for thrombin (3.5.1b, 3.5.1e) but, from the reduced aymptotic approximation (3.5.2), we 
can see that fibrinogen in fact plays no role on this timescale (or in the remaining timescales 
that follow). Its conversion into fibrin is of significance for downstream process that we are not 
concerned with here; on subsequent timescales it is exponentially small and henceforth we can 
therefore legitimately simply set it to zero. 
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Figure 3.4: A comparison of the asymptotic approximation (3.5.3) (dotted line) and the numer-
ical solutions of equations (3.2.10)-(3.2.20) (solid line) for those factors dominant on the initial 
timescale t =O(E) with all nondimensional and rescaled nondimensional parameters set to unity 
(e = 1.1 x 10-3). Factors Xa, Va, thrombin and the complex prothrombinase increase. Fibrino-
gen, the precursor of fibrin decays. 
On all of the timescales we will relate the results back to the original network diagram and de-
scribe the relevant terms and their physiological implications. The network diagram in Figure 
3.5 shows in red the reactions that occur at this initial timescale, with all other reactions in blue. 
It can be seen that activation of factor X is reliant on its initial stimulus and is itself responsi-
ble for the subsequent activation of factor V (jv) and for the conversion of prothrombin (jii) to 
thrombin ( j ~ ) . .
Figure 3.4 is a comparison of the full numerical and the asymptotic solutions for those factors 
that exhibit non-trivial behaviour on this timescale. All nondimensional, rescaled nondimen-
sional parameters and procoagulant initial conditions are set to one: this allows us to assess the 
validity of asymptotic approximation on this timescale and we will use this parameter set for 
all simulations in this section (3.5) unless otherwise stated. 
3.5.2 The second timescale, t =0(e2/ 3 ) 
We obtain the scalings relevant to this timescale from the large time behaviour of the previous 
timescale (3.5.3). For example, since F i ~ ~ is growing like r2 we infer that, with the next reac-
tion entering being the second term in equation (3.5.1d) (whereby the complex prothrombinase 
catalyses prothrombin to thrombin), F i ~ ~ = £ - 2 / 3 t ~ . . This procedure is followed in the following 
timescales. The scalings for this timescale are given by 
r = £-1/3t Fa - £-l/3pa Fa - £-2/3t.a Bxa - £-4/3axa Fa. = £-2/3ta. Ca = E-1/ 3t a 
, x - x' v - v' va - va' II II' • 
Under this rescaling equations (3.5.1) become (with Ii, as already noted, henceforth set to zero) 
(3.5.4a) 
(3.5.4b) 
(3.5.4c) 
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Figure 3.5: Reactions dominant on the initial timescale. Reactions in red are those relevant to the timescale shown with all other reactions in blue. Protein C is 
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Figure 3.6: A comparison of the asymptotic approximation (3.5.6, 3.5.7) (dotted line) and the 
numerical solutions of equations (3.2.10)-(3.2.20) (solid line) for those factors dominant on the 
second timescale with all nondimensional and rescaled nondimensional parameters again set to 
one (€2/3 ~ ~ 0.01). The sole extra term in the asymptotic approximation on this timescale causes 
thrombin ( b ~ : ) ) production to accelerate. 
d t ~ ~ k4a t : b k4ak4bl;; a ~ : : 2/3 ta (3.5.4d) 
dT = + -E ii' Iv + 1 + Iii q4a (fii + k4bm ) 
dlv 
= 
E 2 k 2 a t i ~ / v v E4/3k2ak2bt : Iv (3.5.4e) 
dT Iv +k2am Iv + 1 + Iii 
, 
dlii E4/3q4at :lii E 4 / 3 k 4 b ~ " "Bxa (3.5.4f) = II va dT Iv + 1 + Iii Iii + k4bm 
At leading order these reduce to 
d Iv _ 0 d Iii _ 0 d t: k 
dT - , dT -, dt = 1a')'1a, 
dtg k2bt: Iv d a ~ : : tat.a d t i ~ ~ _ k4a t:lii + k4ak4bl;;Bt: . 
-t = f 1 f' dT = q3a x v' -t - f 1 f (f k ) d JV+ +Jii d JV+ +Jjj q4a J;i+ 4bm (3.5.5) 
Solving equations (3.5.5) sequentially and matching to the initial timescale with the limit T ~ ~
+00 on the first timescale gives 
Iv = Ivo' Iii = I;io, 
tg = k1a')'lak2blvo 12, 
2(fvo + 1 + liiO) (3.5.6) 
as on the previous timescale. The sole extra term is in the equation for thrombin generation 
where the action of prothrombinase ( a ~ : ) ) on prothrombin (fi;) accelerates prothrombins con-
version to thrombin. Here 
(3.5.7) 
Figure 3.6 is a comparison of the full numerical and the asymptotic solutions on this timescale. 
As stated above, we set all dimensional and rescaled nondimensional parameters to one. The 
reactions that are functioning on this timescale are shown in Figure 3.7. 
3.5.3 The third timescale, t =O(E1/ 2) 
From the 1 ~ ~ +00 behaviour of (3.5.4) it follows that the next terms to come into play are the 
second and fifth ones of equation (3.5.4b), whereby factor Xa catalyses the activation of factor 
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V and factor Va is assembled into the complex prothrombinase. We thus obtain the scalings 
relevant to this timescale as 
which, when applied to the equations (3.5.4), give the system 
k 'V e-"rlacI/2t + E5/2k3ak3cca B ~ : : _ E3/2k fa _ El/2k fa fa 
Iada E B ~ g + 1 1 Ib x 3a x v' 
dfa x 
= df (3.5.8a) 
f ~ ~ Iv k2b f: Iv 3/2 k3b i'.xa E2Ca fg i<a i<a 
f k + f ' + E -Dva - f - rx rv' v + 2am v + 1 + J ii q3a E g + 1 
dfa v 
= df (3.5.8b) 
fa fa 3/2k Bxa E2k3cQ3aca R ~ : :
q3a x v - E 3b va - E B ~ g g + 1 ' 
dRxa va 
= dt 
(3.5.8c) 
d f i ~ ~
df = 
EI12k4a f : Iii + k4a k4b!u R ~ : : _ El/2pa. 
Iv + 1 + Iii q4a (Jii + k4bm ) II' 
(3.5.8d) 
Ek2a f t;fv Ek2a k2b f : Iv 
Iv + k2am Iv + 1 + Iii ' 
dlv 
= dt 
(3.5.8e) 
EQ4af: Iii El12k4dii R ~ : :
Iv + 1 + Iii Iii + k4bm . 
dlii 
= dt 
(3.5.8f) 
At leading order, Iv = Ivo, Iii = liio' and f: = kla/la t still hold, and (3.5.8) reduces to the 
third-order linear system 
(3.5.9a) 
(3.5.9b) 
which requires numerical solution (with initial conditions (namely tg = R ~ : : = t i ~ ~ = 0 at t = 0) 
obtained by matching to the previous timescale) and this indicates (see Figure 3.8) that tg, B ~ g g
and f ~ ~ grow exponentially as t -+ +00. To construct appropriate scalings for the next timescale 
we extract the large-time behaviour: looking for a solution of the WKB form 
we find on substitution (see AppendiX A) that 
A = J q3ak4a k4b Ivo liio / (q4a (lvo + k2am) (liiO + k4bm», 
f3 = - (A2 + 2kIalla) / (2kIa/la), 
the value of the constant '1 depending on the evaluation over t -+ +00, moreover 
nxa f'V IJ q3a kla Ila t ~ + 1 e A t t
va A ' 
Fa. f'V '1 k4a k4b q3a kla Ila{iiO tf3+1eAt as t -+ +00. 
1/ Q4a(liiO + k4bm )A 
(3.5.10) 
(3.5.11) 
(3.5.12) 
(3.5.13) 
(3.5.14) 
Figure 3.9 compares the numerical solutions to the full governing equations with the numerical 
solution of the reduced system (3.5.9). Figure 3.10 compares numerical solutions of the reduced 
39 
system (3.5.9) with the asymptotic approximations (3.5.10,3.5.13, 3.5.14). tJ is obtained to fit the 
curve - see Figure 3.11 (A ~ ~ 2.08, f3 ~ ~ -1.02 holds for the parameters given in Table 3.5 and 
A ~ ~ 0.50, f3 ~ ~ -1.13 holds for parameters set to unity.). 
It is on this timescale that we move from the initiation phase to the propagation phase, in which 
thrombin levels have their characteristic explosive growth. Physiologically we can deduce from 
the system (3.5.9) that thrombin's dominant activation mechanism is through prothrombinase, 
factor Xa now having little effect. Factor Va is activated both by factor Xa, as at the previous 
timescales, and by the inclusion of the positive feedback of thrombin. This feedback loop from 
thrombin accelerates thrombin's own generation through the assembly of prothrombinase (see 
Figure 3.12). There is also a conversion term that is dominant for the assembly of factor Va into 
the cofactor VaXa. These reactions and others dominant on this timescale are shown in Figure 
3.13. 
3.5.4 The next two timescales: the reduced 6 model 
Considering the large time behaviour of the previous timescale, whereby Ig f'V tJftleAt, we can 
infer that the next timescale can be expected to be of the form 
f = t In(l/E) - t In In(l/E) + f (3.5.15) 
which when substituted into the large scale behaviour of the previous timescale brings it al-
gebraic. The constants 1> and 'r are yet to be calculated. Using this timeshift and the large 
time behaviour of the variables from the previous timescale we can see that the appropriate 
matching conditions take the form that 
and we have 
I: f'V k1a'rlat In(l/E), I ~ ~ f'V E--r (t)tl (In(l/E))tl-1/I tJeAt, 
~ ~ : : '" e-'Y (t) tl+I (In(l / e) l+1-1/1 tJ q3a ~ I a a 'rIa eA t, 
II:'. fV E--r (2) J!+I (In(l / E) )J!+1-1/1 tJk4a k4b q3a kta 'rIa bo eA t, 
"A q4a(bo + k4bm)A2 
We now introduce the notation 
1 
0= In(l/e)' 
(3.5.16) 
(3.5.17) 
(3.5.18) 
(3.5.19) 
whereby 0 < E < < 0 < < 1 (in practice, and as usual in such problems, 0 is not particularly 
small; in fact 0 ~ ~ 0.15 for E = 1.1 x 10-3), and this implies the scalings 
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Figure 3.8: Numerical solutions for the system (3.5.9) showing the unbounded growth of factor 
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under which equations (3.5.8a) give 
(3.5.20a) 
dIg 
df = 
(3.5.20b) 
£2 (!) k3cQ3ac;a n ~ : :
= t<a t<a 3/2k >'Ixa Q3a1"x 1"v - £ 3b D va - (tl+l-fl ' 
E1-1' (!) nt: + 1 (3.5.20c) 
1/2+1' (1) (-IHf) k t<a ( 
E 1 4al:x Jii k4ak4blii n ~ : : 1 t<a 
= + -£21";;, 
Iv + 1 + Iii q4a (fii + k4bm ) 
(3.5.20d) 
dlv 
= dt 
1-'" (1)(tl+l-fl k t<a ( (1) k k t<a ( E ' 'S 2a1"i;Jv E 'S 2a 2bl:x JV 
Iv + k2am Iv + 1 + I;; 
(3.5.20e) 
(1) t<a ( 1/2-1' (1)(tl+l-f)k (,' >'Ixa E 1 q4al:x Jii E 'S 4bJII "va 
Iv + 1 + Iii Iii + k4bm 
dlii 
= dT (3.5.20f) 
To bring into balance the second term in (3.5.20f), the equation for prothrombin (f;;), we need 
to take 'Y = 1/2 and cp = f3 + 1. This results in the rescalings now being 
t= Ts +t 
~ ~
where 
~ ~ = -.!.. _ (f3 + 1) 15 In (!) 
s 2A A 15 (3.5.21) 
and 
~ a = " , , - I / 2 . r t < a a I'.xa_ -1/2Xxa [:a_ -112[:a "a_ (1)[:a )lI.a_ (l))lI.a (3522) 1"v '" CJ1"v, "va - E "va' ii - E ii' 1"x - "J x' l.. - "J l.., .• 
with the matching conditions (from (3.5.19» being that as t -+ -00 (with It I « 15-1) 
t: '" k1a'YlaTs + ~ k l a ' Y l a t , , tg '" ( 2 ~ ) t l l t]eAt, (3.5.23a) 
n ~ : : '" t]Q3a k la'Yla (-.!..)tl+1 eAt ta. '" 1J k4a k4hQ3a k la'Ylaliio ( ~ ) t l + l l eAt 
A 2A '/I Q4a(fiiO + k4hm )A2 2A ' 
(3.5.23b) 
we impose these conditions numerically at t = -5 with Ts taken from (3.5.21). Ts ~ ~ 1 (with 
parameters set to unity), so that (note that 0 ~ ~ 0.15, so in the first of (3.5.23a) the first term on 
the right hand side dominates the second) 
45 
It ;'J I t , , J J l h : . ~ ~ J J
600 3" 10. 3 0.4 
500 
c: 0 .3 
.2 400 
E 
,,300 0 .2 
" u 
5200 
U 0 .1 
100 
0.5 0.5 00 0 .5 
l l l ~ ) ) ll ,) 
1.5 
0.8 
c: c: 
0 1 0 
. ~ ~ 'g 0.6 
c: c: 
" 
~ ~ 0.4 g 0.5 c: 
0 0 
u U 0.2 
0.5 0 .5 
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model with parameters values set to unity. Ts ~ ~ 1 which applies over ~ O O e l / / ) ) of that va lue 
with e1/2 ~ ~ 0.03. 
Ignoring terms that are algebraically sma ller in e (but retaining a ll the 0 terms) we obtain 
dfv 
dt' 
da xa va 
dt' 
0, rdFg _ F ~ ~ f v _ I'a 1'0 o t' - f k t"x t"v ' d v + 20m (3.5.24a) 
d F ~ ~ ( i"a i"a) dt' = is k 1a 'Yla - k 3at"xt"v ' 
d F ~ ~ k4ak4bfii a ~ g g
dt' = q4a (fii + k4bm) , 
dfii k 4 b f i i i ~ g g
dt' = - fii + k4bm . (3.5.24b) 
which we term the reduced 0 model. This reduced model is represented phYSiologically in the 
network diagram shown in Figure 3.15. This system is valid to all logarithmic orders in e (i.e. 
algebraic orders in 0) and is therefore a useful simplification in its own right, Figure 3.14 shows 
the reactions dominant in this model against the full governing equations. Nevertheless, we can 
simplify it further by taking the limit 0 -+ 0 and this subsidiary asymptotic limit itself involves 
consideration of two distinct timescales. The following expressions are exact for (3.5.24): 
(3.5.25) 
3.5.4.1 The fourth timescale, t - e1 12ln 1/ eTs = O(e l12) 
Using the reduced 0 model (3.5.24), we obtain at leading order in 0 (using the matching cond i-
tions (3.5.23» 
Fa = k1a'Yla pa _ fVD F ~ ~
x 2,\' v - (fvD + k2am) Ff (3.5.26) 
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Figure 3.16: A comparison of the system (3.5.27) (dotted lines) and the numerical solutions of 
the full governing equations (3.2.10)-(3.2.20) (solid line) for those factors dominant on the fourth 
timescale with parameter values set to unity. 
and the third-order system 
d F i ~ ~ k 4 a k 4 b b i i i ~ g g
df = q4a (fii + k4bm) , 
dJii k 4 b J i i i ~ g g
- =- I 
df Jii + k4bm (3.5.27) 
which can be reduced to second order using the last of (3.5.25), and is therefore amenable to 
phase plane analysis (and is in fact separable). From the numerical solution (Figure 3.16) of 
(3.5.27), we can see that at large time prothrombinase ( ( ~ ~ ) ) is linear, thrombin tends to constant 
and prothrombin is exponentially small (and will no longer be tracked). (3.5.25) implies that 
fg --+ ~ J i i O O as f --+ +00. We use the large time behaviour for the calculation of the scalings for 
the next timescale. Thus as f --+ +00 we have 
(3.5.28) 
and Jii decays exponentially, with 
In .k ,....., _! Q3aJvo k4aJiio k4b f2 
/I 2 (fvo + k2am) Q4a k4bm (3.5.29) 
A comparison of the system (3.5.27) and the numerical solution of the full governing equations 
(3.2.10)-(3.2.20) for those factors dominant on timescale 4 can be seen in Figure 3.16. A com-
parison of the system (3.5.27) and the reduced 6 model (3.5.24) for those factors dominant on 
this timescale can be seen in Figure 3.17. Physiologically we can deduce from this system of 
equations that the activation of factor V is no longer reliant on factor Xa but is totally reliant on 
the positive feedback loop from thrombin, and this can be seen in Figure 3.15 (a schematic of 
the reactions dominant for the reduced delta model and for timescale 4). 
3.5.4.2 The fifth timescale, t - c1 12ln 1 / cTs = 0 (c1/2 ln ( ~ ~ ) ) 
At this timescale we are still able to use the reduced 0 model (3.5.24); on the basis of (3.5.28) we 
obtain a new balance in the equations for factor Xa and factor Va by rescaling f = ( ~ ) ) Tt and 
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10 
~ ~ ~ ~ = ( ~ ) ) 8 8 ~ : , , under which (3.5.24) gives 
dtf k k i<a i<a .(2 dtg _ t ~ ~ I vo _ i<a I'a (3 5 30 ) 
dTt = ]a{']a - 3a'x'v' "dTt - I vo + k2am 'x l"v ' .. a 
d ~ ~ ~ ~ t a pa b2 d t ~ ~ _ k4ak4blii ~ ~ ~ ~ b2 d l i ~ ~ = _ k41dii ~ ~ g g . (3.5.30b) 
dTt = q3a x v' dTt - q4a (fii + k4bm) , dT Iii + k4bm 
At leading order in b, with Iii exponentia lly small, we thus have 
d t: k i<a i<a t ~ ~ I vo I'a I'a 
dTt = ]a{'la - k3a ,x ' v' 0 = f k - 'x'v' vo + 2am 
d8 xat va _ t a Fa dTt - q3a x v 
d d ~ ~
'di; = 0 (3.5.31) 
Matching to the previous timescale at Tt = 0 gives 
t a x = 
= 
(k 
'" _ k I voF;io ) Tt + k 10{'la 1a da 30 f + k 21 ' (3.5.32a) 
vo 2am /I. 
( 
Q3nlvoF;io ) Tt. 
I vo + k20m 
(3.5.32b) 
For the original parameter set and with rescaled nondimensional parameters set to unity we 
have k1a {'1a > k3a/ '!iuo (Le. 1 > 0.5). This inequality corresponds to two classes of va 20m 
behaviour within the asymptotic analysis and with an alternate parameter set factor Xa (in 
particular) can in consequence display qualitatively different behaviour. Willems et al. (1991) 
used parameter values similar to ours except k1a was three orders of magnitude lower so that 
k1a {'la < k3a l ~ ' ! i ~ m ' ' Figure 3.18 shows a comparison of simulations of the numerical solutions 
of equations (3.2.10)-(3.2.20), with the rescaled nondimensional parameters set to unity (full 
line), and with the rescaled nondimensional parameters set to unity except for k1a = 0.001 (a 
reduction in three orders of magnitude). With the parameter value adjusted Factor Xa displays 
two peaks in its concentration. However, the time to reach peak concentration and the peak 
concentration in thrombin concentration is similar in the two simulations. We will not pursue 
the asymptotics of this second regime here. 
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Figure 3.18: Numerical solutions for the full nondimensional system (equations (3.2.10)-(3.2.20)) 
showing a comparison between simulations with all nondimensional rescaled parameters set to 
unity (solid line) and simulations with all nondimensional rescaled parameters set to unity ex-
cept kta = 0.001 (broken line) . With the parameter kta adjusted down Factor Xa displays two 
peaks in its concentration. Factor Va displays a solitary peak in concentration and prothrombi-
nase formation is substantially reduced . However, the time to reach peak concentration and the 
peak concentration in thrombin concentration is similar in the two simulations. 
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Figure 3.20: A comparison of the asymptotic approximations (3.5.32) (dotted lines) and the 
numerical solutions of equations (3.2.10)-(3.2.20) (solid line) for those factors dominant on the 
fifth timescale with all nondimensional and rescaled non-dimensional parameters set to one. 
Physiologically, at this timescale, we can see that the assembly of factor Xa into the cofactor 
prothrombinase now becomes a dominant reaction. This, and the other reactions dominant on 
this timescale, are shown in Figure 3.21. A comparison of the asymptotic approximation (3.5.32) 
at this timescale and the reduced delta model (3.5.24) are shown in Figure 3.19. A comparison of 
the asymptotic approximations (3.5.32) and the numerical solutions of the full nondimensional 
model (3.2.10)-(3.2.20) for those factors dominant on the fifth timescale is shown in Figure 3.20. 
3.5.5 The sixth timescale, t = 00) 
We now return to the original € model (3.5.20) with the rescalings for the fifth timescale applied. 
As t = 0(1) applies on the current tomescale, we now include the equations for APC (ea) and 
protein C (c). Considering the large time behaviour of timescale five bringing into balance the 
terms for the depletion of factor V we deduce the new sca lings for this timescale. While we 
introduce Tt here for consitency Tt = t in fact applies in what folJows: 
Tt = O€ - 1/2Tt pa = o€- l/2Fat pa = 0- 1€1/2Fat Bxat = & - l/2Bxat ""a = & - l/2Cat. 
'x x' V v ' va va' l-
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featured reactions and green representing reactions in equilibrium) with all other reactions in blue. The feedback mechanism and factor Va's participation in 
prothrombinase formation is still in equilibrium. Thrombin formation from prothrombin is no longer dominant but factor Xa evolves. 
Applying these sea lings results in the system 
dPt k k CatBxat x 
= 
k 'Y e-1'la71 + E 3c 3a va _ Ek Fat _ k Fat Fat (3.5.33a) dTt la la Bxat + 1 Ib x 3a x v' va 
drat F i ~ t t Iv + k2b F;tlv + /3b Bxat _ fCa*Fg* _ Fat Fat (3.5.33b) v E dT* = Iv + k2am Iv + 1 q3a va Fg* + 1 x v' 
dBxat k C t8xat va 
= Fat Fat k 8xat Eq3a 3c a va (3.5.33c) dT* q3a x v - f 3b va - 8 xa* + 1 
, 
va 
dF!l.t - F i ~ t , , (3.5.33d) II = dT* 
dCat 
kSac - kSbCat, (3.5.33e) dT* = 
dlv 
= 
k2a Fn* Iv k2ak2b F;* Iv (3.5.33f) dTt Iv + k2am Iv+ 1 
dc 
-Eksac. (3.5.33g) dTt = 
Thus, at leading order c is still constant and matching to the previous timescale results in the 
explicit expressions 
(3.5.34a) 
(3.5.34b) 
and the system of differential equations 
drat k -1'1.71 k Fat Fat x 
= dTt la'Ylae - 3a x v' (3.5.35a) 
d8 xat Fat Fat va 
= dTt q3a x v' (3.5.35b) 
dlv 
= 
k2a Fntlv k2ak2b F;t Iv 
dT* Iv + k2am Iv +1 
(3.5.35c) 
This system of differentiable equations is not easily solvable. From equations (3.5.34a), (3.5.35a), 
(3.5.35b) we can see that 
(3.5.36a) 
(3.5.36b) 
From equation (3.5.36) we can see that, with parameters set to unity, we are on a bifurcation 
point that depends on the initial concentration of the procoagulant factor V (fvO). Figure 3.22 
illustrates the effect of varying the initial concentration of the procoagulant factor V by compar-
ing simulations of the full nondimensional model with all parameters and initial conditions of 
the procoagulants set to unity except factor V, which is varied. With Iv = 0.5 factor V settles to 
a positive constant and, when compared to setting Iv = 1, the peak concentration of factor Xa 
is reduced. On the other side of the bifurcation with Iv = 2 factor V decays to zero but factor 
Xa peak concentration increases. 
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Figure 3.23 shows a comparison of the full nondimensional system (equations (3.2.10)-(3.2.20)) 
and the asymptotic approximations (equations (3.5.34), (3.5.35)) for those factors dominant on 
the sixth timescale. Three sets of simulations are shown. The top set (Figure 3.23 A) with initial 
concentration of the procoagulant factor V set to one where we the concentrations of factor Xa 
(F:t) and factor V (jv) decay. With a lower initial concentration of the procoagulant factor V 
(jv = 0.5), factor V now decays exponentially but factor Xa settles to a positive constant (Figure 
3.23 B). The final set of simulations (Figure 3.23 C) has the initial concentration of factor V set 
to 2, we are the other side of the bifurcation point and factor Xa decays exponentially but factor 
V settles to a positive constant. The asymptotic approximations show good agreement for all 
three sets of simulations. 
From Figure 3.23 we can see that as Tt -+ +00 thrombin (F!;t) decays exponentially and will 
henceforth no longer be tracked, and so within these six timescales we have now captured 
the complete evolution of thrombin formation. The remaining factors are still evolving but 
their evolution over the remaining timescales is difficult to capture due to the delicate balance 
between factor Xa and factor Va. From the numerical solutions in Figure 3.23 we can see that 
prothrombinase ( B ~ : t ) ) and APC (cat) tend to constants but the evolution of factor Xa and 
factor Va depends on the initial concentration of factor V. We attempt to follow the asymptotic 
analysis assuming factor Xa is not depleted and settles to a positive constant. The border line 
case with factor Xa and factor Va depleting will be very delicate and so will not be followed. 
From 3.S.33b we observe that Factor Va will increase again as APC and factor Xa decay but the 
timescale over which this occurs will depend on the decay rates and will not be discussed here 
where we assume factor Va is small and set to zero. The dominant reactions relevant at this 
timescale are shown in Figure 3.24. 
3.5.6 The seventh timescale, t =0(£-1) 
Considering the large time behaviour of the previous timescale we find that to move from the 
sixth to the final timescale requires only Tt to be rescaled (Tt = £-1 TO) since all other variables 
are henceforth negligble or are constant for large Tt giving 
k k CatB1'at k e-1T" E 3a 3c va k Fat = la'Ylae + * - E lb x , B ~ g g + 1 
(3.5.37a) 
dB1'at - k 3 b B ~ ; t t - q k CatB1'nt va 3a 3c va dTQ = B1'a* + 1 , va (3.S.37b) 
dCnt kSac - kSbCat, £ dTO = (3.5.37c) 
dc 
-kSac, = dTQ (3.S.37d) 
To leading order, matched to the previous timescale and solving sequentially where possible 
we obtain 
(3.5.38a) 
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Figure 3.22: Numerical solutions for the full nondimensional system (equations (3.2.10)-(3.2.20)) 
showing how al\ factors evolve when the initial concentration of the procoagulant factor V is 
varied. All other initial concentrations of the procoagulants and the rescaled nondimensional 
parameters are set to one. Significant differences are seen in the evolution of factor V, factor Xa, 
factor Va and prothrombinase but not in thrombin concentration. 
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Figure 3.23: A comparison of the numerical solutions for the asymptotic approximations (equa-
tions (3.5.34), (3.5.35)) and the numerical solutions of the full nondimensional system (equations 
(3.2.10)-(3.2.20)) (solid line) for those factors dominant on the sixth timescale with all nondi-
mensional and rescaled non-dimensional parameters set to one except the initial concentration 
of factor V which is varied. A - lvO = 1, B - l vO = 0.5, C - l vO = 2. 
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Figure 3.25: A comparison of the numerical solutions for the system (equations (3.5.39)) (dotted 
line) and the full nondimensional system (equations (3.2.10)-(3.2.20)) (solid line) for those fa c-
tors dominant on the seventh timescale with all nondimensional and rescaled non-dimensional 
parameters set to one. 
and the system of differential equations 
10' 
dFnt 
x 
dTo 
k k CntBxat 3n 3c va k at 
Bxat + 1 - lbFx ' (3.5.39a) 
dBxat va 
dP 
va 
q k cat Bxat k Bxat 3a 3c va 
- 3b va - Bxat + 1 
vn 
(3.5.39b) 
This system reveals that the remaining factors are depleted by the various inhibitory systems. 
The numerical solutions for this reduced system against the full governing equations can be 
seen in Figure 3.25 (matching conditions for F;t, B ~ ~ t t and cat obtained numerically). Factor 
Xa and prothrombinase are inactivated by antithrombin III (prothrombinase is also inactivated 
by APC) and levels of protein C and APe also fall. These final dominant reactions are shown 
in Figure 3.26. 
3.6 Comparison 
We have provided evidence above that the asymptotic analysis is valid, by setting most of 
the dimensional parameters to one. We now compare simulations with parameter values taken 
from the literature (Tables 3.3 and 3.5) with simulations with the rescaled parameters and initial 
conditions set to unity (see Figure 3.27). We note that some parameters are not 0(1). These 
simulations (Figure 3.27) demonstrate that significant differences arise for many factors but, 
when we compare the asymptotic approximations with the numerical simulations of the full 
parameter set, we find that the asymptotics sti ll provides useful approximations and insight. 
With parameter values from the literature (Tables 3.3 and 3.5) factor Xa (Figure 3.27 first plot, 
second row) displays a greater peak concentration (the level of stimulus of factor Xa is now 
k1a = 166) than when the nondimensional parameters where set to unity. Prothrombinase, 
assembled from factor Xa and Va, displays earlier and greater peak concentration and this is 
reflected in the increase in peak thrombin concentration. Activated protein C shows a marked 
increase in peak concentration attributable to the factor C initial concentration (co = 92) not 
being 0(1). Factor Va has a single rise and faU in concentration, settling to a negligible value 
whereas with parameter values set to unity a second peak concentration occurs with factor Va 
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Figure 3.26: Reactions dominant on the seventh timescale. Reactions in red and black are those relevant to this timescale (red arrows representing newly 
featured reactions) with all other reactions in blue. 
settling to this value. This can be attributed to prothrombinase production which now occurs 
earlier. Factor Va released from the prothrombinase complex, when factor Xa is inactivated, can 
be effectively inactivated by activated protein C, now produced at a greater concentration. 
We now compare the asymptotic approximations at each timescale to the full nondimensional 
model. Figure 3.28 compares the asymptotic approximations at timescale one and two with the 
numerical solutions of the nondimensional model. Figure 3.29 compares the asymptotic ap-
proximations at timescale three with the numerical solutions of the nondimensional model. 
This shows close agreement and is where we see factor Va, prothrombinase and thrombin 
growing rapidly. Figure 3.30 compares the asymptotic approximations of the reduced 6 model, 
that encompasses timescale four and five, with the numerical solutions of the nondimensional 
model and Figure 3.31 compares the asymptotic approximation at timescale six with the nu-
merical solutions of the nondimensional model. 
While the foregOing asymptotic analysis does not quantitatively describe all the behaviour for 
parameter values taken from the literature (due to the large number of parameters, some of 
which do not fit naturally within the asymptotic scalings), it does provide considerably quali-
tative insight into the dominant mechanisms, as we now attempt to summarise. 
3.7 Discussion 
As stated previously, the process of thrombin generation is an intricate system of fine tuned 
checks and balances. With this time-dependent asymptotic analysis we have aimed to demon-
strate the step by step processes involved. The complexity of the cascade is highlighted by the 
multiple timescales that this system operates under and this demonstrates how an asymptotic 
analysis can enhance our understanding of biological models in general. The seven timescales 
discussed and their relationship to thrombin generation can be seen in Figure 3.32 and we 
describe each of these timescales below. 
TImescale one, t =O(e). At timescale one we can see that the high stimulus produces robust 
activation of factor X which subsequently activates factor V and prothrombin. At this timescale 
the activation of prothrombin only produces small amounts of thrombin but this is sufficient 
to convert fibrinogen to fibrin. Fibrinogen decays but plays no role on this, and subsequent, 
timescales. 
TImescale two, t =O(€2/3). The asymptotic approximation for timescale two resembles that 
for timescale one. The sole additional term is prothrombinase activation of prothrombin, this 
accelerates thrombin's formation. Timescale two encompass all the reactions of timescale one 
except fibrinogen decay, but fibrinogen plays no role in the previous timescale and so timescale 
one can be neglected. 
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Figure 3.27: A comparison of the numerical solutions of the full nondimensional system (equa-
tions (3.2.10)-(3.2.20)) with the original parameter set (solid line) (Table 3.3 and 3.5) and with the 
rescaled nondimensional parameters and the initial concentrations set to unity (broken line). 
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Figure 3.32: Timeline of asymptotic timescales shown against the simulation of thrombin. 
Timescale three, t =0(101 / 2). It is at timescale three that thrombin displays its characteristic 
explosive growth. At this timescale it is the action of the complex prothrombinase which 
solely activates prothrombin to thrombin. The large growth in thrombin generation can be 
accounted for by the inclusion of the positive feedback from thrombin to the activation of factor 
V; factor Va subsequently being assembled with factor Xa into the complex prothrombinase, 
A closed loop is formed (see Figure 3.12) and thus thrombin enhances its own activation. 
In dimensional form.A = k4b k2a Jvo Jiio / ( k ~ c c (fvo + k2am / k2b",) (fiiO + k4/J", / k4nm )) and 
suggests that thrombins explosive growth is dependent on the initial concentrations of factor 
V and prothrombin as well as the rate that prothrombinase catalyses prothrombin to thrombin, 
the rate that thrombin activates factor V and the rate that ATIII inactivates thrombin. 
The reduced 0 model: timescale four and five. With a timestep of approximately 
ts ~ ~ El/2ln (1/10) tx we capture the peak in factor Va and thrombin concentration. Thrombin 
generation settles to a constant and factor Va concentration starts to fall. Prothrombin, the 
procoagulant of thrombin declines to zero and prothrombinase and factor Xa continue to rise. 
The timeshift at the reduced delta model can be seen as an approximation of the time lag to 
where the large bolus of thrombin concentration is achieved. 
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Timescale six, t =0(1). It is at this timescale that thrombin is inactivated by the action of 
antithrombin III and we see a decline in thrombin levels. Protein C has yet to playa role. 
Timescale seven, t =0(e-1). The remaining inhibitory processes take their effect. Activated 
protein C inactivates factor Va complexed within prothrombinase releasing factor Xa. AIIII 
acts on factor Xa, both within the prothrombinase complex and with out to sequester it to its 
inactive form. The procoagulant protein C decays. 
TImescale six (where we see thrombin decay) and timescale three (where the thrombin concen-
tration increases rapidly) capture the majority of reactions for the formation and inhibition of 
thrombin. 
Within this chapter we have formulated a model that encompass a reduced subset of reactions 
of the coagulation cascade. We have, using Singular-perturbation theory, produced a series of 
reduced models in time that provide insight into the underlying mechanisms responsible for 
thrombin's characteristic time lag, explosive growth and decay. 
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CHAPTER 4 
The thrombin generation assay. 
4.1 Introduction 
Clinical testing of the bloods potential to clot requires, at present, two distinct tests that, while 
widely performed, are blunt and unreliable at detecting new anticoagulant therapies. A new 
clinical test is required and it is thought that the thrombin generation assay (TG) may fulfill 
this role. These experiments allow assessment of the entire coagulation system in plasma. The 
more traditional PT and aPTT assays (described in Sections 2.1.1.1 and 2.1.1.2) terminate with 
the formation of a clot, which occurs when only five percent of thrombin is generated. While 
these are useful in identifying congenital abnormalities, the newer thrombin generation assay 
provides a more accurate description of thrombin generation showing its complete evolution, 
which is relevant for the formation of a blood clot in-vivo, its lag-time and peak concentration 
(Mann et al., 2003). It is possible to watch the concentration of thrombin as it develops in clot-
ting (platelet-rich) plasma and activation is achieved via the more physiologically relevant TF 
rather than via contact activation. 
There is great interest in finding new therapeutic means to disrupt the pathological formation 
of blood clots (thrombosis), as existing drugs target multiple factors within the coagulation cas-
cade and, as a result, have the unwelcome side effect of excessive bleeding. There is particular 
interest in factors XI and XII as therapeutic targets since they are thought to play key roles 
in thrombosis but lesser ones in haemostasis. This makes them ideal candidates for limiting 
thrombus growth, without producing the side effect of excessive bleeding (Gailani & Renne, 
2oo7a). Factor XI appears to lower the incidence of ischaemic stroke in humans and reduce 
thrombus formation in mice (Renne et al., 2006) and, while it seems to playa supportive role 
in haemostasis, a severe factor XI deficiency does not generally produce bleeding tendency 
(Gailani & Renne, 2oo7a). 
There has been some controversy surrounding the activation mechanism of factor XI. While 
it is known that factor XI is activated by factor XlIa, as reflected in the intrinsic pathway and 
the aPPT assay, it is thought that there is an alternative method of activation (Gailani & Renne, 
2oo7a) with congenital deficiencies of factor XII (normal bleeding and a prolonged aPTT) and 
of factor XI (a mild bleeding disorder) being consistent with the existence of an alternative 
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pathway to factor XI activation (Kravtsov et al., 2009). Candidates for activating factor XI in-
clude thrombin and factor XIa auto-activation (Naito & Fujikawa, 1991; Gailani & Broze, 1991). 
While recent studies (Kravtsov et al., 2009; Wielders et al., 2004; Keularts et al., 2001; Oliver et al., 
1999) suggest that the alternative pathway may involve a feedback loop from thrombin, this re-
sult is at variance with other studies (Pedicord et al., 2007) including the theoretical work of 
Kramoroff & Nigretto (2001). Both of these papers suggest that factor XI is auto-activated. 
In this chapter we formulate and analyse a mathematical model that mimics the thrombin gen-
eration assay and use this for investigating the contribution of the intrinsic pathway and factor 
XI to thrombin generation. We extend our previous model of the common pathway of the coag-
ulation cascade by incorporating the intrinsic and extrinsic pathways and factor XI activation 
via thrombin. This allows us to use the resulting system of twenty-nine ordinary differen-
tial equations to produce simulations that we can compare to the experimental work on factor 
XI activation in tissue factor stimulated plasma in the absence of factor XII (Kravtsov et al., 
2009). The results of Kravtsov et al. are consistent with the existence of a feedback loop that 
links thrombin to factor XI and contributes to coagulation in the absence of factor XII. Previous 
mathematical models that include an explicit feedback mechanism from thrombin to factor XI 
(Zarnitsina et al., 1996b; Kramoroff & Nigretto, 2001) are formulated so that they are compara-
ble to experimental data based on the aP'IT assay. Such models do not account for the whole 
coagulation system and are activated via the contact system. 
This chapter is organised as follows. In the next section we develop our model; we describe 
in detail the reactions included in the model and the roles they play within the coagulation 
cascade, we discuss the assumptions which we have made and present the model in full. In 
Section 4.3 we numerically solve subsystems of our model, evaluating the contributions they 
make to thrombin generation in terms of peak thrombin production and time to reach this 
peak. Parameter values are restricted to those found in literature (Table 4.4) and we set initial 
conditions to the levels typical of human plasma (Table 4.3). Model simulations are compared 
to the experimental work of Kravtsov et al. (2009) and are able to detect the contribution to 
thrombin generation of thrombin activation of factor XI. We discuss these results, and further 
modifications that could be made to the model, in Section 4.4. A detailed review of the relevant 
biology and previous mathematical models was presented in Chapter 2. 
4.2 Mathematical model 
4.2.1 Formulation 
In this section we construct a new kinetic model of the coagulation cascade which can be used 
to simulate experiments (Kravtsov et al., 2009) conducted with a Thrombinoscope®. The model 
consists of a system of ordinary differential equations which describe the changes in concen-
tration of factors within the coagulation cascade. We extend the model of thrombin formation 
presented in Chapter 3 to include those factors of the extrinsic and intrinsic pathways. The 
model excludes factors of contact activation so as to mimic experiments carried out in plasma 
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deficient in factor XII. We include three feedback loops from thrombin: to factor V, to factor Vlll 
and, controversially to factor XI. To facilitate a step-by-step description of the model we have 
decomposed the cascade into eleven reactions summarised in Table 4.1, in which we also dis-
tinguish those present in the previous model. We describe the reactions in more detail in Table 
4.2. The factors included in our model are shown diagrammatically in Figure 4.1 while Figure 
4.2 shows the position of each subset of reactions (those of the previous model, the extrinsic 
pathway, the intrinsic pathway and factor XI activation) within the full cascade. 
Factors within the coagulation cascade are numbered 1-13, as indicated by their roman numer-
als. We introduce the variables listed in Table 4.3 where f denotes a factor, with its relevant 
roman numeral as a subscript, and a superscript indicating activation ('a') or inactivation ('i'). 
Complexes are denoted by b being formed by the binding of the two factors indicated in its 
subscript and superscript. The inhibitory factors TFPI and protein C are denoted by p and e 
respectively, while intrinsic tenase is denoted by n. According to the reaction scheme in Table 
4.1, the rate of change in each variable of the common pathway is given by 
dfx 
= -kIf - kIc - kId, (4.2.1a) dt 
df: 
= kIf + kIc + kId + k3c - [kIbl - [k3al- kIt" (4.2.1b) dt 
d f ~ ~
= [kIbl + [k3bl, (4.2.1c) dt 
dfv 
= -[k2al- [k2bl, (4.2.1d) dt 
dfg 
= [k2a1 + [k2bl + [k3bl- [k2cl- [k3al, (4.2.1e) dt 
d f ~ ~
= [k2c1 + [k3cI, (4.2.1f) dt 
dbx• [k3aJ - [k3bJ- [k3cI, (4.2.1 g) v. = dt 
df;; 
= -[k4al- [k4bl, (4.2.1 h) dt 
d f ; ~ ~
= [k4al + [k4bl- [k4cI, (4.2.1i) dt 
dff; 
= [k4cJ, (4.2.1j) dt 
dfj 
= -[k6J, (4.2.1k) dt 
dfr 
= [k6J, (4.2.11) dt 
and the variables of the protein C subsystem evolve in the following way 
de 
-[ksaJ, (4.2.1m) dt = 
de" [ksal - [ksbJ, (4.2.1n) dt = 
de; [kSbl· (4.2.10) = dt 
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Reaction Generation Inactivation 
No. Description No. Description 
Generation and inactivation If X ~ X a a 1b * Xa+ATIII -+ Xa:ATIII 
of factor Xa Ie * X ~ X a a Ie Xa+TFPI -+ Xa:TFPI 
1d X Vllla:IXa, Xa 
Generation and inactivation 2a* V.!!.; Va 2e * Va ~ ~ Va:Inactive 
of factor Va 2b * V ~ V a a
Formation of prothrombinase 3a * Va+Xa f-+ Va:Xa 3b * Va:Xa+ATIII -+ Va+Xa:ATIII 
3e * Va:Xa ~ ~ Va:lnactive+Xa 
Generation and inactivation 4a * II ~ ~ IIa 4e * I1a+ATIII -+ lIa:ATIII 
of thrombin 4b * II Va:Xa. lIa 
Protein C Sa. C.!!.; APC Sb * APC -+ APC:Inactive 
Fibrinogen to fibrin 6. Fb' IIa Fb' 1 nnogen --+ 1 nn 
Generation and inactivation 7a XI.!!.; XIa 7b XIa+ATIII -+ XIa:ATIII 
of factor XIa 
Generation and inactivation Sa I X ~ I X a a Bb IXa+ATIII -+ IXa:ATIII 
of factor IXa 8e IX TF:VJla. IXa 
Generation and inactivation 9a VIII .!!.; VIlla 9b VIlla APe. VIIIa:lnactive 
of factor VIlla 
Formation of intrinsic tenase lOa VIIIa+IXa f-+ VIIIa:IXa lOb VIIIa:lXa APe. VIIIa:lnactive+ IXa 
IDe VIIIa:IXa+ATIII -+ VIIIa+lXa:ATIII 
Activation and inactivation lla f(t) f-+ VIIa:TF llb VIIa:TF+Xa:TFPI -+ VIIa:TF:Xa:TFPI 
of the extrinsic tenase 
Table 4.1: Summary of reactions (detailed in Table 4.2) included in our model (equations (4.2.5, 
4.2.6,4.2.7» of the coagulation cascade. Enzymatic reactions (le, ld, If,2a, 2b, 2c, 3c, 4a, 4b, 7a, 
Sa, &, 9a, 9b, lOb) are represented by Michaelis-Menten kinetics, while mass-action kinetics are 
adopted for other reactions, with Ib, 3b, 4e, Sa, Sb, 6, 7b, Sb and IDe being of first-order and Ie, 
3a, lOa and lIb (complex formation) of second order. Due to the abundance of ATIII, its concen-
tration is assumed to be constant. Reactants (factors) within the cascade are normally denoted 
by Roman numerals (with 'a' indicating an activated factor); prothrombinase is the complex 
formed from factors Xa and Va; intrinsic tenase for the complex formed from factor IXa and fac-
tor VIlla, extrinsic tenase for the complex formed from factor VIla and TF, prothrombin (factor 
II), thrombin (factor lIa), fibrinogen (factor I), fibrin (factor la), the inhibitors being protein C 
(APC in its activated form), TFPI (tissue factor pathway inhibitor) and ATIII (antithrombin III). 
Reactions marked with a * are included in the model from Chapter 3. These reactions are also 
depicted graphically in Figure 4.1. 
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Reaction 1. Generation and inactivation of factor Xa. 
Factor X marks the start of the common pathway. In our previous model of thrombin gen-
eration (Chapter 3) factor Xa production was assumed to depend on tissue damage and the 
extrinsic pathway (via the function H(t)}. In this model we include extrinsic tenase (n) and 
the intrinsic pathway and so factor Xa is activated by the extrinsic pathway (through tissue 
factor and extrinsic tenase VIIa:TF) at rate kIf and the intrinsic pathway (through factor 
IXa) at rate kIc and the intrinsic tenase VIIIa:IXa at rate kId - see equations (4.2.5a), (4.2.6b). 
Competition for extrinsic tenase between factor X and factor IX is also included. Factor X 
is inactivated by antithrombin III which forms an irreversible complex (concentration Xi) 
at rate kIb (see (4.2.6b), (4.2.7c». With the inclusion of TFPI (p) in this model we can now 
include TFPI inactivation of factor Xa by the formation of the complex Xa:TFPI (bt) with 
rate k le (see equations (4.2.5i), (4.2.6b), (4.2.7a)}. 
Reaction 2. Generation and inactivation of factor Va. 
The activation of factor V (fv) is mediated by factor Xa (rate constant k2b ) and by thrombin 
(rate constant k2a) (Asselta et al., 2006; Segers et al., 2(07) (equations (4.2.5b), (4.2.6c». The 
model accounts for competition between factor V and prothrombin (b) for factor Xa and 
between factor V, fibrinogen (fi), factor VIII (fviii) and factor XI (fxi) for thrombin. The 
down-regulation of factor Va activity is achieved by activated protein C (Asselta et al., 2006) 
at rate k2c (see equations (4.2.6c), (4.2.7d». 
Reaction 3. Formation of prothrombinase. 
Prothrombinase is assembled from factor Va and factor Xa at rate constant k3a (see equa-
tions (4.2.6b), (4.2.6c), (4.2.6d)). Down-regulation of prothrombinase is achieved in two 
ways: the factor Xa complexed within it can be inactivated by antithrombin III (rate k3b), 
releasing factor Va (see (4.2.6c), (4.2.6d), (4.2.7c». Alternatively cofactor Va can be inacti-
vated by binding irreversibly to APC (with rate constant k3c) forming inactive factor V (Vi) 
and releasing factor Xa (see (4.2.6b), (4.2.6d), (4.2.7d». 
Reaction 4. Generation and inactivation of thrombin. 
There are two pathways by which prothrombin can be activated to thrombin: via factor 
Xa with rate constant k4a (taking into account competition for factor Xa between factor 
V and prothrombin) - see (4.2.5c), (4.2.6e) - and catalysed by prothrombinase, with rate 
constant k4b - see (4.2.5c, 4.2.6e). Antithrombin III directly converts thrombin (rate k4c) to 
its inactivated form (Xi); see (4.2.6e, 4.2.7e). 
Reaction 5. Protein C system. 
The inhibitory protein C pathway is modelled as a first order reaction, with activation at 
rate kSa - see (4.2.5h), (4.2.6j) - and conversion to its inactivated form (ei) occurs at rate kSb; 
see (4.2.6j, 4.2.7j). 
Continued on next page 
Table 4.2: Detailed description of each reaction listed in Table 4.1. 
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Reaction 6. Conversion of fibrinogen to fibrin. 
The conversion of fibrinogen (g) to fibrin (f) (rate constant k6) is included to account for 
the reduction in the activation rate of factor V caused by the competition for thrombin of 
fibrinogen and factor V (4.2.5d, 4.2.7£). 
Reaction 7. Generation and inactivation of factor Xla. 
Factor XI is activated by thrombin with rate constant k7a (equations (4.2.5e), (4.2.6£). Factor 
XI competes for thrombin with factor V, fibrinogen (g) and factor VIII (viii). Antithrombin 
III inactivates factor XIa (rate k7b ) by binding irreversibly to it (concentration xij) with rate 
k7b (see equations (4.2.6f), (4.2.7h». 
Reaction 8. Generation and inactivation of factor IXa. 
Factor IX is activated by factor XIa with rate constant kSa (see equations (4.2.5f), (4.2.6g». 
Antithrombin III binds irreversibly with factor XIa at rate kSb to form a complex with con-
centration xij (see equations (4.2.6g), (4.2.7g». 
Reaction 9. Generation and inactivation of factor VIlla. 
Factor VIII is activated by thrombin with rate constant k9a (see equations (4.2.5g), (4.2.6h». 
It competes for thrombin with factor V, fibrinogen (g) and factor Xl (xi). Protein C inacti-
vates factor VIII at rate k9b (see (4.2.6h), (4.2.7i». 
Reaction 10. Formation of intrinsic tenase. 
Intrinsic tenase (q) is assembled from factor Villa and factor IXa with rate constant klOa 
(see equations (4.2.6g), (4.2.6h), (4.2.6i». Down-regulation of intrinsic tenase occurs when 
antithrombin III binds to factor IXa (rate k lOc ) releasing factor VIlla (see (4.2.6i), (4.2.6h), 
(4.2.7g». Alternatively cofactor VIIIa can bind irreversibly to APC (with rate klOb) forming 
an inactive factor (viiij) and releasing factor IXa (see (4.2.6i), (4.2.6g), (4.2.7i». 
Reaction 11. Formation of the extrinsic tenase. 
In the absence of suitable data, we assume that the extrinsic pathway is initiated at the level 
of the extrinsic tenase and model its formation by a function G(t) = kllae-kllMxt represent-
ing the variable production of extrinsic tenase, where klla is the total amount of extrinsic 
tenase (concentration n) produced, the rate constant k llax is associated with the loss of the 
stimulant by its degradation. G(t) is modified (via parameters k lla, kllax ) so that the simu-
lation of the TF:VIIa complex approximates data from Orfeo et al. (2005) of extrinsic tenase 
concentrations over time in response to tissue factor activation of plasma (see Figure 4.3). 
Extrinsic tenase is inhibited by binding to the complex Xa:TFPI at rate km (4.2.6a, 4.2.7b). 
Table 4.2: Detailed description of each reaction listed in Table 4.1. 
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Figure 4.1: A schema of our model of the coagulation cascade based on the reactions shown in Table 4.1. The boxes correspond to coagulation factors and lower 
case letters denote concentrations. Red boxes (with superscript a) denote active factors, yellow procoagulants and green (with superscript i) inactivated factors. 
Arrows pointing into boxes represent conversion from one species to another while those directed at other lines correspond to catalysis. Rate parameters are 
shown above their respective reactions. Dashed lines show protein C inhibition. There is no variable for antithrombin m as it occurs at such high levels that it 
is not considered rate limiting. 
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Figure 4.2: A schema of the coagulation cascade based on the reactions shown in Table 4.1. Boxes correspond to coagulation factors, with the lower case letters 
in brackets being used in the mathematical model to designate concentrations. Boxes denote factors included in the model presented in Chapter 3 (pink), factors 
of the extrinsic pathway (blue), factors of the intrinsic pathway (magenta) and factors relevant to thrombin activation of factor XI (white). Arrows pointing 
into boxes represent conversion from one species to another while those directed at other lines correspond to catalysis. Rate parameters are shown above their 
respective reactions. Dashed lines show protein C inhibition. 
The changes in variables of the extrinsic pathway are 
dn 
dt 
d b ~ · P P
dt 
dbt 
dt 
dp 
dt 
= G(t) - kllb 
= kIIb, 
= kle - kllb, 
= -kIt', 
and the changes in variables of the intrinsic pathway are given by 
dfx; 
= -k7a, dt 
df:; 
= k7a - k7b' dt 
d f ~ ; ;
= k7b' (it 
df;x 
= -ksa - k8c' (it 
dfrx 
= kSa + k8c + klOb - klOa - kSb, (it 
df/x 
= kSb + klO" dt 
dfv;;; 
= -k9a, dt 
d f ~ i i i i
= k9a + klOc - klOa - k9b' dt 
d f ~ j j j j
= k9b + klOh· dt 
dbix• v;;;. 
= klOa - klOh - klOCt 
-;It 
(4.2.2a) 
(4.2.2b) 
(4.2.2c) 
(4.2.2d) 
(4.2.3a) 
(4.2.3b) 
(4.2.3c) 
(4.2.3d) 
(4.2.3e) 
(4.2.3f) 
(4.2.3g) 
(4.2.3h) 
(4.2.3i) 
(4.2.3j) 
where k; indicates the relevant reaction number from the Table 4.1. Reactions common to this 
model and that presented in Chapter 3 are shown in square brackets. Reactions Ie, Id, If, 2a, 
2b, 2e, 3e, 4a, 4b, 7a, 8a, 8e, 9a, 9b, lOb (described in Table 4.1) are enzymatic reactions, with 
subscript m denoting Michaelis-Menten saturation coefficients. The complexes prothrombi-
nase, intrinsic tenase, Xa:TFPI and VIIa:TF:Xa:TFPI are assembled at binding sites (reactions 
Ie, 3a, lOa, lIb) on activated platelets or on negatively charged phospholipids that are exposed 
following cell damage (Spronk et al., 2003). Consequently their rates of assembly will vary 
with the availability of these sites. Such variation is not included in the model where the rate 
of assembly is assumed to be proportional to the products of the substrate concentrations. Due 
to the abundance of ATIII, its concentration is assumed to be constant and reactions lb, 3b, 4e, 
7b 8b and IDe are effectively first order. As in chapter 3 we follow Willems et al. (1991) and treat 
the protein C system and the conversion of fibrinogen to fibrin as first-order reactions (Sa, Sb, 6). 
74 
Variable Description Initial condition 
Dim. Nondim. 
bX• * v. Prothrombinase (VaXa) 
bix• 
viii. Intrinsic tenase 
b ~ a a Inactivated factor X 
c* protein C 60nM 1.68 
c
Q 
* activated protein C 
ci • inactivated protein C 
Ii· Fibrinogen 8300nM 2.22 
If * Fibrin 
Ijj • Prothrombin, factor II 1400nM 24.14 
l i ~ ~ • 11hrornbin,factorIIa 
Ifi * Thrombin, inactivated 
Iv * Factor V 21nM 1.92 
Ig * Activated factor V 
I ~ ~ • Inactivated factor V 
IViii Factor VIII O.7nM 6.25 x 10-6 
I ~ i i i i Activated factor VIII 
I ~ i i ; ; Inactivated factor VIII 
lix Factor IX 90nM 3.75 
Ifx Activated factor IX 
If x Inactivated factor IX 
Ix Factor X 133nM 0.71 
I: * Activated factor X 
I ~ ~ * Inactivated factor X 
Ix; Factor XI 25nM 0.60 
I:i Activated factor XI 
I ~ i i Inactivated factor XI 
n Extrinsic tenase 
ni Inactivated extrinsic tenase 
p TFPI 2.5nM 1.68 
Table 4.3: Summary of dependent variables; concentrations, where indicated, are typical factor 
levels for human plasma (taken from Butenas et al. (1999» .• indicates variables common to this 
model and the model presented in Chapter 3. The nondimensional variables are described in 
equations (4.2.8) and (4.2.9). 
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We note that with this extended system we have conservation (in their various forms) of fib-
rinogen, prothrombinase, protein C, factor V, factor X, factor XI, factor IX, factor VIII, TFPI, 
complexes Xa:TFPI, VIIa:TF:Xa:TFPI and intrinsic tenase in the form 
fii + f i ~ ~ + fli = fiio, 
fv + fg + f ~ ~ + b ~ : : = fvo + b ~ : :0' fviii + f ~ i i i i + f ~ i i i i + b ~ i ; . . = fv;i;O + b ~ i ; . o ' '
fix + ftx + fIx + b ~ : i i . . = fixo + b ~ ~ i i . O ' ' fx + f: + /1 + b ~ : : = fxo + b ~ : o ' '
. rt 
n + n' = io G(t')dt' + no· (4.2.4) 
For each reactant we substitute in (4.2.1) - (4.2.3) the functional forms for the reactions listed 
in Table 4.3 formulating an ordinary differential equation. The equations for the procoagulants 
can be written as follows: 
dfx 
dt 
dfv = 
dt 
dfii = 
dt 
dfi = 
dt 
dfxi (F= 
dfix = 
dt 
dfviii 
dt = 
fii + k4am(1 + xi;;) 
-k6 f;, 
k bvii., 4b x. J ii 
fii + k4bm ' 
I:: t= ~ ' '+k 1+ + v + ' fxi tam ( 6m :z.m ~ . m m ) 
kSa 1:i fix k& n fix 
/;x + ksam fix + k&m(l + Ix )' rv.;; 
k 9 a f ~ ~ fV;ii 
- fv;;; + k9am (1 + /:;. + ~ ~ + I!)' 
de 
dt = -kSa c, 
dp = 
dt 
The evolution for the activated factors is described by the following system of ODEs 
dn 
"'it = G(t) - kllb bt n 
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(4.2.5a) 
(4.2.5b) 
(4.2.5c) 
(4.2.5d) 
(4.2.5e) 
(4.2.5f) 
(4.2.5g) 
(4.2.5h) 
(4.2.5i) 
(4.2.6a) 
dbX• ~ ~
= dt 
d f i ~ ~
= dt 
df:i 
dt 
dffx 
= lit 
dbix• 
viii. = (it 
k a bX• k fa (a k bX 3c C Va 3a X Jv - 3b v: - bX• + k ' Va 3cm 
k4a f: f ~ ~ + k4b b ~ : : fii - k4c J i ~ ' '
J J ~ ~ + k4am (1 + Iv) fii + k4bm II r;,;; 
k7a f i ~ ~ fxi _ k fa, 
( Ii Iv IViii) 7b XI' Jxi + k7am 1 + r;;;; + ~ ~ + t;.;;;; 
kSa J:i fix + ksc n fix + k10b ca b ~ i i a a( + k Ir -b,"-'x-a --k----'=- - ktoa f i ~ ~ f;iii 
Jix Sam fix + k&m(l + r;;:) viii. + IObm 11m • 
- k S b f i ~ ' '
k9a f ~ ~ fviii k bix. k la la { .. , k ( -It k: /'::) + IDe viii. - 10aJixJviii 
J VIII + 9am 1 + + + o. 6m tam _m 
k9b ca f;iii 
f;;;; + k9bm ' 
k ca biXa k la la .. , _ lOb viii. k bix• 
lOa J IX J VIII bix. + k - 10e viii.' 
viii. 10bm 
= kSa C - kSb Ca. 
(4.2.6d) 
(4.2.6e) 
(4.2.6f) 
(4.2.6g) 
(4.2.6h) 
(4.2.6i) 
(4.2.6j) 
In 4.2.6a G(t) = klloe-kuar/ represents the variable production of extrinsic tenase (this is dis-
cussed further in Section 4.2.3). The evolution of the complex Xa:TFPI, which, though an inacti-
vated factor, participates in the above equations by forming a complex with the extrinsic tenase 
(n), is given by 
(4.2.7a) 
Finally, the downstream, inactivated factors and fibrin are goverened by the following ODEs: 
d b ~ · P P
km b ~ . . n, (4.2.7b) dt = 
d f ~ ~
= klbf: + k3b b ~ : , , (4.2.7c) dt 
d f ~ ~ k2c CO fg k3c c4 b ~ : : (4.2.7d) lit = fg + k2em + b ~ : : + k3cm ' 
dffi 
= k 4 c f i ~ ' ' (4.2.7e) dt 
dfr 
= k6fi, (4.2.7f) dt 
dffx 
= kSb f i ~ ~ + ktoc b ~ ~ i i . ' ' (4.2.7g) dt 
d f ~ i i
= k7bJ:i' (4.2.7h) dt 
d f ~ i i i i k9b CO f;iii k a bix• 
= + 
lOb C viii. (4.2.7i) 
dt f;iii + k9bm b ~ ~ i i . . + ktobm , 
dci kSb CO. (4.2.7j) = dt 
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Estimates for the values for the dimensional parameters are taken from literature where pos-
sible (Table 4.4). The kinetic parameters for coagulation are generally well established, blood 
being a relatively easy biological system to test in vitro. While estimates are available for the 
majority of the parameters required, those involving the binding of the complex intrinsic tenase 
and the activity of protein C are less well defined and established estimates have been used. 
Initial conditions are typical factor levels for human plasma (taken from Butenas et al. (1999», 
it being assumed that no activated or inactivated factors are present at t = ° with the levels 
of the procoagulants taken to be lio = 8300nM for fibrinogen, liio = 1400nM for prothrombin, 
fvo = 21nM for factor V, Iviiio = 0.7nM for factor VIII, lixo = 90nM for factor IX, fxo = 133nM 
for factor X, fxio = 25nM for factor XI, Co = 60nM for protein C, and Po = 2.5nM for TFPI, i.e. 
we set 
at t = 0, fi = fiO, Iii = liio, Iv = Ivo' IViii = fvii;o, lix = lixo, fx = Ixo' Ixi = Ix;o' 
C = Co, P = Po, fr = 0, f ; ~ ~ = 0, Ifi = 0, I ~ ~ = 0, I ~ ~ = 0, I ~ ; ; i i = 0, I ~ j j j j = 0, 
f ; ~ ~ = 0, ffx = 0, f: = 0, I ~ ~ = 0, f:; = 0, f ~ i i = 0, b ~ ; ; = 0, b ~ ~ f ; a a = 0, b ~ a a = 0, 
bXaP 
- ° n - ° Cd - ° ci - ° n , 0-, , .
4.2.2 N ondimensionalisation 
We nondimensionalise equations (4.2.5), (4.2.6), (4.2.7) in a manner similar to that in which we 
rescaled the model of thrombin generation in Chapter 3. TIme is scaled in the same manner 
as in Chapter 3, with kit? so that f = k4ct denotes nondimensional time, (k,;:.1 is an interme-
diate timescale, representing the rate at which antithrombin III inhibits thrombin). The vari-
ables common to both models (see equations (4.2.6b), (4.2.7c), (4.2.5b), (4.2.6c), (4.2.7d), (4.2.6d), 
(4.2.5c), (4.2.6e), (4.2.7e), (4.2.5h), (4.2.6j), (4.2.7j), (4.2.5d), (4.2.7f)) are scaled as in Chapter 3 so 
that 
r = k4c r 
x k3a x' / - k
4c r 
x - k3a x' Iv = k2bm!v, I ~ ~ = k2cml:, (4.2.8a) 
I ~ ~ = k 2 c m l ~ , , bXa - k fl' v. - 3cm v.' Iii = k4am/;;, tr- = k2cmk4c l' II k2a II' (4.2.8b) 
It = k2Cmk4c!{ 
II k2am II' 
C = k2cmk4c C 
k2c ' 
a _ k2cmk4c ca 
,- k2c ' 
,I = k2cm k4c ci, 
k2c 
(4.2.8c) 
Ii = k6mJ;, Ir = k6mJr. (4.2.8d) 
The remaining variables (see equations (4.2.5f), (4.2.6g), (4.2.7g), (4.2.5g), (4.2.6h), (4.2.7i), 
(4.2.5e), (4.2.6f), (4.2.7h), (4.2.6a), (4.2.7a), (4.2.6i), (4.2.5i), (4.2.5a), (4.2.7b» are scaled as follows 
to minimise the number of parameters in the dimensionless equations: 
fiX = kscm/;x, a _ k8ck1fm ha fix - k ix' 
1/ 
. k8cklfm l 1/ -;x - kIf ix' (4.2.9a) 
fViii = k9am!v;;i, f ~ j j j j = k 9 b m ! ~ i i i ' ' I ~ i i i i = k 9 b m ! ~ i i i ' ' (4.2.9b) 
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Ixi = k7amlxi' fa, = k7a
k2cm la, 
XI k2a XI' 
/ ' = k7ak 2cm Ji, 
XI k2a XI' (4.2.9c) 
_ k lfmk4c _ bn = kl/mk4c bn bixa - k bixa (4.2.9d) n - k n, x.p k X.P' viiia - IObm viiia' 11 1/ 
p = k4c 1', Ix = kl/mlx, p -p (4.2.ge) kIt' bXa = klfmbxa' 
where tildes denote dimensionless variables. The dimensionless parameter groupings common 
to the present model and that from Chapter 3 are: 
k2a = k 2cm , 
k2bm 
if _ k2cm 
'73a - --, 
k3cm 
k4a 
if4a = k k' 4am 3a 
- kSb 
kSb = k4c' 
The dimensionless parameters introduced in this chapter are 
if _ klck8c r k lcm r _ kldk 3ak lOhm 
'7lc - k k ' I(.lcm = -k-' I(.Id - k 2 ' 
If 4c 11m 4c 
r kIt' kIf T_ klfmk3a 
1(.11' = -k ' ifll' = -k ' I(.lf = , 
3a 4c k4c 
- k7b 
k7b = k4c' 
r k8ck lfm 
1(.& - :---:--
- k&mkl/' 
1. k2h 
1(.2b = k ' k3a 2cm 
k3c = k3c, 
k2c 
T k4hm 
1(.4bm = k--' 
4am 
(4.2.10a) 
(4.2.10b) 
(4.2.10c) 
(4.2.10d) 
(4.2.11a) 
(4.2.11b) 
(4.2.11c) 
(4.2.11d) 
k - klOak9hm 
lOa - k4c ' 
klObk2cm qlob = k k' (4.2.11e) 
lObm 2c 
II k IObk2cm 
"lOb = , 
k9bmk2c 
k - klOcklObm 
10c - k k ' 4c 9bm 
_ k IOhmkl! 
210c - k k ,(4.2.11f) 
I!m & 
k _ kllakI! 
Ila - k k 2' 
11m 4c 
1. kuax 
1(11ax = k4c ' (4.2.11 g) 
The equations representing the procoagulants (4.2.5) transform to give 
d Ix nIx qlclfx Ix 
dt = - Ix + (1 + lix) Ix + k 1cm 
dlv k2al;Vv 
dt = - Iv + k2am(l + Ii + Ixi + Iviii) 
d Iii _ q4a If Ijj q4h b ~ : : Ii; 
dt - - 1 + Iv + Iii - Iii + k 4hm ' 
d ~ ' 'd/ = -k6li' 
d Ixi k7a I ~ ~ Ix; 
lit = - Ix; + (1 + Ii + Iv + Iviii)' 
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kId b ~ ~ i i a a Ix 
kIf (fx + k1dm)' 
k2ak2blf Iv 
1 + Iv + Ii;' 
(4.2.12a) 
(4.2.12b) 
(4.2.12c) 
(4.2.12d) 
(4.2.12e) 
(4.2.12f) 
00 
o 
Paramo Description Value References Source 
k 1b Xa+ATIII --+ Xa:ATIII 0.347 nM-1 min-1 Anand et al. (2008) Wiebe et al. (2003) 
k 1c X ~ X a a keat = 0.04 min-I, k m = 2000 oM Kogan et al. (2001) Rawala-Sheikh et al. (1990) 
and Hultin (1982) 
kId X VIIIa:IXa) Xa keat = 2391 min-I, k m = 160 oM Anand et af. (2008) Rawala-Sheikh et af. (1990) 
keat = 174Omin-1,km = 190 oM * Kogan et af. (2001) Rawala-Sheikh et af. (1990) 
k 1e Xa+ TFPI --+ Xa:TFPI 0.48 nM-1 min-I Anand et al. (2008) Huang et af. (1993), 
and Jesty et al. (1994) 
1 x let> oM-I min-1 Khanin et al. (1998) Jesty et al. (1994) 
klf X ~ X a a kellt = 103 min-I, k m = 380 oM Khanin et al. (1998) Komiyama et al. (1990) 
kellt = 103 min-I, k m = 240 oM * Anand et al. (2008) Komiyama et al. (1990) 
k2a V.!!; Va kellt = 27min-1,km = 140.5 oM * Anand et al. (2008) Monkovic & Tracy (1990) 
kellt = 27 min-I, k". = 141 oM Khanin et af. (1998) Monkovic & Tracy (1990) 
kellt = 14 min-I, k m = 72 oM Kogan et al. (2001) Monkovic & Tracy (1990) 
kellt = 14 min-I, k m = 72 oM Willems et al. (1991) Monkovic & Tracy (1990) 
k2b V ~ V a a kellt = 2.6 min-I, k". = 10.4 oM Kogan et al. (2001), Willemset al. (1991) Monkovic & Tracy (1990) 
k2£ Va ~ ~ Valnactive kellt = 10.2min-1,k". = 14.6nM * Anand et al. (2008) Solymoss et al. (1988) 
kellt = 24 min-I, kIll = 20 oM Willems et al. (1991) Solymoss et al. (1988) 
k311 Va+Xa ++ Va:Xa 0.1 nM-1 min-1 • Anand et al. (2008) Mann (1987) 
10 nM-1 min-1 Willems I.'t al. (1991) Giesen et al. (1991) 
Continued on next page 
Table 4.4: Summary of parameters and their corresponding reactions, values and sources. Parameter values used in previous mathematical models are indicated 
(references) with the relevant biological sources (sources). * indicates value used in numerical simulations. Where values are available from multiple sources 
we have tried to take a consistent approach, following Anand et al. (2008). We have not included references to models that use second-order kinetics (such as 
(Kramoroff & Nigretto, 2001; Bungay et a1., 2003» in place of Michaelis-Menten kinetics for enzyme reactions. 
00 
...... 
Paramo Description Value References Source 
k3b VaXa+ATIII -+ Va+Xa:ATIII 0.05 min-I Willems et al. (1991) Schoen et al. (1989) 
k'3c VaXa APC, Valnactive+Xa keat = 24 min-I, k m = 20 oM Willems et al. (1991) Solyrnoss et al. (1988) 
k4a II ~ ~ IIa keat = 2.25 min-I, k m = 58 oM Kogan et al. (2001), Willems et al. (1991) Rosing et al. (1980) 
k4b II Va:Xa, I1a keat = 1344 min-I, k m = 1060nM • Anand et al. (2008) Krishnaswamy et al. (1987) 
keat = 1700 min-I, k m = 1000 oM Khanin et al. (1998) Krishnaswamy et al. (1987), 
and Tracy et al. (1985) 
keat = 2000 min -I, k m = 210 nM Willems et al. (1991) Rosing et al. (1980) 
k4c I1a+ATIII -+ I1a:ATIII 1.3 min-I Willems et al. (1991) 
ks" C-+APC 0.0014 min-I Willems et al. (1991) 
--
kSh APC -+ APClnactive 0.35 min-1 Willems et al. (1991), 
--
0.34 min-I Qiao et al. (2004) Rezaie & Esmon (1993) 
k6 Fibrinogen.!!; Fibrin keat = 3540 min-I, k m = 3160 nM • Anand et al. (2008) Tsiang et al. (1996) 
keat = 5040 min-I, k m = 7200 2M Kogan et al. (2001) Higgins et al. (1983) 
k,at not listed, k m = 2000 nM Willems et al. (1991) Smith (1984) 
k7a XI.!!; Xla k'Dt = O.OO78min- l ,km = SOnM Anand et al. (2008) Gailani & Broze (1991) 
k7b XIa+ATIII -+ Xla:ATIII 1.6 x 10-3 nM- I min-1 Anand et al. (2008) Soons et at. (1987) 
ks.. IX E;IXa k'Dt = 11 min-1,km = 160nM • Anand et al. (2008) Sun & Gailani (1996) 
keat = 225min-l,km = 3SOnM Kogan et al. (2001) Walsh et al. (1984), 
Sinha et al. (1987), 
Continued on next page 
Table 4.4: Summary of parameters and their corresponding reactions, values and sources. Parameter values used in previous mathematical models are indicated 
(references) with the relevant biological sources (sources). * indicates value used in numerical simulations. Where values are available from multiple sources 
we have tried to take a consistent approach, following Anand et al. (2008). We have not included references to models that use s e c o n d ~ r d e r r kinetics (such as 
(Kramoroff & Nigretto, 2001; Bungay et al., 2003» in place of Michaelis-Menten kinetics for enzyme reactions. 
00 
N 
Paramo Description Value References Source 
and Wam-Cramer & Bajaj (1986) 
kSb IXa+ATIII -+ lXa:ATIII 0.0l62nM-1 Anand et al. (2008) Wiebe et al. (2003) 
k& I X ~ I X a a keat = 32.4 min-I, km = 24nM Anand et al. (2008) Komiyama et al. (1990) 
k9a VIII ~ ~ VIlla keat = 194.4 min-I, km = 112000 nM Anand et al. (2008) De Cristofaro et al. (2003) 
k9b VlIIa APC) VIIIalnactive keat = 10.2 min-I, km = 14.6nM Anand et al. (2008) Due to lack of data, 
assumed to be the same as k2c• 
k10a VIIIa+IXa H VIlla:lXa 1 nM-1min-1 Khanin et al. (1998) 
--
10 nM-1min-1 Kogan et al. (2001) 
--
klOb VIIIa:IXa ~ ~ VIIIalnactive+ lXa keat = 10.2 min- t , km = 14.6nM Due to lack of data, assumed 
to be the same as (k9b) 
kux VIIIa:IXa+ATIII -+ VIlla+IXa:ATIII 0.0l62nM-1 Due to lack of data, assumed 
to be the same as (kSb) 
k11a I(t) = klla e-kllarl 3 x 10-5 nM min- l fitted to experimental data 
k11n /(t) = l11a e-klla.rt 0.2 fitted to experimental data 
11111 VIIa:TF + Xa:TFPI 0.64 nM-1 min-1 Khanin et al. (1998) Jesty et al. (1994) 
-
~ ~ -
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Table 4.4: Summary of parameters and their corresponding reactions, values and sources. Parameter values used in previous mathematical models are indicated 
(references) with the relevant biological sources (sources). * indicates value used in numerical simulations. Where values are available from multiple sources 
we have tried to take a consistent approach, following Anand et a1. (2008). We have not included references to models that use second-order kinetics (such as 
(Kramoroff & Nigretto, 2001; Bungay et al., 2003» in place of Michaelis-Menten kinetics for enzyme reactions. 
dlix k8a I:Jix k8' n lix 
Cit = - lix + k8am lix + 1 + Ix' 
d IViii k9a I ~ ~ IViii 
dt = - IViii + (1 + Ii + Iv + Ixi)' 
de 
dt = -ksa e, 
~ ~ ~ = -kle pI;· 
The equations for the activated factors (4.2.6) transforming to give 
dn k t n lit = kl1ae- l10x - kl1b bx• p n 
d I: klf n Ix + qlcklf Ifx Ix + kId b ~ ~ i i J X X + k3ck3a eI' b ~ : :
dt = Ix + (1 + /;x) Ix + klcm Ix + k1dm b ~ : : + 1 
- k1bl: - k3a l: Ig - pI;, 
dIg = 1 ~ / v v + k 2 b / ~ / v v + k3b b ~ : :
dt Iv + k2am (1 + Ii + Ixi + Iviii) Iv + 1 + Iii q3a 
e
a Ig fa (a 
- Jg + 1 - x Jv' 
dbX' k a bX' v. fa (a k bX 3cQ3a e v. (it = Q3a x J v - Q3a 3b v: - bI , + 1 ' 
v. 
d I ~ ~ _ k4a J: Iii + k4ak4b b ~ : : Iii - f ~ ~
dt - Iii + 1 + Iv Q4a (fii + k4bm) II' 
d!:i _ l i ~ ~ Ixi k fa 
-d - f ( ( ( () - 7b xi' t xi + 1 + J i + J v + J viii 
d (a k fa (. k eI' bix, . 
....:!.il. _ 8a XiJIX + nlix + lOb VIII, _ k (a (a ... 
d - k ( ( k ) ( ( f ) ix lOa J IX J Vlll t & J ix + 8am J ix + 1 + x b . ~ . . + 1 VIII, 
- k 8 b l i ~ ' '
d I ~ i i i i Q9a l i ~ ~ IViii k bix, (a (a dt = IViii + 1 + Ii + Ixi + Iv + lOe viii, - QlOa J ix J viii 
k9b eI' I ~ i i i i
I ~ i i i i + 1 ' 
dbix•. kID qlob CO bix,. . ~ ~ = _a (a (a ... _ Vlll. _ Q b / ~ ~ . .
dt Z 0 lIx J Vlll bix. + 1 10c VIII,' 
1 C viii, 
del' dt = kSa e - kSbCa, 
(4.2.12g) 
(4.2.12h) 
(4.2.12i) 
(4.2.12j) 
(4.2.13a) 
(4.2.13b) 
(4.2.13c) 
(4.2.13d) 
(4.2.13e) 
(4.2.13f) 
(4.2.13g) 
(4.2.13h) 
(4.2.13i) 
(4.2.13j) 
(4.2.13k) 
and those equations for the downstream, inactivated factors and fibrin (4.2.7) transform to give 
(4.2.14a) 
(4.2.14b) 
(4.2.14c) 
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(4.2.14d) 
df/i = f ~ ~
dt J /I' (4.2.14e) 
df,a 
d; = k6fi' (4.2.14f) 
dc i Tt = k5b Ca • (4.2.14g) 
d fix k fa bix• Cit = 8b J ix + ZIDc viii.' (4.2.14h) 
d f ~ i i k fa Cit = 7b xi' (4.2.14i) 
d fi k a fa Z Ca bix• 
J viii = 9b C J viii + lOb vi;;. 
dt f:iii + 1 b ~ ~ 7 i . . + 1 (4.2.14j) 
The dimensionless initial conditions are listed in Table 4.3. Our model comprises twenty-nine 
ordinary differential equations and has forty-two nondimensional parameters ( see Table 17). 
4.2.3 System activation 
We assume that the concentrations of the procoagulants and regulatory proteins are initially 
equal to those in human plasma (Table 4.3). This is a static environment with no replenishment 
of factors as would occur by convection in vivo. The experimental system (Kravtsov et a1., 2009) 
is activated (at t = 0) by the addition of TF. Our model does not include a separate species for 
TF and is instead assumed to be activated by the VIIa:TF complex. Orfeo et al. (2005) provide 
data profiles of VIIa:TF expression in response to TF activation (see Figure 4.3). We mimic 
this data by adjusting the parameters of the function G(t) = knae-kllnt to provide a similar 
profile of VIIa:TF expression to that provided by Orfeo et al. (2005) (see Figure 1 (8». Obtaining 
a profile of extrinsic tenase in response to activation by TF 5 pM requires klla = 3 x 10-5 nM 
min-I, kllax = 0.2. This approach to activating the coagulation cascade follows Anand et al. 
(2008) who estimate initial conditions for their model of the formation and lysis of blood clots 
by matching profiles of VIIa:TF to data provided by Orfeo et al. (2005) for the expression of 
extrinsic tenase. 
4.3 Numerical solution 
We proceed by first numerically solving two subsystems of the full model: this enables us to 
investigate the contribution of each pathway to the full model. Subsystem one comprises the 
extrinsic and common pathway. This subsystem is obtained by assuming that the concentra-
tions of the procoagulants of the intrinsic pathway are initially set to zero (XI = 0, IX = 0, 
and V III = 0; see pink and blue boxes in Figure 4.2), so that the effects of reactions associated 
with the intrinsic pathway can be neglected. We discuss this subsystem in Section 4.3.1 and 
the second subsystem in Section 4.3.2. The second subsystem comprises the extrinsic, common 
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Nondim. Nondim. Nondim. Nondim. 
paramo value paramo value 
klb 0.267 k6 2.723 x UP 
qIc 0.010 k71l 8.436 x 10-5 
k Icm 8.333 k7b 0.001 
kId 2.066 x lIP k8ll 0.001 
kIdm 0.667 k8llm 6.667 
k Ie 4.8 kSb 0.0125 
qle 73.23 k& 3.146 
kIf 18.462 k91l 9.386 x 10-4 
k2a 1.404 q9a 7.2 
k2am 13.510 k9b 1.000 
k2b 1.781 klOa 11.231 
kJa 1.123 qlOa 58.073 
qJa 0.730 klOb 0.193 
k3b 0.053 qlO" 1 
k3c 2.353 %10" 1.431 
k4a 32.007 klOc 0.0125 
q41l 0.388 qlOc 0.0125 
k4b 3.565 %lOc 0.193 
k4bm 18.276 kllil 7.618 x 10-6 
kSa 0.001 kllllX 0.154 
kSb 0.269 kllb 1.182 
Table 4.5: Dimensionless parameters and values. The dimensionless groups are described in 
equations (4.2.10), (4.2.11). 
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Figure 4.3: The evolution of the concentration of extrinsic tenase (VIIa:TF) in plasma in response 
to activation by 5 pM TF (VIIa:TF derived from endogenous VIla (broken line); VIIa:TF derived 
from VIla activated during coagulation (solid line)): data from Orfeo et al. (2005). 
and intrinsic pathway, neglecting thrombin activation of factor XI (see pink, blue and magenta 
boxes on Figure 4.2). We obtain this subsystem by setting the initial condition of the procoagu-
lant XI to zero. The initial conditions for all other variables are taken from Table 4.3. We solve 
the full model and discuss the implications of including thrombin activation of factor XI in Sec-
tion 4.3.3.1. Throughout this chapter, simulations are computed in Matlab using a stiff solver 
(ode1Ss) with parameter values that, as described in Table 4.3 occur over many orders of mag-
nitude. Numerical results showed no significant changes to variations in tolerance and step 
size. Simulation results are obtained by solving the nondimensional model (equations (4.2.12), 
(4.2.13), (4.2.14» but presented in dimensional form to facilitate comparison with experimental 
data. A summary of the figures presented (and the simulations they demonstrate) is provided 
in Appendix B. 
4.3.1 The extrinsic pathway 
Simulations of the reactions of the extrinsic and common pathway are obtained (Figure 4.4) 
by numerically solving equations (4.2.12), (4.2.13), (4.2.14) using parameter values from Table 
4.4 and initial conditions from Table 4.3, except for factors Xl, IX, and VIII of the intrinsic 
pathways which we set to zero so that Ixi = I:i = I!i = lix = I ; ~ ~ = I/x = IV;ii = I:iii = 
I ~ i i i i = b ~ 7 i i i = 0 for all t. The resulting set of equations is similar to the model presented in 
Chapter 3. However, it includes the extrinsic tenase, its activation of factor X, and inhibition 
of factor Xa by TFPI which subsequently inactivates the extrinsic tenase. Early mathematical 
models (Willems et al., 1991; Khanin & Semenov, 1989» excluded the intrinsic pathway believ-
ing that the extrinsic and intrinsic pathways were not linked and so activation by tissue factor 
did not involve the reactions of the intrinsic pathway. In seminal work (Osterud & Rapaport, 
1977) demonstrated that the two pathways are linked through activation of factor IX via the 
extrinsic tenase (Colman et al., 2000) and later mathematical models take this into account 
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Oones & Mann, 1994; Khanin et al., 1998). We exclude the intrinsic pathway to help us eval-
uate the contribution of this pathway to coagulation. 
In Figure 4.4 (A) we present a time-dependent solution for the concentration of the TF:Vlla 
complex. The production of factor Xa in response to TF:VIIa activation is shown in Figure 4.4 
(C). The second peak in factor Xa production can be explained by the action of protein C on the 
prothrombinase complex. When protein C interacts with prothrombinase, factor Xa is released 
from the complex and inactivates factor Va by degradation. Our understanding of this is en-
hanced by the asymptotic analysis provided in Chapter 3. At timescale 5 we found a bifurcation 
where with sufficiently low levels of factor Xa activation two peaks in factor Xa concentration 
occur. ATIII and TFPI form complexes Xa:ATIII and Xa:TFPI respectively (Figure 4.4 (D» when 
they come into contact with factor Xa. The binary complexes Xa:TFPI and extrinsic tenase (Fig-
ure 4.4 (B» can combine to form VIIa:TF:Xa:TFPI and, in this form, factor Xa participates in its 
own inhibition (see Figure 4.5). Factor Va is generated via a feedback loop involving thrombin 
(see Figure 4.4 (C» and participates in the formation of prothrombinase (Figure 4.4 (C». As in 
Chapter 3, it is the feedback from thrombin to factor V and the subsequent formation complex 
prothrombinase which is responsible for the burst in thrombin concentration that occurs after 
approximately 25 minutes (see Figure 4.4 (C». 
The prothrombin time (PT) is traditionally used to assess clinical problems with factors within 
the extrinsic and common pathways. The test is activated with very high tissue factor concen-
trations (greater than 200 nM) which subsequently overwhelm the TFPI anticoagulant mecha-
nism and convert all prothrombin to thrombin within 15 seconds (Baglin, 2(05). For thrombin 
generation to be sensitive to all procoagulant concentrations within the extrinsic and intrinsic 
pathway much lower levels of initiation (at least 4 - 5 orders of magnitude) are thought to be 
needed (Baglin, 2005). The thrombin generation assay that we simulate is activated with low 
levels of tissue factor, 5 pM or less, a decrease in tissue factor concentration of 6 orders of mag-
nitude. While we cannot exactly replicate activation of the model by 200 nM TF (as we have no 
data for extrinsic tenase formation in response to this level of activation) we can show that at 
high levels of activation (k lla = 300 nM-l min-I) all prothrombin is converted to thrombin in 
less than 30 seconds (see Figure 4.6 (B». Panel (A) in Figure 4.6 demonstrates that much lower 
levels of activation are required for incomplete conversion of the procoagulant prothrombin to 
thrombin (k lla < 0.003nM-1 min-I). 
4.3.2 The full cascade - without factor XI activation 
We now explore the contribution of the intrinsic pathway to thrombin formation. In the full 
coagulation cascade, factor X activation occurs via two pathways: the extrinsic tenase and the 
intrinsic tenase. Thus the intrinsic tenase can contribute to a higher level of factor Xa. The 
intrinsic tenase is composed of factors IXa and Villa, factor IX is activated via extrinsic tenase 
and factor VIII is activated via feedback from thrombin; once both factors have been activated 
the complex can form. Congenital deficiencies in components of the intrinsic tenase lead to 
severe bleeding disorders such as haemophilias A (factor VIII deficiency - see Figure 4.10 for 
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Figure 4.4: Time-dependent solutions of subsystem one obtained by solving equations (4.2.12), 
(4.2.13), (4.2.14) and neglecting factors associated with the intrinsic pathway. Parameters are 
taken from Table 4.4 and initial conditions from Table 4.3, except that the initial concentration 
of the procoagulants of the intrinsic pathway are set to zero (X 11 = 0, X I = 0, and V III = 0) . 
Factor Xa which is activated by the extrinsic tenase (D) reaches its peak concentration after 12 
minutes. Factor Xa can activate thrombin which in turn activates fa ctor Va, whose levels then 
peak after 22 minutes. Factors Va and Xa form prothrombinase (peak formation 24 minutes) 
which promotes thrombin formation which peaks at a level of 4 nM after 25 minutes. The 
profiles of Factor Xa and prothrombinase have been multiplied by 103. 
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Figure 4.6: Time-dependent solutions of subsystem one demonstrating that high I vel of ac-
tivation result in complete prothrombin conversion to thrombin (8) wher a at low r I vel of 
activation incomplete conversion is acheived (A). umerica l simulations of equations (4.2.12), 
(4.2.13), (4.2.14) neglecting factors of the intrinsic pathway. Initial conditions from Table 4.3, x-
cept that the initial concentrations of the procoagulants of the intrinsic pathway are t to z ro 
(X II = 0, X I = 0, and V III = 0) . Parameters are taken from Table 4.4 exc pt simulations (A) 
use kUa = 0.003 nM- I min- I and (8) kJlQ = 300 nM- I min- I. 
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simulations) and B (factor IX deficiency - see Figure 4.10 for simulations); these results highlight 
the importance of this complex for generating sufficient levels of coagulation for haemostasis. 
Typical simulations of the full model (equations (4.2.12), (4.2.13), (4.2.14» including the intrinsic 
pathway are presented in Figures 4.7 and 4.8. Initial conditions are taken from Table 4.3, with 
the initial concentration for factor XI set to zero, so that thrombin activation of factor XI can be 
neglected. 
In the presence of TFPI, the effect of the extrinsic pathway is damped and the intrinsic path-
way is thought to playa key role in the propagation of coagulation (Colman et ai., 2000): our 
simulations are consistent with this view. Figure 4.7 (A) shows the time-dependent evolution 
of factors IX and X, both being activated by the extrinsic tenase. Factor IXa can then activate 
factor X. However, when complexed with factor VIlla it does this at a greatly enhanced rate. 
These simulations were initiated by the same level of activation from the extrinsic tenase as 
the simulations in the previous section (Figure 4.4) and the marked ten-fold increase which we 
see in peak factor Xa concentration, when compared to simulations of subsystem one, where 
factor X was activated solely by extrinsic tenase, can be accounted for by the contribution of 
the intrinsic tenase to activation of factor X. Simulations of factor Xa are no longer bimodal (as 
they were in subsystem one) with a higher level of activation being provided via the intrinsic 
tenase. Factor VIII is activated by thrombin and Figure 4.8 (B) shows the evolution of this and 
the subsequent formation of the VIIIa:IXa complex (intrinsic tenase). The evolution of factors 
V and Va and the subsequent formation of prothrombinase (Va:Xa) is shown in Figure 4.8 (A). 
Figure 4.7 (B) shows the time-dependent evolution of thrombin, which reaches a peak concen-
tration of 520 nM in approximately 24 minutes. We conclude that, at this level of activation, the 
intrinsic pathway makes a significant contribution to peak thrombin formation. 
The contribution of the intrinsic pathway is further illustrated in Figure 4.9 (A) where we show 
time-dependent solutions of subsystem one (solid line) and two (broken line) for thrombin in 
response to varying levels of activation. At high levels of activation (kll a = 3 nM-1 min -1) 
thrombin formation shows little dependence on the intrinsic pathway, with solutions of sub-
systems one (solid line) and two (broken line) simultaneously producing almost identical peak 
concentrations of thrombin. At decreasing levels of activation the contribution is more pro-
nounced. With klla = 0.003 nM-1 min-1, the contribution of the intrinsic pathway produces 
not only a substantial increase in peak thrombin concentration but this peak occurs slightly 
earlier (subsystem one produces peak thrombin concentration of 170 nM in 7 minutes wheras 
subsystem two produces 760 nM in 6.5 minutes). In Figure 4.9 we show how peak thrombin 
concentrations (B) and time to reach peak (C) vary as a function of the level of activation (kna). 
Solutions of subsystem one and two make it clear that the take-home message is that at low 
levels of activation peak thrombin concentration is significantly enhanced by the inclusion of 
the intrinsic pathway and their the time to reach this peak being reduced slightly. 
Investigators report that plasma from individuals with either haemophilia A or B is unable 
to generate intrinsic tenase and, will lead to a slight prolongation of the time to clot but a 
major impairment in peak thrombin generation (Mann et ai., 2003). Below, we use our model to 
simulate haemophilia A and B to determine whether our model can reproduce these results. 
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Figure 4.7: Time-dependent solutions of the coagulation cascade (equations (4.2.12), (4.2.13), 
(4.2.14)) when thrombin activation of factor XI is neglected. Parameters are taken from Table 4.4 
and initial conditions from Table 4.3, except that the initial concentration of the procoagulant 
factor XI is set to zero. (A) shows the evolution of factors X, Xa, IX nd IXa, which are activated 
via the extrinsic tenase. (8) shows the evolution of factor Xa, the prothrombinase complex and 
thrombin, the two former activating the later. Same simulations as Figure 4.8 which provides 
additional variables. 
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Figure 4.8: Time-dependent solutions of the coagulation cascade (equations (4.2.12), (4.2.13), 
(4.2.14» neglecting thrombin activation of factor XI. Parameters are taken from Table 4.4 and 
initial conditions from Table 4.3, except that the initial concentration of procoagulant factor XI 
is set to zero. (A) shows the time dependent evolution of factor V and its contribution to the 
complex prothrombinase. (8) shows the evolution of factor VIII and its contribution to the 
intrinsic tenase. Same simulations as Figure 4.7 which provides additional variables. 
92 
4.3.2.1 Simulations of haemophilia A 
Haemophilia A is caused by a congenital deficiency of factor VIII and is the most common form 
of haemophilia. Figure 4.10 shows the time-dependent profile of thrombin concentration for 
numerical solutions of subsystem two with initial concentrations taken from Table 4.3 except 
that the initial concentration of factor VIII is varied (100%,80%, 60%, 40'10, 20%, 10%,5% in 
each successive simulation). Parameter values for all simulations are taken from Table 4.4. Our 
simulations demonstrate that 46 percent of maximum thrombin generation was achieved with 
only 5 percent of factor VIII (a reduction from 540 nM (100% factor VIII) thrombin to 250 nM (5% 
factor VIII». With no factor VIII the peak level of thrombin production was that observed with 
solutions of subsystem one (4 nM). The greatest increase in peak thrombin formation occurs 
between 0 and 5 percent (an increase of 246 nM). The time to reach peak thrombin concentration 
increased from 24 minutes (100% factor VIII) to 38 minutes (5% factor VIII), an increase of 58 
percent. The time to reach peak and the peak thrombin concentration reveals the influence of 
factor VIII on the coagulation cascade. An experimental study of the influence of factor VIII on 
a thrombin generation assay (Salvagno et al., 2009) uses healthy plasma diluted with factor VIII-
depleted plasma to obtain different factor VIII concentrations. Maximum thrombin generation 
of 362 nM (100% factor VIII) reduced to 160 nM (5% factor VIII), a reduction of 56 percent. 
The study measured the lag phase (i.e. the time to the start of the main bolus of thrombin 
generation) rather than time to peak thrombin concentration and found this to be increased 
from 11 minutes to 18 minutes (an increase of 64 percent). The experimentally-observed trends 
in the time to peak and the reduction in peak thrombin concentration are reproduced by our 
model. 
4.3.2.2 Simulations of haemophilia B 
Haemophilia B involves congenital deficiencies in factor IX (which is also known as Christmas 
factor (Giangrande, 2003». Figure 4.11 shows time-dependent thrombin concentration for nu-
merical solutions of subsystem two when the initial concentration of factor IX is varied (100%, 
80%,60%,40%,20%, 10%,5% of original plasma concentration in each successive simulation). 
Our simulations demonstrate that 43 percent of maximum thrombin generation was achieved 
with only 5 percent of factor IX (a reduction from 540 nM thrombin to 310 nM). When no factor 
IX was present the peak level of thrombin production was that observed with solutions of sub-
system one (4 nM). As levels of factor IX decrease from normal plasma levels, the time to reach 
the peak thrombin concentration also decreases attaining a minimum value when it is present 
at 20% of normal levels. For lower values the time to reach peak increases. 
The profiles for peak thrombin concentration are similar to those for haemophilia A (Figure 
4.10) in that the peak thrombin concentration falls as the concentration of factor IX is re-
duced. An experimental study using a thrombin generation assay on plasma from patients with 
haemophilia B revealed a similar correlation between the peak thrombin concentration and the 
factor IX concentrations but they observed a steady increase in time to reach peak thrombin 
concentration as levels of factor IX were reduced (Dargaud et al., 2(05). The poor agreement for 
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Figure 4.9: Simulations illustrating the contribution of the intrinsic pathway to thrombin gen-
eration. (A) The time-dependent evolution of thrombin is presented for olution of ubsy tern 
one (solid line) and subsystem two (broken line) using parameter values taken from Table 4.4, 
except that each successive pair of simulations has k lla decreased to adjust the level of activa-
tion: (1) klla = 3, (2) k lla = 0.3, (3) k ll a = 0.03, (4) k lla = 0.003 nM - 1 min- 1. (6) hows peak 
thrombin concentrations as a function of the level of activation (k lla ). Numerical olution of 
subsystem two (broken line) show consistently greater peak thrombin concentrations than so-
lutions of subsystem one (solid line) until klla = 30 nM- 1 min- 1 when the contribution of the 
intrinsic pathway to thrombin formation becomes negligible. (C) shows how the time to reach 
peak thrombin concentration varies with klla for subsystems one (solid line) and two (broken 
line) . At low levels of activation there is a slight decrease in the time to reach peak thrombin 
concentration when the inclusion of the intrinsic pathway is active. 
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concentration shows unusual behaviour with a reduction in time to reach peak for a decrea e in 
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time to reach peak between our model simulations and the experimental results is discussed in 
Section 4.3.4. 
4.3.3 The full cascade 
4.3.3.1 Sensitivity of thrombin generation to factor XI 
Kravtsov et al. (2009) performed experiments to determine how thrombin generation depends 
on factor XI. Plasma deficient in factor XI was activated by the addition of factor XIa. To repli-
cate these experiments, we numerically solve the full model, with parameter values from Table 
4.4 and initial conditions taken from Table 4.3. Additionally, we fix klla = 0 nM-I min- l so 
that the extrinsic pathway is not activated and we set the initial concentration of factor XI to 
zero (ensuring that thrombin activation of factor XI does not occur). In separate simulations 
we set the initial concentration of factor XIa to 300, 3D, 3, 0.3 and 0.003 pM, so that the model 
is activated via the intrinsic pathway. While our numerical solutions (Figure 4.12) are qualita-
tively similar to experimental results (Kravtsov et al. (2009), Figure 2) in that similar profiles are 
obtained with decreasing peaks, our simulations show greater peak thrombin concentrations 
for identical levels of activation. Numerical solutions of our model under activation by 300 pM 
factor XIa show peak thrombin levels of 950 nM after 8 minutes. Experimental results show 
peak thrombin production of 460 nM in 10 minutes. Activation by 30 and 3 pM of factor XIa 
lead to reductions in peak thrombin formation and increased times to reach the peak. Experi-
mental data for activation by 0.3 pM factor XIa show no detectable thrombin formation while 
our simulations show 700 nM being formed after 58 minutes. 
4.3.3.2 Thrombin activation of factor XI 
The model was built to investigate the effect of factor XI on thrombin generation and this can be 
seen in Figure 4.13. Numerical simulations of our model are obtained for subsystem two and 
the full model for decreasing values of extrinsic tenase activation (kll a = 300, k lla = 3D, klla = 
3, klla = 0.3 klla = 0.03, klla = 0.003, klla = 0.0003 nM-I min-I). These results are similar 
to those obtained in Figure 4.9 where we discuss the contribution of the intrinsic pathway and 
find that, at high levels of extrinsic tenase activation, the contribution of the intrinsic pathway 
is negligible. At lower levels of activation the intrinsic tenase contributes significantly to peak 
thrombin formation. 
Figure 4.13 demonstrates that, at high levels of activation (k lla = 300 nM-l min-I), the contri-
bution to thrombin activation of factor XI is negligible, with simulations of subsystem two and 
the full model producing peak thrombin formation of approximately 1150 nM after 1 minutes. 
At lower levels of activation (klla < 0.3) numerical solutions of the full model, when compared 
to solutions of subsystem two, show an increase in peak thrombin production and an increase 
in the time to reach that peak. In the region 0.3 > klla < 30 factor XI produces a decline in 
peak thrombin concentration. While the increase in peak thrombin concentration due to the 
inclusion of the feedback from thrombin to factor XI at low levels of activation corresponds to 
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Figure 4.12: Series of profiles obtained from numerical simulation of equations (4.2.12) and 
(4.2.14) showing how factor XIa influences Thrombin generation in factor XI deficient plasma. 
Parameters values are taken from Table 4.4 and initial conditions from Table 4.3 except that 
factor XI = 0 and factor Xla varies: (1) 300, (2) 30, (3) 3, (4) 0.3 pM. 
experiments results (Kravtsov et al. (2009), Figure 1) a decrease in peak thrombin concentration 
and an increase in the time to reach peak is at variance with the experimental results. 
4.3.4 Modifications 
Results presented in Sections 4.3.2.2 and 4.3.3.2 are at variance with experimental results. We 
now present a simplification of the nondimensional system (equations (4.2.12), (4.2.13), (4.2.14» 
in which competition for thrombin (between fibrinogen and factors V, VIII and XI) for the in-
trinsic tenase (between factor IX and X) and for factor Xa (between factor V and prothrombin) 
is neglected. 
The equations for the procoagulants (equations (4.2.12» simplify to give 
d Ix nIx Qlc Ifx Ix k Id b ~ ~ i ; Q Q Ix 
-=---- - , dt Ix + 1 Ix + k Icm kIf (jx + kIdm) (4.3.1a) 
d Iv k2alUv k2ak2b I: Iv 
Cit = - Iv + k2am - 1 + Iv ' (4.3.1b) 
d I;; Q4a If Iii Q4b b ~ : : Iii 
-=- - , 
dt 1 + Ii; Ii; + k4bm 
(4.3.1c) 
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Figure 4.13: Simulations demonstrating the contribution of thrombin activation of fa ctor Xl to 
the generation of thrombin. Initial conditions are taken from Table 4.3 and parameter value 
from Table 4.4 except that klla is varied to adjust the level of activation via the extrinsic tena e: 
(1) k lla = 300, (2) klla = 30, (3) klla = 3, (4) kll Q = 0.3 (5) k lla = 0.03,(6) k ll a = 0.003, (7) 
klla = 0.0003, nM min - I (simulations in Figures 4.4,4.7,4.8 use kIl n = 0.00003 nM min - 1). (A) 
Simulations of the full model (solid line) and subsystem two (broken line). (8) Peak thrombin 
concentrations as a function of the level of activation (kIlo) ' (C) The time to reach peak thrombin 
concentration as a function of the level of activation (kll a)' Numerical solutions of the full model 
(full line) show greater peak thrombin concentrations than solutions of subsystem two with 
300 > kllQ > 30 and k lla < 0.3. Between this region the contribution of thrombin activation of 
factor XI produces a decline in peak thrombin concentration. 
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The equations for the activated factors (4.2.13) simplify so that 
- kSbfix, 
d f: iii _ q9a f ~ ~ fviii + k b i x ~ . . _ q fa fa ... 
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k9b ea f:iii 
f ~ j j j j + 1 ' 
dbix• k Ca bix• 
viii. = lOa fa fa ... _ qlOb viii, _ q b i x ~ . .
dt z J IX J VIII b ; ~ ~ . . + 1 lOe VIII.' 
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(4.3.1d) 
(4.3.1e) 
(4.3.1f) 
(4.3.1g) 
(4.3.1h) 
(4.3.li) 
(4.3.2a) 
(4.3.2b) 
(4.3.2c) 
(4.3.2d) 
(4.3.2e) 
(4.3.2f) 
(4.3.2g) 
(4.3.2h) 
(4.3.2i) 
(4.3.2j) 
(4.3.2k) 
and the equations for the downstream inactivated factors and fibrin (4.2.14) simplify to 
d b ~ . . = qle p fa _ kllb b ~ ~ n 
dt kIf x qIe • ' (4.3.3a) 
(4.3.3b) 
(4.3.3c) 
(4.3.3d) 
(4.3.3e) 
(4.3.3f) 
(4.3.3g) 
(4.3.3h) 
(4.3.3i) 
(4.3.3j) 
All parameter values, initial conditions and nondimensional groupings are as before. 
Simulations of this simplified system, which show how factor XI contributes to thrombin ac-
tivation of the generation of thrombin, are presented in Figure 4.14. These profiles show a 
reduction in peak thrombin concentration and an increase in the time to reach peak concentra-
tion for simulations of subsystem two relative to the full model. This trend is more consistent 
with the experimental data. 
Our original simulations of haemophilia B also showed a discrepancy with experimental data, 
in that the time to reach peak reduced with reductions in factor IX concentrations from l00'},o 
to 20% (see Figure 4.11). New simulations neglecting competition show better agreement with 
the experiments with the time to reach peak thrombin concentration increasing as factor IX 
concentration decreases (see Figure 4.15). 
Thrombin activation of factor IX and factor VIII, that forms a complex with factor XI, is poorly 
understood and therefore competition for thrombin could be more complicated than we origi-
nally presumed. The simulations from the reduced model are more consistent with experimen-
tal data and provide the better model for the biological information that is available. 
4.4 Discussion 
Our model of the common pathway from Chapter 3 has been extended to include the extrinsic 
and intrinsic pathways. The resulting model provides a description of the full coagulation cas-
cade which neglects contact activation and factor XII while including the controversial feedback 
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from thrombin to factor XI. Our model replicates the thrombin generation assay which, unlike 
the traditional PT assay which is activated with very high levels of tissue factor, is activated 
by low concentrations of tissue factors, therby allowing investigation of the whole coagulation 
cascade. Prior to the development of this assay, analysis of the factors of the intrinsic pathway 
were always performed using the aPlT assay (which is still in clinical use), where plasma is ac-
tivated via the contact pathway. Contact activation is not known to be physiologicaly relevant 
(Renne et al., 2006; Gailani & Renne, 2oo7a) wheras tissue factor activation is thought to be the 
predominant mechanism for haemostasis (Colman et al., 2000). 
The impact of each pathway was investigated by comparing solutions for two subsystems. 
Subsystem one comprises the extrinsic and common pathway and subsystem two additionally 
includes the reactions of the common pathway neglecting thrombin activation of factor XI. The 
effect of neglecting the intrinsic pathway was studied by comparing peak thrombin generation 
and time to reach peak for the two subsystems. We found that, at low levels of activation, the 
absence of the intrinsic pathway restricts the amount of thrombin produced and increases the 
time to reach the peak. At high levels of activation the contribution of the intrinsic pathway has 
a negligble effect on both the magnitude of peak thrombin generation and the time to reach it. 
These results are consistent with experiments using the traditional PT assay, which is activated 
with high levels of tissue factor (2000 nM). With such high levels of activation the contribution 
of the intrinsic pathway cannot be detected and clinicians have to use the aPlT assay to detect 
deficiencies in factors of the intrinsic pathway (Baglin, 2005). 
By running successive simulations of subsystem two with decreasing initial concentrations of 
the procoagulants VIII and IX, we were able to compare our model predictions to experimen-
tal observations of thrombin formation for plasma deficient in factors VIII and IX which can 
be related to haemophilia A and B respectively. Simulations of haemophilia A show a close 
correlation to experimental data with simulations demonstrating that 46 percent of maximum 
thrombin generation was achieved with only 5 percent of factor VIII. The time to reach peak 
thrombin concentration increased from 24 minutes (100% factor VIII) to 38 minutes (5% factor 
VIII), an increase of 58 percent. Experimental data of the influence of factor VIII on a throm-
bin generation assay (Salvagno et al., 2009) demonstrate a maximum thrombin generation re-
duction of 56 percent. The time to the start of the main bolus of thrombin generation (rather 
than time to peak thrombin concentration) increased 64 percent. Simulations of Haemophilia 
B demonstrated a fall in peak thrombin concentration as the concentration of factor IX was re-
duced which agreed with an experimental study (Dargaud et al., 2005) but the time to reach 
peak thrombin concentration as levels of factor IX decreased demonstrated poor agreement. 
We then solved the full model and discussed the effect of thrombin activation on factor XI and 
its contribution to thrombin generation. Simulations of the full model under activation by fac-
tor XIa exhibited behaviour qualitatively similar to experiments (Kravtsov et al. (2009), Figure 
2) designed to assess the sensitivity of thrombin production to factor Xla activation. They do, 
however, show a marked increase in peak thrombin formation. These discrepancies could be 
due to a number of factors. For example, we have had to rely on established estimates for the 
parameters representing the rate of intrinsic tenase formation and the rate that protein C and 
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Figure 4.14: Simulations of the simplified system (equations (4.3.1), (4.3.2), (4.3.3)) demon trat-
ing the contribution of thrombin activation of factor Xl to the generation of thrombin . Th e 
simulations are of equations with competition for thrombin between fibrinogen, factor V and 
factor VIII removed . Initial conditions are taken from Table 4.3 and parameter value from Ta-
ble 4.4 except that klla is varied to adjust the level of activation via the extrinsic tenase: (1) 
klla = 300, (2) klla = 30, (3) klla = 3, (4) klla = 0.3, (5) klla = 0.03, (6) k11a = 0.003, (7) 
klla = 0.0003 nM min- 1 (simulations in Figures 4.4,4.7,4.8 use klla = 0.00003 nM min- 1) . (6) 
shows peak thrombin concentrations as a function of the level of activation (kll a)' Numerical 
solutions of the full model (full line) show consistently greater peak thrombin concentra tions 
than solutions of subsystem two, the extrinsic, in trinsic and common path way (broken line). 
(C) compares the time to reach peak thrombin concentration. 
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Figure 4.15: Simulations of the simplified system (equations (4.3.1), (4.3.2), (4.3.3» demonstrat-
ing the effect of reducing the initial concentration of the procoagulant IX. Numerical imulations 
are of subsystem two with initial conditions from Table 4.3 (except for IX varied to 100%, 80%, 
60%,40%,20%, 10%,5% of plasma IX concentration in each successive simulation). Parameter 
values are from table 4.4. 
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ATIII break it down into its constitutive parts. Our model also neglects other important biologi-
cal features such as the interaction of cell-surfaces. By extending our model to include these and 
other processes it should be possible to improve agreement with experimental observations. 
The model was designed to replicate experimental conditions in which thrombin generation 
is measured in plasma stimulated by the addition of TF. While more detailed mathematical 
models of coagulation exist, our model, which accounts for the biochemistry of the coagula-
tion cascade and limits parameter values to those taken from literature, is able to demonstrate 
that thrombin activation of factor XI can affect thrombin generation in plasma. This contradicts 
results from a previous mathematical model (Kramoroff & Nigretto, 2(01) that specifically in-
vestigated factor XI activation. The model was formulated to reflect the APlT screening assay 
and hence was based on a subset of reactions of the coagulation cascade that excluded the 
extrinsic pathway and was activated via high levels of factor XII. 
There were discrepancies between simulations of equations (4.2.12), (4.2.13), (4.2.14) and ex-
perimental data for haemophilia B and for the contribution that thrombin activation of factor 
XI makes to peak thrombin concentration. A simple modification to neglect competition be-
tween fibrinogen and factors V, VIII and XI for thrombin, between factors IX and X for extrinsic 
tenase and between factor V and prothrombinase for factor Xa produces simulations that show 
a stronger correlation to experiments. Our approach of removing competition may be clumsy. 
Greater knowlwdge of the mechanisms of competition within the cascade and relevant param-
eter values may enable us to investigate this further. 
Our approach may have oversimplified some aspects of the coagulation cascade. Due to the 
paucity of biological knowledge and kinetic data, we activate our model at the level of the 
extrinsic tenase. It would, however, be of interest to include the formation of this complex from 
factor VII and tissue factor, allowing better comparison with experimental data activated by TF. 
The effect of cell surfaces has also been neglected. The availability of platelets and cell surfaces 
are thought to be rate-limiting for the formation of the complexes prothrombinase and extrinsic 
and intrinsic tenase (Hoffman, 2003). The influence of platelets on factor XI is not considered in 
our model even though there is evidence that platelets enhance its rate of activation by throm-
bin (Kravtsov et al., 2009; Baglia & Walsh, 1998). We neglect spatial effects; this is justifiable as 
we develop the present model to replicate in-vitro experimental conditions carried out in well-
mixed plasma. However thrombin activation of factor IX is thought to proceed far from the site 
of injury and it would be interesting to investigate this further. To mimic in-vivo conditions the 
impact of fluid flow would need to be included since this effects the rates of which different 
factors are delivered to, and from, the site of injury. 
While our model is a simplification it has however shown close correlation to experimental 
data in a number of areas and has shown that a mathematical model of the thrombin generation 
assay can detect a contribution from thrombin activation of factor XI to thrombin formation. 
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Figure 5.1: 
Part II 
Inflammation 
The v isible signs of inflammation . Court y of Mol u lar M diein w b it 
by Dr. Danjele Focosi, MD at www.myhematologist.n t. 
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CHAPTER 5 
Inflammation Background 
This chapter is divided into two main parts. We present a description of the biological processes 
involved in an inflammatory response to tissue damage in Section 5.1 and follow this, in Section 
5.2, with a review of the current mathematical literature relevant to soft tissue inflammation. 
5.1 Biological background 
Inflammation has long been recognised by its clinical symptoms of heat, redness, swelling, pain 
and loss of function described by Celsus in the first century (see Figure 5.1). It is the body's 
first line of defence against tissue damage and invading pathogens that attempts to kill the 
pathogens and remove damaged and dead tissue so healing can proceed. It is a key component 
in the repair process that soft tissue undergoes and is triggered in response to real or perceived 
threats: these include the introduction of pathogens and mechanical stress (Butterfield et a1., 
2006). Inflammation can occur in both sterile and non-sterile conditions, where the body reacts 
to tissue trauma as if the emergency is infection (Nathan, 2002). Haemorrhage, surgical wounds 
(Szpaderska & DiPietro, 2005) and muscle loading (Koh & Pizza, 2009) can each trigger an in-
flammatory response that appears to be independent of infection (Nathan, 2002). 
Inflammation is normally a beneficial process, removing dead tissue and killing pathogens be-
fore initiating the subsequent healing phases and subsiding, but it can have an alternative fate 
- instead of subsiding it can progress to a self-perpetuating, chronic inflammatory condition 
where tissue repair is compromised (Giles & Lawrence, 2008; Serhan et a1., 2008). Chronic low 
grade inflammation has long been know to contribute to many diseases including rheumatoid 
arthritis, chronic bronchitis and asthma but in recent years it has also been recognised as play-
ing a key role in illnesses such as Alzheimer's disease, cardiovascular disease, Parkinson's dis-
ease and cancer (Serhan et al., 2008; Perretti & Flower, 2008). Inflammation has also been shown 
to have a relationship to obesity, insulin resistance and ageing (Vassileva & Piquette-Miller, 
2010), all topics of increasing interest. 
The mechanisms involved in the resolution of inflammation are now widely studied. While 
the signals and mechanisms that promote inflammation have been well studied and are un-
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derstood, the events and signals that contribute to its resolution are less so. Until recently 
resolution was thought to be a passive process which terminates the chemotactic signals and 
gradients bum out (Majno & Joris, 2004). There is now agreement that it is an active process 
and that deficiencies within it contribute to many inflammatory diseases (Serhan et al., 2(08). 
The inflammatory reaction in soft tissue is depicted in Figure 5.2 Endogenous pro-
inflammatory chemical mediators such as vasoactive and chemotactic chemicals are released 
from damaged tissue. These mediators are many and include histamine from damaged 
mast cells, clotting system products (plasmin, fibronectin and fibrin), lipid-derived inflamma-
tory mediators (such as prostaglandins and leukotrienes), cytokines and chemokines (such as 
interleukin-1) and oxygen derived radicals (Gilroy et al., 2004). White blood cells (both neu-
trophils and macrophages) respond to these signals by migrating from the surrounding vascu-
lature into the damaged tissue where they drive the inflammatory response with the further 
release of pro-inflammatory mediators such as LTB4 (Serhan, 2(07). 
Neutrophils are the first white blood cells to arrive, being smaller and faster moving than 
macrophages (Majno & Joris, 2004). Once within the tissue they become activated and set about 
digesting (phagocytosing) any foreign material or necrotic debris left over from the original in-
jury. They are essential for the removal of invading micro-organisms but, in attempting to neu-
tralise these micro-organisms they generate substances such as reactive oxygen species (ROS) 
that can be toxic for healthy tissue (Giles & Lawrence, 2(08). Neutrophils have a short lifes-
pan, dying within 6-8 hours by a process called apoptosis (Summers et al., 2010), during which 
they release signals that are recognised by the later arriving macrophages, which respond by 
phagocytosing them. Rates of neutrophil apoptosis can be modified, with pro-inflammatory 
signals and bacterial derived products supporting neutrophil survival, and phagocytosis of 
neutrophils by macrophages produces growth factors that decrease neutrophil survival induc-
ing their death (Heasman et al., 2003; Kobayashi & Deleo, 2009). Macrophages are considered 
to have differentiated from resident monocytes and those that have migrated from the sur-
rounding vasculature (Gordon & Taylor, 2(05). Once within inflamed tissue they are activated 
to release prO-inflammatory mediators and phagocytose necrotic debris and apoptotic neu-
trophils. It is now thought that macrophages can alter their activation state so that at the point 
at which they engulf apoptotic neutrophils, they switch to a pro-resolution phenotype pro-
ducing anti-inflammatory mediators such as transforming growth factor beta (TGF-/3) which is 
associated with resolution and repair (Giles & Lawrence, 2(08). The mechanisms responsible 
for this transition are still unknown but are thought to include macrophage recognition and 
phagocytosis of apoptotic neutrophils (Porcheray et al., 2005; Sampson, 2000; Gordon & Taylor, 
2005; Stout et al., 2005; Arnold et al., 2007). 
The removal of apoptotic neutrophils is also thought to be crucial in the resolution process due 
to the dual role of neutrophils in inflammation (Whyte et al., 2(08). Initially, neutrophils provide 
a beneficial effect by removing debris and killing any perceived local pathogen. However the 
agents they release to kill the pathogens can, of high enough concentrations, damage healthy 
tissue, and thereby amplify the inflammatory response (Serhan, 2(08). Additionally, damage 
can occur if the neutrophils undergo necrosis, a process of violent cell death during which the 
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Figure 5.2: Events in acute inflammation. 'Triggers' such as surgica l trauma, tissu injury and 
invad ing pathogens activate the release of pro-inflammatory m diator . Th e r cruit whit 
blood cells, both neutrophils and macrophages, which can further nhan th pr e . u-
trophils, through the release of toxic agents to kill invadi ng micro-organi m and through n cr -
sis, can cause ongoing stimulus by damage otherwise healthy tissu . Thi can be limit d by th 
timely removal of apoptotic neutrophils by macrophage, which pro mot a temp ral wi tch to 
a pro-resolutory signalling network whereby anti-inflammatory m diator bring th inflamma-
tory response under control. 
neutrophils lose their membrane integrity and spill their toxic cont nt lnt th urr unding ti -
sue. Necrosis can be stimulated by tissue damage. Equally, if th ria d lay in th I a ranc f 
apoptotic neutrophils, they undergo secondary necrosis, leading to damag and p r i t nt in-
flammation (Lawrence & Gilroy, 2007; Van Hov et al., 2008; Ro i & Sawatzky, 200 ). S ,b th 
the behaviour of neutrophils and their apoptotic r moval by macrophag ar th ught t b 
crucial to the resolution of inflammation (see Figur 5.3). Finally, macr phag it 
of inflammation and it is thought that they migrate pr dominantly t th n ar t lymph n d 
where they die by apoptosis (Van Hove et al., 2008). 
For the inflammatory response to subside the injurious ag nt mu t b cI ar d. It i th n that 
anti-inflammatory signals and events can be set in motion in ord r to count r th many pr in-
flammatory signals (Serhan, 2007). These regulatory substance r v r va cular chang , in-
hibit leukocyte migration and activation and promote th saf r moval of inflammatory c II , 
exudate and fibrin, thereby leading to restoration of the inflamm d ti ue (Gilr yet al., 2004). 
Anti-inflammatory mediators include cytokines such a Interleukin-10 «(L-10) and tran form-
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Figure 5.3: A schematic of neutrophil removal and its implication. Their ar variou factor that 
influence the apoptotic rate of neutrophils. Once neutrophils hav und rgon ap pt i th Y 
can be phagocytosed by macrophages, furth r to this there i no r lea of pro-inflammat ry 
mediators but an up-regulation of anti-inflammatory mediators by macr phage. If th n u-
trophils become apoptotic but are not removed by macrophag s th y can und rg , condary 
necrosis'. Neutrophils can also undergo necrosis befor phagocytosis. ith r (orm of necro i 
has the potential to cause tissue injury and through the release of pro-inflammatory m diator 
amplify the inflammatory process. Modified from Ward eJ al. (1999). 
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ing growth factor beta (TGF-J3), glucocorticoids, resolvins and protectins (Van Hove et al., 2(08). 
Aspirin is known to be anti-inflammatory, due to its ability to limit the formation of lipid me-
diators such as thromboxanes and prostraglandins. It is also thought to trigger the production 
of the newly identified lipid mediators resolvins (resolution phase interaction products) and 
protectins. These are generated from omega-3 polyunsaturated fatty acids and are thought to 
reduce vascular permeability, retard the entry of new neutrophils to sites of damage and stim-
ulate macrophages to ingest and clear apoptotic neutrophils (Serhan, 2007; Serhan et al., 2008; 
Serhan & Savill, 2005; Singer et al., 2008). TGF-J3 production, linked to neutrophil apoptosis, 
also suppresses a wide range of pro-inflammatory signals, though not notably of chemokines 
such as MCP-1 that are involved in attracting mononuclear phagocytes (Serhan & Savill, 2005; 
Henson, 2(05). Glucocorticoids are thought to accelerate the uptake of apoptotic neutrophils 
(Serhan, 2007). These anti-inflammatory mediators, and other events within the resolution of 
inflammation, still require detailed characterization (Serhan & Savill, 2(05). 
The understanding of both pro-inflammatory and pro-resolution responses is complicated by 
the high degree of redundancy. Nonetheless there is a need for new ways to control inflam-
mation: by understanding the mechanisms of the resolution of inflammation it is hoped that 
we may identify new ways to control inflammation that can be exploited by novel therapeutic 
agents (Gilroy et al., 2004; Nathan, 2002; Whyte et al., 2008). Apoptosis has a fundamental role 
in the resolution of inflammation and both enhanced apoptosis, as occurs in Alzheimer's dis-
ease, Parkinson's disease and multiple sclerosis, and inappropriate inflammatory responses 
with tissue damage and delayed apoptosis have been observed (Gilroy et al., 2(04). In our 
mathematical model we aim to capture these distinct anti-inflammatory events, to investigate 
the dual role played by neutrophils and to assess the importance of macrophages in removing 
apoptotic debris. 
5.2 Mathematical background 
Inflammation is a complex process involved in many diseases and as such many computational 
and mathematical models exist that describe the inflammatory process downstream of the ini-
tial acute inflammatory response or seek to model different disease scenarios (Tran et al., 1995; 
Gammack et al., 2005; Warrender et al., 2006; Kumar et al., 2(08). We limit our review to those 
mathematical models that are specific to a generic inflammatory response or show significant 
overlap to the biological mechanisms that we include in our model. 
Some of the earliest models of the acute inflammatory response were developed by Lauffen-
burger and coworkers. For example, Lauffenburger & Keller (1979) produced a model that 
looks at a bacterial infection in a microscopic area of tissue surrounding a single venule. The 
model consists of three partial differential equations for bacterial density, leukocyte density and 
chemoattractant concentration and is used to study the effectiveness of the inflammatory re-
sponse against bacterial infection and its dependence upon the values of the leukocyte random 
motility and chemotactic parameters. A later, macroscopic model (Lauffenburger & Kennedy, 
1981) also considered an inflammatory response to bacteria and was formulated as a system of 
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two coupled ordinary equations for bacteria and leukocytes where the dynamics of the leuko-
cyte effectiveness in clearing a bacterial infection are studied. This model was later extended 
to investigate the influence of spatial effects (Lauffenburger & Kennedy, 1983). By varying the 
importance of cell motility and chemotaxis the authors showed how cell densities can be highly 
localised if the bacteria are not eliminated, with the subsequent potential for severe tissue dam-
age. Alt & Lauffenburger extended Lauffenburger & Kennedy's microscopic model by includ-
ing an additional equation for a chemoattractant (Alt & Lauffenburger, 1985). The resulting 
model was approximated by a system of two nonlinear ordinary differential equations and 
used to show that defects in leukocyte chemotaxis correlate with an increase in severity of bac-
teria infection but not with the concentration of leukocytes. 
Kumar et al. (2004) presented a simple model to describe an inflammatory response to a 
pathogen. The model consists of three ordinary differential equations representing a pathogen 
and two phases of an inflammatory response (early and late). The authors used their model to 
investigate whether the inflammatory response can clear the invading pathogen or whether it 
stimulates a sustained inflammatory response. Reynolds et al. (2006) presented a reduced ODE 
model that they used to investigate the resolution of the inflammatory response to a bacterial 
invasion, building on the previous model of Kumar et al. (2004) by adding an anti-inflammatory 
mediator. The resulting system of four ODEs with dependent variables representing pathogens, 
activated phagocytes, tissue damage and anti-inflammatory mediators was examined by first 
considering two subsystems of the model and then combining them to give the complete sys-
tem. By building up the models to a three and then "complete" four variable system the role 
and "therapeutic" use of anti-inflammation was analysed. The model of Day et al. (2006) re-
places the pathogen equation of the previous model with an equation for endotoxin so they can 
emulate multiple administrations of endotoxin, successfully matched by experimental studies 
in mice. 
Other mathematical models exist that, while not modelling a similar inflammatory response in 
soft tissue, involve white bloods and we list a few of these, some of which we have used as 
a source for parameter values. Maree et al. (2005); Maree et al. (2006,2008) model macrophage 
clearance of apoptotic ~ - c e l l s s in mice using two simple ODE models and generate simulations 
that show a wave of apoptosis in ~ - c e l l s s leading to a chronic condition. Waugh & Sherratt (2006, 
2007) discuss macrophage dynamics within the context of wound healing under diabetic condi-
tions. An ODE model, with three variables representing two distinct macrophage phenotypes 
and T F G - ~ , , is extended to include further mediators and fibroblast and collagen densities. By 
simulating different treatment protocols, they find that the key mediator for successful heal-
ing is hyaluronan and successfully correlate time-to-healing results to clinical trials. Previous 
mathematical models that investigate macrophage dynamics in the context of mycobacterium 
tuberculosis include Wigginton & Kirschner (2001), who developed an ODE model for the var-
ious macrophage classes, T cells, cytokines and intracellular and extracellular bacteria. Sim-
ulations of disease trajectories are obtained and show a dependence on the effective removal 
of bacterially-infected macrophages. Gammack et al. (2004) developed a model consisting of 
reaction-diffusion-advection POEs governing macrophages, bacteria and mediators in a tuber-
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colosis infected environment. Numerical simulations show two infection outcomes: controlled 
and uncontrolled formation of granulomas (clumps of macrophages). 
5.3 Discussion 
In this chapter we have provided a biological introduction to inflammation, focussing on as-
pects that will be relevant to the mathematical models that are developed in the following 
chapters. We also reviewed relevant existing mathematical models. Previous models of the 
inflammatory response have not focused on the processes that limit inflammation, particularly 
the interactions of white blood cells. In the next chapter (Chapter 6) we produce an ODE model 
concentrating on these interactions. We then reduce our model, showing that this simplification 
retains the same outcomes, and extend it to include spatial effects (Chapter 7) . 
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CHAPTER 6 
The Resolution of Inflammation 
6.1 Introduction 
The acute inflammatory response initiated by tissue damage involves a cascade of events 
that normally resolves within hours (Rossi & Sawatzky, 2(08). It has the aim of remov-
ing any cellular and tissue debris caused by the initial injury, killing any invading micro-
organisms and initiating the healing phases during which damaged tissue is replaced (pro-
liferation) and remodelled. In general, inflammation is a self-limiting process but, if it remains 
unchecked, as it can if the injurious agent persists, it can progress to chronic inflammation, a 
self-perpetuating process that can last for weeks, months or even years. While knowledge about 
the mechanisms involved in inducing and perpetuating the inflammatory response are we11-
characterised, those that limit and down-regulate it are less well understood (Butterfield et al., 
2006; Eming et al., 2007). However, there is evidence that apoptosis and the timely removal of 
neutrophils by macrophages play key roles in the resolution of inflammation (Kobayash et al., 
2003; Serhan & Savill, 2005; Rossi & Sawatzky, 2008). 
We present, below, a time-dependent model that is formulated as a system of ordinary differen-
tial equations and concentrates on neutrophils, macrophages and their interactions. Where pos-
sible, parameter values are taken from the literature and otherwise, we make estimates guided 
by our understanding of the biology. In Section 6.3 we investigate the different qualitative be-
haviours that our model exhibits and discuss them in terms of the inflammatory response and 
its possible outcomes. In Section 6.5 we construct bifurcation diagrams in order to study the 
effects of varying some key control parameters such as the rate of neutrophil apoptosis. We 
discuss the biological implications of these results, and possible model modifications in St>ction 
6.6. 
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6.2 Mathematical model 
6.2.1 Formulation 
The model describes the evolution of nine variables (see Table 6.1) over a time-scale of sev-
eral days. Unlike previous mathematical models of inflammation that consider only a single 
population of white blood cells (Lauffenburger & Keller, 1979; Lauffenburger & Kennedy, 1981, 
1983; Alt & Lauffenburger, 1985; Reynolds et al., 2006), our model distinguishes between dis-
tinct populations of white blood cells by incorporating the following cell types: two distinct 
macrophage phenotypes, namely the initial inflammatory form (population size m) (t» and 
the later anti-inflammatory phenotype (m2(t) that initiates the subsequent reparative phases, 
and active and apoptotic neutrophil populations (n) (t) and n2 (t) respectively). Most previ-
ous models (Lauffenburger & Kennedy, 1981, 1983; Alt & Lauffenburger, 1985; Kumar et al., 
2004) do not include an anti-inflammatory mediator, concentrating instead on the processes 
that drive inflammation. Being interested in both pro and anti-inflammatory pathways, we in-
clude a generic prO-inflammatory mediator (concentration e(t» that is chemotactic for white 
blood cells and a generic anti-inflammatory mediator (g(t) that is released from macrophages 
when they remove apoptotic neutrophils. The reference space for our model is a generic 
soft tissue. We distinguish between damaged (volume fraction w(t) and healthy (h(t» tis-
sue and, as we are interested in neutrophil death and its implications for the resolution of 
inflammation, we include, in a single variable (u(t), the concentration of toxic substances re-
leased by necrotic neutrophils and by active neutrophils in their attempt to clear pathogens. 
Since we wish to specialise the model for musculoskeletal disorders, we incorporate an exter-
nal stimulus (f(t» to represent the effects of damage caused by mechanical stress. Previous 
models (Lauffenburger & Kennedy, 1981, 1983; Alt & Lauffenburger, 1985; Kumar et al., 2004; 
Chow et al., 2005; Reynolds et al., 2006) have concentrated on the response from an evolving 
pathogen and our model could be modified to incorporate this by modifying the functional 
form of J(t). 
In the next section we introduce our model process by process with the aid of increasingly 
detailed schematics. The schematics enable us gradually to reveal the full model. We then use 
this network diagram (Figure 6.8) to formulate a system of nine ordinary differential equations 
(6.2.6). The dimensional model parameters are defined in Table 6.2. 
6.2.2 Process 1: Tissue damage 
We distinguish between healthy (volume fraction h (t) and damaged (volume fraction w( t) tis-
sue. Healthy tissue can be damaged by an external stimulus (f(t) at rate kht (equation (6.2.1a» 
reflecting an injury such as mechanical trauma. Upon damage, a variety of chemical media-
tors are released (cell adhesion molecules, cytokines, chemokines etc.) from distressed resident 
cells such as mast cells (Luster et al., 2005). These chemical mediators initiate and augment the 
inflammatory response and include chemokines such as IL-8 (Adams & Lloyd, 1997). While 
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Figure 6.1: A schematic depicting the variables (blue r ctangl ) and r action (solid 
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by an external stimulus J(t) that caus 5 the r I a of ch moattr tant (c) . 
Table 6.2 for a definition of the parameters. 
more than fifty chemoattractants have b en identifi d for whit bl d c 1J (Burk & wi I 
2002; Reid et al., 2006), we make no distinction b tw en th m, in t ad making th implifying 
assumption that there is a single chemical r gulator (cone ntranon c) which attra both n u-
trophils and macrophages. The regulator is r leas d up n damag t ti u (r t 
and decays at rate 'rc. These events ar d picted in igur 6.1 and th (inc mpl t Ii.. in-
cluding only the terms that have b en describ d thu far) as ociat d qua non for h althyand 
damaged tissue and the chemoattractant can b writt n as follow : 
dh 
-d = - klrd(t)h I 
t ~ ~
damage 
dw 
-d = klrd(t)h, 
t ~ ~
damage 
dc 
-d = kcwf(t )h - ICC. 
t '-v--" "'-v-"' 
release decay 
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(6.2.1a) 
(6.2.1b) 
(6.2.1c) 
Cells 
1/2 max. infux 
hemoattractant 
Figure 6.2: White blood cell influx is a saturating function of chemoattractant 
concentration (the parameters kx, f3x relate to neutrophils and kxlll , f3xlII to 
macrophages). 
6.2.3 Process 2: Migration of white blood cells into damaged tissue 
Neutrophils and monocytes migrate from the surrounding capillari into th ti su in r pon 
to a concentration gradient in the chemoattractant in the r gion surrounding th sit of injury. 
Neutrophils are assumed to enter the tissue in active form (111) (in practic activation i 
tremely rapid and so we neglect any time lag). Monocyt also migrate into th damag d 
tissue where they differentiate into macrophages (d nsity siz n11) ' As with neutrophil w 
omit the initial activation and differentiation phas s of th macrophag ,a uming that th y 
arrive activated. We assume that the rates of migration of both c II typ i an incr a ing and 
saturating function of the chemoattractant concentration of th form hown in igur 6.2. Th 
sa turating form places a physical limit on th rate at which c II n 
their passage through the tissue. We assum that crowding d 
denote by kx and kxm the maximal rates of neutrophil and macrophag influ , r p ctiv Iyand 
by f3x and f3xm the chemoattractant concentration at which th rat ar h If-ma imal ( 
equations (6.2.2a)). These events are depicted in Figure 6.3 and, with th n wly intr du d 
equations for nl and m] shown in red, the system is now giv n by: 
dnl kxc 
dt f3x + c ' 
"--v--' 
migration 
dml kxmc 
Cit = f3xm +- c ' 
~ ~
migrali n 
dh dw dt = - khd(t)h, dt = khd(t)I1, 
dc 
dt = kcwf(t}h - ' cC. 
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(6.2.2 ) 
(6.2.2b) 
(6.2.2c) 
f(t) : 
Healthy tissue 
(h) 
r - - - - ~ ~ ~ -f[ - - - ACli\c neulrophll 
(II I ) 
Damaged tissue 
(w) 
Macrophages 
(m l ) 
Figure 6.3: A schematic depicting the variables (blue r ctangl ) and r action ( lid lin ) 
associated with white blood cell migration into damaged tissu ( etion 6.2.3). Th variabl 
(grey rectangles) and the reactions (dashed lines) introd uced in Figur 6.] ar includ d (or 
clari ty. Populations of neutrophils (n l ) and macrophages (ml ) arriv in r pon 
tractants (concentration c) which are released when healthy ti u is damag d. 
for a definjtion of the parameters. 
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6.2.4 Process 3: Neutrophil death 
We assume that neutrophils can exist in two states, active (density n1) and apoptotic (d n-
sity 112) ' Neutrophils are activated once in tissue and die by a normal death proce ca ll d 
apoptosis. Whilst neutrophils normally have a short lifespan, dying by apoptosis within 6-10 
hours, it is well known that the rate at which neutrophils undergo apopto is can b modifi d 
by extra-cellular stimuli (Whyte et al., 2008). For example their lif span is thought to increa 
several-fold once they are in inflamed tissue (Akgul et al., 2001) and there is som evidenc that 
this effect is due to pro-inflammatory mediators (Rossi & Sawatzky, 2008; Lee ef al., 1993). W 
model the reduction in the rate of neutrophil apoptosis (kn) under inflammatory conditions by 
viewing the chemoattractant as an inflammatory marker (the parameter fi e is th lev I of th 
chemoattractant that the effect, of the chemoattractant on the rate of neutrophil apopto is, i 
half-maximal: see equations (6.2.3a), (6.2.3b) noting the placement of fi e when compar d to fi x 
varies). Apoptotic neutrophils are non-functional, unable to mov in r sponse to chemoattrac-
tants and have little phagocytic abiHty (Kobayashi & DeL 0,2009). 
We also allow for necrotic death of neutrophils: this is premature death and, in contra t to 
apoptosis, results in a loss of membrane integrity and spilling of th n utrophil c nt nt , which 
we treat as one species (concentration (1) (Lawrence & Gilroy, 2007; Kobaya h et al., 2003) . 
Chemoattractants are also spilled upon necrotic death. For activ n utrophils w a um th t 
necrosis is induced by an external stimulus (f(t ) and we quantify thi pr by 'Yn1 ( qu ti n 
(6.2.3a», this rate parameter being included in both th term for th pilling of n utrophil on-
tents (along with parameter ked (equation (6.2.3f) and th corr ponding t rm for th r I a 
of chemoattractants (along with parameter kenl ) (equation (6.2.3g». Apoptoti n utrophil m y 
also undergo necrosis: this occurs naturally, their membrane br aking d wn wh n th yag . W 
quantify this effect via the parameter 'Yn2 and includ the rat con tant kU3 f r th ub qu nt 
release of neutrophil contents (see equation (6.2.3f) and th param t r kcn2 f r th 
chemoattractants (equation (6.2.3g» (Rossi & Sawatzky, 200 ; Ward et al., 19 9». 
Damaged tissue is a broad category which includ s n cr n fa t r 
kW1' kW2 )' The events described above are depicted in Figur 6.4 and, with th n wly intr du d 
terms and equations (shown in red), the system now r ad 
dnl kxc f( ) knn1 
dt = fi x + C - ~ ~ - (1 c ) , 
n rotic d 3th irr 
d112 knn1 
= 
dt (1 + fc ) 
~ ~
apoptotic death 
dml kxmc 
- = , 
dt fi xm + c 
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~ ~
apopto i 
'Yn21l2 
---.....-
ondary nc r IS 
(6.2.3 ) 
(6.2.3b) 
(6.2.3c) 
f(t) 
<:} -- --
: k hl 
Damaj!ed tissue 
(w) 
f..oIf--,..-__________ ---t:::::::... ____ --....:=_-rJlOptotic neutrophil 
k .. 2 (n,) 
Figure 6.4: A schematic depicting the the variables (blue r ctangl s) and r action ( lid lin ) 
associated with neutrophil death (Section 6.2.4). Variabl s (gr y r tang l ) and r a nons 
(dashed lines) introduced in Figures 6.1 and 6.3 are includ d for clarity. Activ n utr phil 
(popu lation size n1) die by first becoming apoptotic (population iz "2), th rat of apopt -
sis (k ll ) being reduced in an inflammatory situation. Both active and apoptotic n utr phil can 
undergo necrosis. Necrotic neutrophils contribute to damag d tissue (rat kW1' kW2). Tabl 
6.2 for a definition of the parameters. 
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Variable Description Unit 
nl active neutrophils cells mm - 3 
n2 apoptotic neutrophils cells mm - 3 
n71 pro-inflammatory macrophages c lis mm - 3 
n72 anti-inflammatory macrophages cells mm - 3 
w damaged tissue and debris volum fraction 
h hea lthy tissue volum fraction 
u neutrophil toxic contents pgmm- 3 
C chemoattractants pg mm - 3 
g growth factors pg mm - 3 
Table 6.1: Definjtions of the model variables and their units (s e Table 6.2 for a definition of 
the dimensional variables). ote h + w is not conserved, i.e. does not r main equal to one 0 
'volume fraction' should be interpreted as the amount p r unit volume of the original ti u . 
dh 
dt = - k/lIf(t)l1, (6.2.3d) 
dw Cit = kht/( t)11 + ~ W l l 'Yn,j(t ) 111 + k U l 2 ' ' n 2 1 l l , ,
v 
( .2.3 ) 
necrotic neut rophil debn 
du dt = ~ u 2 ' Y n , j ( t ) n l l + k U U ' Y Y 2 1 l l , ,
v 
( .2.3 f) 
production 
dc 
dt = kcwf(t)h + ~ c n l ' Y n , , ( t ) 1 1 1 1 + k c n 2 ' ' n 2 1 l ~ ~ - 'YeC. 
v 
( .2.3g) 
produ Ii n 
6.2.5 Process 4: Neutrophil toxicity 
Activated neutrophils seem to be programmed to tr at an injury a inf t d, r I a ing t 
chemicals that they have stored in granules within them in an att mpt to ount r th inf tion 
(Scott et at., 2004; Nathan, 2002). These cherrucals, which includ rea tiv 
highly toxic and, while effective at killing bacteria, can cau damag to th urr unding ti -
sue if present at high enough concentrations (Haslett, 1999). For simplicity w tr at th 
chemicals as neutrophil contents (concentration 0") and assume that th yar r I a d by a tiv 
neutrophils (rate constant kUl). We assume neutrophil cont nt cau damag at low I v I . 
However, as these contents accumulate, the damage they caus to h althy ti u , at-
urating at high levels of 0" to a maximal value of k". They cau th r lea of h m attr tant 
in a similar manner to a maximal value of kelt. We use th functional form depict d in Figur 
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k" 1 
Q) 0.8 
01) 
ce 
E 0.6 
ce 
"0 
Q) 
;:::I 
0.4 
Vl 
Vl 0.2 f= 
0 
0 0.5 
~ a a (J 
Figure 6.5: Sketch of the Hill function (with Hill coefficient 
two) used to model the rate of tissue damage caused by neu-
trophils contents (0') . Maximal damage, at rate k" occurs when 
0' -+ 00, and f3 (T is the value of 0' at which the rate of damage 
is half-maximal. 
6.2, denoting by f3 (T the amount of (J required for half-maxima l damag to tissue. W as urn 
that these chemicals undergo linear decay (rate constant "Yu) and ar con um d whil d maging 
hea lthy tissue (rate "Yult ), producing pro-inflammatory mediator including ch moattractant . 
These events are depicted in Figure 6.6 and, with th newly introduc d t rm and quation 
(depicted in red), our model now reads 
dn11 kxmc 
Cit = f3 xm +c ' 
~ ~ = = k h , f ( t ) ) - k h h ( ( 2(J2 2) ' f3u + (J 
, # 
v 
damag d by u 
~ ~ ~ = kh,f(t)h + khh ( 2 (J2 2) +kwl "YnJ/(t) 11, + kW2"Yn2112, f3u + (J 
, ; 
v 
damaged by u 
dd(Jt = ku1nl +ku2"YnJ/(t) nl + ku3"Yn2112 - "YIT/,Il ( 2 (J2 2) - "YIT(J , 
.........".... f3/T + (J '-v-' 
product ion ' '" ' d ,'y 
uplakl' 
~ ~ ~ = kcwf(t)h + kc"h ( 2 (J2 2) + kcll1"YIlJ/(t)nl + kCl12"Y1l2112 f3u + (J 
, ; 
'" colorreddamage 
- ("Ycn I1 1 + "Ycm n11) C - "YcC. 
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(6.2.4 ) 
(6.2.4b) 
(6.2.4 ) 
(6.2.4d) 
(6.2.4 ) 
(6.2.4f) 
(6.2.4g) 
Healthy tissue 
(h) 
f(t) : 
_ k ~ , _ ~ ~ __ _ 
Chemoattractants 
(c) 
\ 
\ ' \ 
\ I 
kx" ;'( 
\ 
, 
--:=-- - - - - ... 
*x Active neutrophil 
(nl) 
I I , 
I 
I • 
f(t) I 
Y. I 
, ........ .;" ~ ~ / J 
.... ken I ... .... .... ..{' 
-- __ - " .J. 
_ - - - - I . - - - " C C ~ ~ " 
eutrophil contents ka2 I 
(0) / 
- I 
--I'k I • 
-' k. 1 
\ I 
<J- ~ ( ! ! - -
: kill 
\ I 
\ I 
'I, 
Yo 
I ko) ~ ~ / 
\ I 
Damaged tissue 
(w) 
I , \ ,," 
v 
~ ~ \ 
:<: ' 
I ...... .". "' ...... ....... Yn2 
_____ ____ ___ _____ ., :: ________ :: = ii • popl ti neutrophil 
k .. 2 I (nl ) 
, 
, 
p 
Macrophages 
(ml) 
Figure 6.6: A schematic depicting the variables (blue r ctangl ) and r acti ns ( olid lin ) < -
sociated with neutrophil toxicity (Section 6.2.5). Activ n utrophil r I a n utr phil nt nt 
in an attempt kill any bacteria present (kO' }). damag t h althy ti -
sue (kh ) and the subsequent release of chemoattractants (kcl,). Th variabl (g r y r ctangl ) 
and reactions (dashed lines) introduced in previous Figur (6.1,6.3, 6.4) ar includ d f r clar-
ity. See Table 6.2 for a definition of the parameters. 
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k, 
t •• 
k •• , 
, 
, 
, 
'. ---1:/ 
, . 
Figure 6.7: A schematic depicting the variables (blu r ctangl ) and r acti n lid lin } a -
sociated with macrophage removal of neutrophils ( ction 6.2.6). Macr phag r m v ap p-
totic neutrophils and switch phenotype to an anti-inflammat ry ( rm r I a in r wth (a t r 
Growth factors dampen neutrophil influx and incr a n utrophil ap pt h vari bl 
(grey rectangles) and reactions (dashed line) introduc din pr viou igur (6.1, .3, 6.4) ar 
included for clarity. See Table 6.2 for a definition of the param t r . 
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6.2.6 Process 5: Macrophages remove neutrophils 
Macrophages are known to be heterogeneous in thei r response to variou m diator and to 
exhibit a range of activated states. Several researchers have proposed that, in an inflamma-
tory environment, macrophages sequentially exhibit pro- and anti-in flammatory prop rti 
(Stout et al., 2005; Porcheray et al., 2005; Gordon & Taylor, 2005). We introduc a population of 
anti-inflammatory macrophages (m2) in addition to the pr viously describ d pro-inflammatory 
phenotype; both types of macrophages (pro-inflammatory and anti-inflammatory) and activ 
neutrophils are phagocytes and remove damaged tissue at rates kwml' kwm2 and k wn r p c-
tively. Recognition of apoptotic neutrophils by macrophages is thought to cau macrophag 
to become reprogrammed to release a range of anti-inflammatory signa ls, including IL-IO and 
TGF-,6 (Lawrence et al., 2007; Lawrence & Gilroy, 2007; Henson, 2005; Serhan & Savill, 2005), 
and it is this transition that we model by introducing a switch in macrophag 5 from a pro-
inflammatory phenotype to an anti-inflammatory on at a rat proportion I to th rat at 
which prO-inflammatory macrophages engulf neutrophils (ra t constant km). To simplify th 
model we assume also that this change of phenotyp is irreversibl , though th re is om v-
idence to the contrary (Porcheray et al., 2005). Macrophag s (both pro-inflamm tory nd anti-
inflammatory) respond to signals from apoptotic n utrophil and ngulf th m (rate constant 
knml and knm2, respectively): this prevents the neutrophils from undergoing ondary n 
and spilling their toxic contents (Lawrence & Gilroy, 2007; Van H v et al., 2008). W n gl t 
macrophage death, assuming instead that the two phenotyp I av th ti u (t rat 1ml' 
1m2). We also neglect macrophage proliferation. We make no distinction b tw n th diff r nt 
signals released by anti-inflammatory macrophages, making th implifying a umpti n that 
they release a single generic growth factor (concentration ) with rat con tant kg. Thi gr wth 
factor is anti-inflammatory, taking an active role in th r olution of inflamm ti n, mp n-
ing the effect of chemoattractants on active n utrophil and incr a ing n utr phil ap pt i 
(Serhan, 2007). We assume growth factors d cay lin arly (rat c n tant 18). ,6"g i th n-
centration of g over which the effect of g, on the rat of apopto i ,i half-ma im I. f3 cg i th 
concentration of g over which the effect, on th rat of influx f n utr phil, i half-ma im I. 
Healthy tissue is replaced in the downstream prolif rativ stag in whi h gr wth fact r initi-
ate tissue repair (rate constant khg ). All of these events ar depict din igur 6.7 and th 
with the newly introduced terms described abov (d pict din r d), ar : 
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(6.2.5a) 
(6.2.5b) 
(6.2.5c) 
down tream repair 
- k wm ]n1]w - kwm2n12W - k wlI lll W , 
" .I v 
phagocyto is 
~ ~ ~ = kUl n] + ku2l111 f(t)nl + ku3'Y112n2 - 'Yu/rlt ( t t ~ : : ()"2 ) - 'Yu()", 
~ ~ ~ = kcwf(t)h + kc/rh ( 2 ()"2 2) + kcIl1 'Y1IJ/(t) 1l1 + kC1l2'Y1I2 112 t3u + ()" 
- ('Ycn n l + 'Ycmml) C - 'YeC, 
dg Cit = kgm2 - 'Ygnl11g - 'Ygg . 
'-v-" -.........--.- '--v-" 
production uptake decay 
6.2.7 Model summary 
(6.2.5d) 
(6.2.5 ) 
(6.2.5f) 
(6.2.5g) 
(6.2.5h) 
(6.2.5i) 
The complete network d iagram is shown in Figur 6.8 and, for clarity, w r tat th or 
sponding system of equa tions: 
~ ~ ~ = ku1nl + ku2l1lJ/(t )nl + ku3'Yn2n2 - 'Yu/r11 ( 2 ()"2 2) - 'Yu()", t3u + ()" 
~ ~ ~ = kewf(t)h + kcIJh ( 2 ()"2 2) + kenl'YnJ/( t )111 + kell2'Y1I2 11 2 f3u +()" 
- ({enn] + 'remm]) C - 'reC, 
dg Cit = kgm2 - 'Ygllnlg - 'Ygg. 
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(6.2. a) 
(6.2. b) 
(6.2. 
( .2. 
(6.2. 
(6.2.6f) 
(6.2. g) 
(6.2.6h) 
(6.2.6i) 
Figure 6.8: A schematic depicting the model for the resolution of inflammation, variabl ar 
denoted by blue rectangles and reactions by solid li nes. Se Tabl 6.2 for a d finition f th 
parameters. 
6.2.8 N ondimensionalisation 
We nondimensionalise equations (6.2.6), using tildes to r pre nt d im n i nl quanti ti . W 
scale time with the timescale for the decay rat of th ch moattractant c nc ntr ti n, th t T = 
'Yet. The chemoattractant is rescaled with the typical ini tia l c nc ntration of h m attra tant 
released in response to tissue damage, such that 
c = kew c. 
'Ye 
We rescale neutrophils, 11} and 112 such that 
kx _ 
11] = - 11] , 
'Yn2 
a ratio of a typical population of neutrophils p r unit volum t th initial n-
centration of chemoattractants released upon damag . W proc d in a imilar mann r fo r th 
macrophages with nI } and m 2 being rescaled such that 
Neutrophil contents (cr) and growth factors (g) are r caled, to ba lanc pr duction with d ay 
in response to initial concentrations of neutrophils and macrophag r p ctiv Iy 
ku2'Yn2 kx _ 
cr = - - - --cr, 
'Yu 'Y1I2 
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kg kxm _ g = --g. 
'Yg 'Ym2 
Under the above sea lings (and dropping the tildes), the number of system parameters reduces 
from thirty-nine to thirty-three and the governing equations (6.2.6) transform to give: 
dn2 knnl (1 + ~ ) )
lit = (1 + e ') - 'Yn2n2 - (ml - knm2m2) knmI n2, 
Tch. 
dml 'Ym2C (it = (f3xmf3
x 
+ c) - kmknmImIn2 - 'Yml'Ym2ml, 
dm2 (it = kmknmlmln2 - 'Ym2 m2, 
dh khg ( cr2 ) dt = f3eg gh(l-h-w)-kht/(t)h-khh f 3 ~ + c r 2 2 ' 
~ ~ ~ = kht/(t)h + khh ( 2 cr2 2) + kwl'Ynt!(t)nl + kw2n2 130' + cr 
- (kwmIml +kwm2m2)knmlW-kwnkwlnlw, 
(6.2.7a) 
(6.2.7b) 
(6.2.7c) 
(6.2.7d) 
(6.2.7e) 
(6.2.7f) 
~ ~ ~ = kO't'YO'nl + 'YO''Ynt!(t)nl + kO'3'Yn2n2 - 'YO'hh ( f 3 ~ : : cr2) - 'YO'cr, (6.2.7g) 
~ ~ ~ = f(t)h + kchh ( 2 cr2 2) + kent'Ynt!(t)nl + ken2'Yn2n2 
130' + cr 
- ('Yennl + 'Yemml) c - c, 
dg 
dt = 'Ygm2 - 'Ygnkwlnlg - 'Ygg. 
(6.2.7h) 
(6.2.7i) 
In equations (6.2.7) we have introduced the following dimensionless parameter groupings: 
- keh 
keh = -k ' 
cw 
k- _ khg f3cg hg - --;:y;-' 
k knm2 
nm2 = -k-' 
nml 
kwml = kwml, 
knml 
kO'3 = kO'3'YO' , 
kO'2'Yn2 
~ x x = f3x'Yc, 
kcw 
~ ~ _ 'Ycmkxm 
lem - k' 
'Ym2 cw 
~ ~ 'Yn2 
In2 = -;y;' 
1O'h = 'Y O'h'YO' • 
kxkewkO'2 
ftc = ::' 
ii f3xm 
/-,xm = f3x' 
_ 'Yg 
'Yg =-, 
'Yc 
1m2 = 'Ym2, 
'Yc 
r. _ kcn2kx 
/Cen2 - --. 
'Yn2 
- kn kn =-, 
'Yc 
r. kwtkx 
/Cwl = --, 
'Yc 
k w n = ~ ' 'kwt'Yn2 
a _ f3cg'Yg'Ym2 
/-'eg - k k ' g xm 
'Ygn 
19n = -k--' 
wI 'Yn2 
'Yml 1ml = ~ , ,
1m2 
r. _ knmlkxm 
/C nm l - '\' '\' ' Ie 1m2 
kW2 = kw2'Yc , 
ku'l 'Yn2 
kO'I = ~ , ,
kO'2'Yn2 
a f3ng 
/-,ng = -13 ' 
cg 
~ ~ _ 'Ycnkx 
/Cn - --, 
'Yn2kcw 
~ ~ 'Ynl Inl = ~ , ,In2 
'YO' 
10' = 'Yc' 
We assume that at t = ° all tissue is healthy (h = 1, w = 0) and that there are no white blood 
cells (nl = 0, n2 = 0, ml = 0, m2 = 0) or mediators present (cr = 0, c = 0, g = 0). See Table 6.2 
127 
Paramo Definition Unit Value Sources 
keh c from u pg mm-3 day-l 10 estimated 
kenl c from necrosis of nl pg cell-1 1 x 10-3 estimated 
ken2 c from necrosis pg cell-1 1 x 10-3 estimated 
g kew c from damage to tissue pg mm-3 day-l 7 x 10-3 estimated 
.J:: kg g from m2 pg cell-1 day-l 0.07 Waugh & Sherratt (2007) u 
::s 
--g kul u from nl pg cell-1 day-l 1 x 10-2 estimated 
... Q.. 
kU2 U from damage to nl pg cell-l 1 X 10-2 estimated 
kU3 u from necrosis pg ceU-1 1 x 10-2 estimated 
kx max. nl influx cell mm-3 day-l 650 Butterfield et al. (2006) 
kxm max. ml influx cell mm-3 day-l 150 Warrender et al. (2006) 
knml n2 by ml cell-1 mm3 day-l 1 X 10-3 Maree et al. (2005), 
<Il 
.[ji 
Wigginton & Kirschner (2001) 0 
.... 
~ ~ knm2 n2 by m2 cell-1 mm3 day-l 1 x 10-4 Maree et al. (2005), be 
n:s 
..c: Wigginton & Kirschner (2001) Q.. 
kwml tissue by ml cell-1 mm3 day-l 0.01 estimated 
kwm2 tissue by m2 cell-1 mm3 day-l 0.01 estimated 
kwn tissue by nl ceU-1 mm3 day-l 0.01 estimated 
kh damage to tissue by u day-l 0.1 estimated 
~ ~ khg repair of tissue pg-l mm3 day-l 1.0 estimated 
::s 
<Il kht external damage to tissue day-l 3 x 10-3 estimated <Il 
.J:: 
kWl necrotic debris from nl ceU-1 mm3 4 x 10-3 estimated 
kW2 necrotic debris from n2 ceU-1 mm3 4 x 10-4 estimated 
f3e c damping nl apoptosis pgmm-3 3 x 10-1 estimated 
f3eg g damping nl migration pgmm-3 5 x 10-1 estimated 
<Il f3ng g enhancing nl apoptosis pgmm-3 0.8 estimated .... I: 
n:s 
.... f3u u damage to tissue pgmm-3 <Il 0.1 estimated I: 
0 
u f3x half max neutrophil influx pgmm-3 0.6 estimated ...; 
n:s 
III f3xm half max macrophage influx pgmm-3 0.6 estimated 
..... 
'Yem cbymI cell-1 mm3 day-l 1 x 10-3 estimated 
0 
~ ~ 'Yen cbynl 
n:s 
cell-1 mm3 day-l 1 x 10-3 estimated 
.... Q.. 
'Ygn gbynl cell-1 mm3 day-I 1 x 10-3 estimated ::s 
'Yuh ubyh pg mm-3 day-l 1 x 10-3 estimated 
Continued on next page 
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Paramo Definition Unit Value Sources 
km switch from ml to m2 nondimensional 10 estimated 
kn nl apoptosis day-l 2.77 Summers et al. (2010) 
'Ye decay of c day-l 4 Schugart et al. (2008) 
'Yg decay of g day-l 9 Waugh & Sherratt (2007) 
'Yml removal of ml day-l 0.0495 Waugh & Sherratt (2006) 
Owen & Sherratt (1997), 
Wigginton & Kirschner (2001), 
Warrender et al. (2006) 
'Ym2 removal of m2 day-l 0.0495 Waugh & Sherratt (2006), 
Owen & Sherratt (1997), 
Wigginton & Kirschner (2001), 
Warrender et al. (2006) 
'Ynl nl necrosis day-l 1 estimated 
'Yn2 secondary necrosis day-l 2.77 Haslett (1999) 
'Yu decay of (T day-l 4 estimated 
Table 6.2: Definitions, units and values of the parameters. We remark that, in the absence 
of suitable data, many of these parameters are estimated (as marked). Explanations for other 
values are presented in Section 6.2.9. Limited parameter sensitivity has been performed and the 
model was robust to changes within reasonable changes. 
for the parameter values used and Table 6.3 for the corresponding nondimensional parameter 
values. TIssue damage (f(t» takes the form shown in Figure 6.9 and the steady states are 
dependent on the termination of this damage (f(t) = 0). 
6.2.9 Parameter estimates 
For several reasons it is difficult to determine precise values for all the parameters: some bi-
ological mechanisms remain unclear; there is a lack of published data; and, the values of pa-
rameters can vary between tissue types, individuals and over time. Where no specific data are 
available, estimates are taken from the cited literature, and extra weight attached to data from 
humans or human cells and soft-tissue-specific data relative to data from other sources. If no 
data are available then order of magnitude estimates that give biologically realistic results are 
employed. We will investigate these values and their effect on the outcome of the inflammatory 
response. A brief description of the parameter values employed and the sources considered is 
included below, while Table 6.2 contains a summary of the values used. 
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Neutrophils. Neutrophils are the first white blood cells to arrive in areas of damaged tissue, 
responding faster than macrophages so that kx > kxm (Butterfield et al., 2006; Majno & loris, 
2004). They are known to have a short lifespan of 6-12 hours (Summers et al., 2010) , although, 
within inflamed tissue, the rate of neutrophil apoptosis can decrease. This leads us to set 
kn = 2.77 day-I. Many different stimuli, including mechanical trauma, can cause damage 
and death (necrosis) to healthy tissue and cells. We account for this in our model via the term 
/(t) which represents an external stimulus that causes damage to both healthy tissue (h) and 
to neutrophils (nl) (we neglect damage to macrophages as we could find no evidence that they 
contribute to damage in an inflammatory setting). Inl is a parameter specific to neutrophil 
necrosis and is included to reflect this process in all the relevant terms, the resultant release 
of neutrophil contents (in product with k( 2) and chemoattractants (kent), and the addition of 
necrotic neutrophils to damaged tissue (kwI)' All three of these parameter will need to be esti-
mated based on producing qualatively realistic simulations as no data are available. Different 
functional forms of /(t) will be employed and the parameter InI fitted to reflect the damage 
to active neutrophils. The mechanisms of secondary necrosis of neutrophils are still unclear: 
following (Haslett, 1999) we set In2 = 2.77 day-I. 
Macrophages. Warrender et al. (2006) assume a maximal recruitment rate for macrophages 
of 100 cells ml-l s-l. Accordingly we fix kxm = 150 cell mm-3 day-I. Macrophages are 
known to live within tissue for days, weeks or months (Owen & Sherratt, 1997) with most 
leaving via the lymphatics. Previous models involving macrophages assume half lives in the 
range 3 - 63 days (Waugh & Sherratt, 2006; Owen & Sherratt, 1997; Wigginton & Kirschner, 
2001; Warrender et al., 2006). We assume macrophages of both phenotypes are removed at the 
same rate 0.0495 day-l (ImI, 1m2), equating to a half life of fourteen days. 
We assume that recognition and engulfment of apoptotic cells or debris are fast processes. 
While the rate of this process is likely to vary with environmental factors, such as tissue 
type and health, as well as the type of particle being removed, we assume that it occurs at 
a constant rate. The rate at which macrophages engulf apoptotic thymoctes (cells present in 
the thymus) in-vitro has been estimated for mice by M a n ~ e e et al. (2005) to be 10-7 - 10-6 mL 
cell-I h-1 whereas Wigginton & Kirschner (2001) use values of macrophage phagocytosis of 
1.25 x 10-9 -1.25 X 10-7 mL cells-1 day-l in a model of mycobacterium tuberculosis. While 
we realise that these rates may not correlate with our model, we use them to obtain an initial es-
timate of 1 x 10-3 mm3 cell-1 day-I for knmI' the rate at which pro-inflammatory macrophages 
remove apoptotic neutrophils and assume that the rate at which pro-resolution macrophages 
remove neutrophils (kmn2) is reduced due to them being partially sated. The rates at which 
macrophages, and active neutrophils, consume generic damaged tissue (kwmt, ku'm2, kwn ) are 
unknown and will be estimated below. The nondimensional parameter km, included in the the 
switch of active neutrophils to apoptotic will be adjusted to produce the most realistic simmu-
lations. 
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Nondimensional Value Nondimensional Value 
parameter parameter 
kch 1.4 x 103 ~ c c 0.50 
kenl 0.16 ~ c g g 0.02 
ken2 0.23 ~ n g g 1 
kh 2.5 x 10-2 ~ x x 342.86 
khg 0.13 ~ x m m 1 
kht 7.5 x 10-4 ~ o ' ' 35.16 
kn 0.69 1cn 33.52 
knml 0.76 1cm 432.90 
knm2 0.10 19 2.25 
km 0.77 19n 0.09 
kwl 0.65 1nl 0.36 
kW2 0.14 1n2 0.69 
kwml 10 1ml 0.01 
kwm2 10 1m2 1 
kwn 0.90 10' 1 
kO'I 0.36 1O'h 0.09 
kO'3 1.44 
Table 6.3: Nondimensional parameter values. See Table 6.2 for a definition of the dimensional 
parameters. 
131 
Tissue and external damage. In the absence of suitable data, parameters relating to tissue in 
its healthy and unhealthy states (kh' khg, kht , kw2) must be estimated to give the best biologically 
expected results. 
Chemoattractant. In the context of this model there are no available data for the rates of pro-
duction of generic chemoattractants (ken2, kew, keh) or for their uptake ('Yen, lem). Therefore 
these values will be estimated. We expect mediators to have half lives that are at least an order 
of magnitude smaller than those of cells. Accordingly we follow Schugart et al. (2008) and use 
a value of ,e = 4 day-l for chemoattractant decay. With no data available we estimate f3x, f3x m 
f3e. 
Neutrophil contents. Parameter estimates for the production, uptake and decay rates of neu-
trophil contents (kul' kU3, 'Yuh, f3cr) are not available. We assume that they are similar in magni-
tude to the corresponding values for the growth factors and chemoattractants. We assume that, 
as neutrophils would only release a small amount of granule contents in response to bacteria, 
kul < ku3. 
Growth factors. FollOWing, Waugh & Sherratt (2007) who estimated the rate of production of 
TGF-f3 by macrophages we fix kg = 0.07 pg cell- t day-t. We also adopt their estimate of 9 
day-l for the linear decay rate of the growth factors (,g)' In the absence of suitable data we 
estimate the rate of uptake of growth factors by neutrophils ('Yen). Growth factors are assumed 
to increase rates of neutrophil apoptosis. Since there is a lack of data for the concentration of 
growth factor ({3ng) required for this to occur, it will be estimated assuming it is of a similar 
order of magnitude to ({3x)' 
6.3 Model outcome and steady states 
Inflammation has two possible outcomes: resolution and chronic inflammation. Resolution is 
successful if neutrophils and macrophages leave the tissue, inflammatory mediators subside 
and the subsequent healing phases are achieved. By contrast, self-perpetuating (or chronic) 
inflammation is initiated if white blood cells remain within the tissue, causing further tissue 
damage. While it is thought that chronic inflammation can resolve successfully it more often 
progresses to poor healing and an inferior tissue prone to injury (Barr, 2(04). We argue that a 
realistic model of inflammation should exhibit bistability, the two steady states corresponding 
to resolution and chronic inflammation. A bistable system typically exhibits hysteresis and 
key parameters must exceed a threshold value to effect a switch between the two stable steady 
states. If the stimulus is gradually removed, the system may remain in the state. We would 
expect a low level of damage to result in our model returning to a steady state where all cell, 
mediator and damaged tissue levels are zero (resolution). If a threshold level of damage is 
passed, then the model would settle to a second steady state where cell, mediator and damaged 
tissue levels settle to some positive value (chronic response). 
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Figure 6.9: An example of external damage /(t). 
Due to the complexity of our system it is not possible to derive explicit analytical expressions for 
the steady state solutions for the general case. However by integrating the ODEs numerically 
(using ode15s, a stiff ODE solver within MATLAB) it is possible to identify two distinct stable 
steady states. To obtain these steady states we use the parameter values described above. These 
are summarised in Table 6.2. The following simulations use the healthy steady state for initial 
conditions of the variables with all cells, mediators and damaged tissue set to zero and healthy 
tissue set to one. 
In Figure 6.10 we present simulation results of the nondimensional model (equations (6.2.7)), 
scaled back to dimensional form, showing the response to one cycle of periodic damage (A = 1) 
with f(t) = H(An - t) sin2(t) where 
{ 
1 ift < An 
H(An - t) = 
o if t > An 
(see Figure 6.9 for a sketch of f(t) which is dimensionless}. This causes damage to tissue and 
the release of chemoattractants. In response, neutrophils and macrophages are recruited (see 
Panels A and B). Neutrophils undergo apoptosis, but can also undergo necrosis, releasing their 
toxic contents (Panel D). Macrophages remove apoptotic neutrophils, and this triggers a switch 
in macrophage phenotype where they release growth factors. All inflammatory cells and their 
mediators subside and the system returns to a normal steady state which we term steady state 
I (551), evidence that the model can simulate resolution of inflammation. In this figure (6.10) 
and subsequent time-dependent solutions we provide a conversion from cells (neutrophils and 
macrophages) to volume fractions. Macrophages are know to have a variable volume, changing 
in response to stimulus, we use a constant volume of 10-6m",3 to convert macrophages per 
mm
3 to a volume fraction (Poulter & Turk, 1975). Neutrophils are smaller than macrophages 
and less variable in volume. We use a volume of to-7m",3 to convert neutrophils per mm3 to a 
volume fraction (Ting-Beall et al., 1993). 
Keeping the same form of f(t) (see Figure 6.9), but increasing the number of cycles of damage 
from one to four, with the same initial conditions and parameter values, we find that a second 
stable steady state exists. 5imulations of this are shown in Figure 6.11. 
In contrast to 551, we observe a significant amount of tissue damage (Figure 6.11 C). Levels of 
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Figure 6.10: Numerical simulations of equations (6.2.7) illustrating how the system evolve to 
steady state I. Inflammation subsides with all cells and mediators settling to zero. It is /(1) that 
causes the inflammatory response, its duration being shown in panel D. One cycle of damag 
results in an increase in chemoattractants, neutrophils and their contents: it is not enough to 
sustain damage (Panel C) and upon cessation of damage al1 cells and mediators subside. Panel 
E shows a zoomed in region of C demonstrating that some damage does accumulate. Parameter 
values are taken from Table 6.2. In Figure 6.11 we present results from a simulation in whkh all 
system parameters and initial conditions are identical to those here, apart from /(1) which is the 
same functional form but increased from one to four cycles of damage. Assuming a macrophage 
volume of 10- 6 mm3 (Poulter & Turk, 1975), 0.1 macrophages per mm3 equates to a volume 
fraction of 10- 7. Similarly, assuming a typical neutrophil volume of 10- 7 mm3 (Ting-Beall el al., 
1993),0.1 neutrophils per mm3 converts to a volume fraction of 10- 8. 
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Figure 6.11: Numerical simulations of equations (6.2.7) illustrating how the system evolve to 
steady state II. This is an unhealthy response to injury where positive values persist for all cell 
and mediators. The majority of macrophages have switched to an anti-inflammatory pheno-
type (B), releasing growth factors (D) that reduce the level of neutrophils but some neutrophil 
persist. Physiologically we relate this to chronic inflammation. Damage occurs to tissue (Panel 
C) and Panel E shows a zoomed in region of C demonstrating that at 5511 " i= 1. Note that th 
model is not designed to account explicitly for volume fractions such that" + w i= 1. Param ter 
values are shown in Table 6.2. It is f(t) that causes the inflammatory response, its duration 
being shown in panel D. In Figure 6.10 we presented results from a simulation in which all sy -
tern parameters and initial conditions are identical, apart from f(t). Assuming a macrophage 
volume of 10- 6 mm3 (Poulter & Turk, 1975), 1000 macrophages per mm3 equates to a volume 
fraction of 10- 3. Similarly, assuming a typical neutrophil volume of 10- 7 mm3 (Ting-Beall e/ al., 
1993),100 neutrophils per mm3 converts to a volume fraction of 10- 5. 
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Figure 6.12: Numerical simulations of our model illustrating the oscillations that re ult wh n 
kg = } pg cell - 1 day- l, kcn2 = O.O} pg cell - 1, The remaining parameter values are hown in 
Table 6,2, Initial conditions nl = n2 = m1 = m2 = 0 cell mm - 3, h = I, W = 0, U = g = 0 pg 
mm- 3 , c = 0.1 pg mm- 1, It is the positive initial value of the chemoattractant that drive th 
inflammatory process, Assuming a macrophage volume of 10- 6 mm3 (poulter &: Turk, 1975), 
}OOO macrophages per mm3 equates to a volume fraction of 10- 3, Similarly, assuming a typical 
neutrophil volume of 10- 7 mm3 (Ting-Beall et ai" 1993), 100 neutrophils per mm convert to a 
volume fraction of 10- 5, 
all cells and mediators are significantly greater than in Figure 6.10. As levels of anti-
inflammatory macrophages and growth factors rise there is a drop in the levels of neutrophil , 
chemoattractants and neutrophil contents (all pro-inflammatory), However this is not sufficient 
to ensure a return to 55!. Instead the cells and their mediators settle to positive steady values 
and we term the resulting solution steady state II (5SII), Physiologically we can relate 5S11 to 
chronic inflammation where successful healing is not achieved because the inflammatory re-
sponse is not resolved. 
The model is also found to display damped oscillatory behaviour. This is dependent on mod-
ifications to the parameter values representing the production of growth factors (kg) and the 
production of chemoattractants in response to secondary necrosis (kcn2)' Figure 6,12 shows 
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simulations exhibiting such behaviour. This oscillatory behaviour may be unphysiological but 
could be seen as repeated attempts to heal alternating with enhanced inflammation gradually 
subsiding and ending up at the non-trivial steady state. 
As discussed above many of the parameter values had to be estimated or modified from the 
literature. Therefore, in the next section, we perform bifurcation analysis to understand better 
the system dynamics, investigating the influence of parameter variations on the outcome of 
the system (varying one parameter at a time, holding all others fixed). We will also discuss 
our intuitions about the effect of the positive and negative feedback mechanisms through the 
bifurcation diagrams. As the parameter space is vast we focus on a small subset comprising 
what we believe to be the key control parameters. 
6A Feedback loops 
The system (6.2.7) displays bistability. The positive and negative feedback loops incorporated 
in our model are shown schematically in Figures 6.13 and 6.14 respectively, and are intimately 
associated with the system's bistability. Only those feedback loops that are independent of ex-
ternal damage (f(t) '" 0) are shown as it is assumed that all externally derived damage has 
been removed at the steady state. Positive feedback mechanisms (independent of f(t» occur 
via two main pathways. Active neutrophils release their toxic contents (kq}), in defence against 
suspected bacteria infiltration. These can cause damage to healthy tissue releasing, chemoat-
tractants (kch ). Active neutrophils die, naturally, by apoptosis (k,,). If apoptotic neutrophils are 
not removed they can undergo necrosis <1'''2), releasing neutrophil content (kq 3) and chemoat-
tractants (kc,,2). These positive feedback loops drive inflammation. 
All negative feedbacks operate through macrophages, which increase within the system in re-
sponse to chemoattractants. Macrophages remove apoptotic neutrophils (rate constants k"ml, 
k"m2) having a negative effect by preventing them undergoing secondary necrosis (1',,2) the lat-
ter being a positive feedback mechanism. Macrophage engulfment of apoptotic neutrophils re-
sults in a switch in macrophage phenotype to an anti-inflammatory form whereby macrophages 
release various mediators (rate constant kg). Growth factors have a complicated interaction 
with positive feedback loops. They dampen neutrophil influx and increase the rate of neu-
trophil apoptosis. Decreasing the population of active neutrophils is clearly anti-inflammatory 
as active neutrophils release toxic neutrophil contents (kq1 ). An increase in the population 
of apoptotic neutrophils can be pro-inflammatory (if they undergo secondary necrosis (rate 
1',,2» but, if macrophages safely remove apoptotic neutrophils then the pathway has an anti-
inflammatory effect. Negative feedback loops can push the inflammatory response towards 
resolution and a healthy outcome. 
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Figure 6.13: Network diagram showing the positive, pro-inflammatory f dback loops. P i-
tive feedbacks that effect the stability of the steady stat sop rat through two pathway . Th 
first through the release of neutrophil contents from active n utrophil (ku 1) that c n c u 
damage to healthy tissue (not shown to simplify the diagram) and the sub qu nt r I a 
chemoattractants (kc/J. The second pathway operates via neutrophil apopto is (kill which can 
then tum necrotic releasing neutrophil contents (ku3l and chemoattractant (kcII2)' gati 
feedback loops are showin in Figure 6.14. 
6.5 Key control parameters 
We focus on three key param ters: th production rat of anti-inflammat ry gr wth f t r (kg), 
which forms part of the negative feedback loop that p rat thr ugh dam n utr phil 
influx enhancing neutrophil apopto iSi th rat f n utr phil ap pt i (k ll ); n th r t at 
which neutrophils undergo secondary n cro i ('rn2), a p itiv f db k m h ni m. r. t 
of neutrophil apoptosis (kn ) is of particular inter t as a th rap utic targ tit b in b Ii th t 
increasing this rate will enhance th r solution of inflammati n (Hall tt t nl., 2 
2007). All bifurcation diagrams are produc d with AUT with th r ulting ata pi tt with 
MATLAB. They all show the steady state of th ch m atta tant a a fun ti n f th 
being varied. We choose th is variabl as the chemoattra tant i 
inflammation. 
ntr I t th 
6.5.1 Anti-inflammatory growth factor (rate constant kg) 
A generic growth factor or anti-inflammatory m diator (g) i includ d in th m I. It ha 
two anti-inflammatory eff cts: it nhanc th rat of n utrophil ap pt i and dam u-
trophil influx (see Figure 6.14). It hould be not d that whil damp ning n utr phil inOu 
clearly anti-inflammatory, increasing neutrophil apopto i play a m r 
the growth factor to have an anti-inflammatory ff t th incr a d 1 v 
trophils n ed to be remov db fore th y progr ss to s condary n cro i . 
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Figure 6.14: Network diagram showing the negative, anti-inflammatory feedback loops (blu ). 
Positive feedback loops are shown (black) for completeness. Macrophages are central to n g-
ative feedback loops acting through the removal of apoptotic neutrophils (knml' knm2) and 
through the release of growth factors (rate kg), which dampen neutrophil influx and increas 
the rate of neutrophil apoptosis. 
Figure 6.15 illustrates the bifurcation behaviour of the system (6.2.6) in terms of the conc ntra-
tion of the chemoattractant as kg varies. LPl-4 indicate limit points and HBl-2 indicate Hopf 
bifurcations. There is an interval of bistability (LP1 < kg < HB1) where both steady stat s ar 
stable. For values of kg < LP1 the system is monostable with SSI stable. This is unexp ct d: 
biologically we would expect the system to resolve to SSII (an unhealthy sta te) if I v Is of th 
anti-inflammatory growth factor are low. Time-dependent solutions of th system with va lue 
of kg in this range (Figure 6.16) illustrate that levels of healthy tissue decline to zero, which is 
of Course unphysical. With h = 0 the positive feedback loops (functioning through neutrophil 
contents (0'» that normally drive inflammation are turned off. The system then s ttl s to 5SI, a 
healthy response. 
Steady state II gains stability at LP1, and loses stability via a subcritical Hopf bifurcation at 
HB1. A Hopf bifurcation involves the loss of stability of a steady state and the m rgenc of a 
periodic solution and as we can see time-dependent solutions of the system with kg s t to just 
before the Hopfbifurcation display damped oscillations (see Figure 6.17). 
For values to the right of HB1 only the lower steady state is stable, while the upper and th 
middle are unstable. Tissue damage now results in excitable behaviour, in the sens that ther 
is a large build up of cells and mediators before the system ultimately relaxes to steady stat 
I (see Figure 6.18). The unstable steady state that folds under from steady state II r mains 
positive for its entire length. Tune-dependent solutions with values of kg to the right of LP2 
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result in resolution to 551 (see Figure 6.19) biologically this is expected, with anti-inflammatory 
mechanisms dominating the response. Due to the small parameter space, and the unphysical 
range in which the parameters occur the limit point LP4 and Hopf bifurcation at HB2 are not 
investigated further. 
6.5.2 Neutrophil apoptosis (rate kn) 
Under normal conditions activated neutrophils undergo apoptosis within a few hours. 
This rate is thought to be affected by both pro- and anti-inflammatory mediators 
(Kobayashi & DeLeo, 2009; Heasman et ai., 2003). We include both of these effects in our model; 
the chemoattractant acts as a pro-inflammatory marker, decreasing the rate of neutrophil apop-
tosis, while growth factors increase the rate of neutrophil apoptosis. 
The bifurcation diagram showing how the steady state concentration of the chemoattractant 
varies with the parameter kn (the rate of apoptosis), is presented in Figure 6.21. LPl-2 indi-
cate limit points and HBI-2 Hopf bifurcations (these are not necessarily related to the similarly 
numbered points described in the Figures 6.15 and 6.26). Steady state I is stable for all values 
of kn. For very low values of neutrophil apoptosis (kn < LPI (see Figure 6.15» there is a unique 
stable steady state which corresponds to 551 (values of kn in this range are unlikely to be phys-
ical, neutrophils would die very slowly). There is a fold bifurcation at kn = LP1 and for LPI 
< kn < HBI we have a small area of parameter space where the system has one stable steady 
state and two unstable. At the subcrisitical Hopf bifurcation (HBl) we have a second branch of 
stable solutions which correspond to 5511. In fact, we have bistability for all kn > HB1. 
It could be expected that a high level of neutrophil apoptosis would have an anti-inflammatory 
effect with the system always settling to steady state I. The bifurcation diagram (Figure 6.21) 
does not display this behaviour. From time-dependent simulations (Figure 6.23) with a high 
rate of neutrophil apoptosis (kn = 10 day-I) we can see that though there is a large number of 
macrophages present neutrophils, though declining significantly, are not being fully removed. 
By increasing the rate of macrophage phagocytosis of neutrophils (knm1 ) we can modify the 
structure of the bifurcation diagram (see Figure 6.22). Now, even with a high level of stimulus, 
time-dependent solutions with a high value of neutrophil apoptosis (kn = 10) result in the 
model resolving to steady state I (see Figure 6.24). Due to the upper two steady states being 
unstable this takes a large excursion through parameter space before all mediators and cells 
settle to zero. . 
6.5.3 Secondary necrosis (rate ')'n2) 
Apoptotic neutrophils eventually break down, losing membrane integrity so that their gran-
ules release their toxic content and chemoattractants into the surrounding tissue. This has a 
prO-inflammatory effect, termed secondary necrosis, that is incorporated in our model via the 
parameters ')'n2, kU3 and kcn2• 
In Figure 6.26 we present a bifurcation diagram showing the concentration of the chemoattrac-
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Figure 6.15: Bifurcation diagram showing how the existence and stability of the steady state s0-
lutions change as kg (the rate that macrophages produce growth factor) varies, other parameter 
values held fixed (see Table 6.2). 55I is represented by the green line and 5511 by the blue. Stable 
steady states are shown as solid lines and unstable ones by dotted lines. The system is bistable 
for an intermediate range of kg (LP1< kg <HB1). 5511 gains stability at LP1 and loses stability 
via a subcritical Hopfbifurcation (HB1). To the right of HB1 there is an area where the upper two 
steady states are unstable and the lower stable (see Figure 6.18 for time-dependent solutions in 
this range). At kg > LP2 there is only one steady state (55I) (see Figure 6.19 for time-dependent 
solutions in this range). (LP1, kg = 7.88 X 10-4, C = 6.91 X 10-1; LP2, kg = 2.73, c = 5.15 X 10-4; 
LP3, kg = 4.66 X 10-4, C = 6.44 x 10-4; LP4, kg = 3.26 x 10-3, C = 6.2.77 x 10-2; HBI, 
kg = 8.29 X 10-2, C = 4.21 x 10-1; HB2, kg = 3.26 X 10-3, C = 6.272 x 10-2.) 
141 
~ ~
:.c: Q, g 
::s 
'" Z 
A 
600 
500 
400 
300 
200 
100 
0 
C 
0.8 
0.6 
0.4 
0.2 
10' 
o - - - - - - - - - - - - ~ - - - ~ ~.... 
- 0 . . ' - - - ~ ~ - - - - ~ - - - ' '
10' 10' 
'" 
'" OIl .. 
..::: 
c.. 
e 
u 
.. 
::! 
~ ~
!:! 
.. 
'B 
::! 
B 
1200 
1000 
800 
600 
400 
200 , 
, 
0 
10' 
D 
3 
2.5 
2 
1.5 
10' 
' \ 
' . 
' \ , \ , I , I , 
I 
, 
, 
, 
, 
, 
Time 
.-. 
! \ 
! .. 
.. 
'\ 
... 
I 
.. 
" 
'\ 
... 
\ 
Time Time 
D I'll ~ ~ --
I 
I 
\ , 
10' 
[j , -t •.• 
10' 
Figure 6.16: Time-dependent solution of equations (6.2.6) illustrating resolution to 55! for very 
low values the parameter kg. Healthy tissue being depleted (panel C). Parameter values taken 
from Table 6.2 except kg = 0.0001 pg cell - 1 day- I. Initial conditions are slightly perturbed from 
551 (nl = n2 = mI = m2 = 0 cell mm- 3, (J = g = 0 pg mm- 3, c = 0.4 pg mm- 3 h = 1, W = 0). 
Assuming a macrophage volume of 10- 6 mm3 (Poulter & Turk, 1975), 1000 macrophages per 
mm3 equates to a volume fraction of 10- 3. Similarly, assuming a typical neutrophil volume of 
10- 7 mm3 (Ting-Beall et al., 1993), 100 neutrophils per mm3 converts to a volume fraction of 
10- 5. 
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suming a macrophage volume of 10- 6 mm3 (Poulter & Turk, 1975), 100 macrophages per mm3 
equates to a volume fraction of 10- 4. Similarly, assuming a typical neutrophil volume of 10- 7 
mm3 (Ting-Beall et al., 1993), 100 neutrophils per mm3 converts to a volume fraction of 10- 5. 
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Figure 6.18: Time-dependent solutions of equations (6.2.6) illustrating excitable behaviour. Pa-
rameter values taken from Table 6.2 except kg = 1.55 pg cell - day- t (a point between HBl and 
LPl in the bifurcation diagram shown in Figure 6.15). Initial conditions are slightly perturbed 
from 551 (n) = n2 = m) = m2 = o cell mm- 3, (T = g = 0, c = 0.001 pg mm- 3, /, = 1, W = 0). As-
suming a macrophage volume of 10- 6 mm3 (Poulter & Turk, 1975), 100 macrophages per mm3 
equates to a volume fraction of 10- 4 . Similarly, assuming a typical neutrophil volume of 10- 7 
mm3 (Ting-Beall et al., 1993), 100 neutrophils per mm3 converts to a volume fraction of 10- 5. 
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between HB1 and LP2 in the bifurcation diagram shown in Figure 6.15). Initial conditions are 
slightly perturbed from S51 (n1 = n2 = '"1 = '"2 = 0 cell mm- 3, (T = g = 0, c = 0.001 pg 
mm- 3, h = I, w = O).Assuming a macrophage volume of 10- 6 mm3 (poulter & Turk, 1975), 
0.1 macrophages per mm3 equates to a volume fraction of 10- 7. Similarly, assuming a typica l 
neutrophil volume of 10- 7 mm3 (Ting-Beall et a1., 1993), 0.1 neutrophils per mm3 converts to a 
volume fraction of 10- 8. 
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Figure 6.20: Time-dependent solutions of equations (6.2.6) illustrating resolution to 551 with 
very low values of neutrophil apoptosis. Parameter values taken from Table 6.2 except kn = 
0.0003 day- to Initial conditions where such that the system was slightly perturbed from 551 
(n1 = n2 = '"1 = '"2 = 0 cell mm- 3, (T = g = 0, c = 0.1 pg mm- 3, h = I, w = 0). Assuming a 
macrophage volume of 10- 6 mm3 (Poulter & Turk, 1975), 1000 macrophages per mm3 equates 
to a volume fraction of 10- 3• Similarly, assuming a typical neutrophil volume of 10- 7 mm3 
(Ting-Beall et a1., 1993), 10000 neutrophils per mm3 converts to a volume fraction of 10- 3. 
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kn with other parameter values fixed (see Table 6.2). Full and broken curves indicate stable 
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values of kn result in the system settling to steady state I (see Figure 6.20); values of kn this low 
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Figure 6.22: Bifurcation diagram demonstrating the introduction of an additional Hopf bifur-
cation when the rate of macrophage removal of apoptotic neutrophils is increa d . Th dia-
gram is for the concentration of the chemoattractant as a function of kn. All oth r param t r 
values are fixed (see Table 6.2) apart from kn (neutrophil apoptosis), knml and knm2 (the rat s 
of macrophage phagocytosis of apoptotic neutrophils) which is different for each bifurcation 
curve. The original bifurcation curve (Figure 6.21 (knm = 0.00(1» is shown in blue and wh r 
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states respectively. The introduction of HB3 (kn ~ ~ 0.15 day- l) changes the stability of II 
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Figure 6.23: Time-dependent solutions of equations (6.2.6) illustrating that at hjgh levels of 
neutrophll apoptosis macrophages fail to remove all apoptotic neutrophlls and the system set-
tles to ssn. Parameter values as per Figure 6.20 except kn = 10 day- t. Initial conditions 
(nI = n2 = mI = m2 = 0 cell mm- 3, (T = g = 0, c = 0.1 pg mm- 3, It = I, W = 0,). As-
suming a macrophage volume of 10- 6 mm3 (Poulter & Turk, 1975), 1000 macrophages per mm3 
equates to a volume fraction of 10- 3. Similarly, assuming a typical neutrophil volume of 10- 7 
mm3 (Ting-Beall et al., 1993), 1000 neutrophlls per mm3 converts to a volume fraction of 10- 4 . 
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Figure 6.24: Time-dependent solutions of equations (6.2.6) illustrating that at high levels of 
neutrophll apoptosis the system resolves to SS!. This is dependent on the increase on the rate 
that macrophages remove neutrophlls (knmI' k nm2), which we have increased. Parameter values 
taken from Table 6.2 except k n = 10 day- I, knmt = 0.01, knm2 = 0.001 cell - J mm3 day- t . Initial 
conditions where such that the system was perturbed from 551 (nJ = n2 = mI = m2 = 0 cell 
mm- 3, (T = g = 0, c = 0.1 pg mm- 3, h = I, W = 0). Assumjng a macrophage volume of 
10- 6 mm3 (Poulter & Turk, 1975), 1000 macrophages per mm3 equates to a volume fraction of 
10- 3. Similarly, assuming a typical neutrophil volume of 10- 7 mm3 (Ting-Beall et al., 1993), 100 
neutrophlls per mm3 converts to a volume fraction of 10- 5. 
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Figure 6.25: Time-dependent solutions of equations (6.2.6) illustrating resolution to 55! with 
HBI < In2 < HB2 (Figure 6.26). Parameter values taken from Table 6.2 except 1112 = 0.035 
day- l. Initial conditions are slightly perturbed from 551 (n1 = n2 = ml = m2 = 0 cell mm - 3, 
(T = g = 0, C = 0.1 pg mm- 3, h = I, W = 0,). The simulations show that a small perturbation 
from 55! results in all species returning to 55! after a large excursion in parameter space. As-
suming a macrophage volume of 10- 6 mm3 (Poulter & Turk, 1975), 1000 macrophage per mm3 
equates to a volume fraction of 10- 3. Similarly, assuming a typical neutrophil volume of 10- 7 
mm3 (Ting-Beall et al., 1993), 100 neutrophils per mm3 converts to a volume fraction of 10- 5. 
tant as a function of 'Yn2, the rate of secondary necrosis. Once again Steady state I is stable for 
all values of 'Yn2. Very low values of secondary necrosis ('Yn2 < LPl) result in macrophage 
being able to remove all apoptotic neutrophils before they can undergo necrosis. There are two 
areas of bistability, steady state II gains stability at LPI and loses stability via a Hopf bifurcation 
HB1 for a small area of parameter space. 55II then gains stability at a further Hopf bifurcation 
and retains this until very high values of secondary necrosis (LP2). Figure 6.25 shows time-
dependent simulations for a rate of secondary necrosis in the middle region between the two 
Hopfbifurcations ('Yn2 = 0.01 day- l). In this region steady state 1 is stable and both branches of 
steady state II are unstable, a small perturbation from steady state I results in all sp cies return-
ing to steady state I through a large excursion. TIme-dependent simulations with 'Yn2 cia e to 
HB1 or HB2 display damped oscillations (see Figures 6.27 and 6.28 respectively). Large values 
of secondary necrosis ('Yn2>LP2 result in the system settling to 551, while values of secondary 
necrosis this large are entirely unphysical this is slightly unexpected . 
6.6 Discussion and further work 
In this chapter we have presented a model of the inflammatory response to tissue damage. 
Inflammation is not only of interest as a response to skeletal tissue damage but persistent in-
flammation is recognised as a central process in the pathogenesis of many diverse diseases 
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solutions change as I'n2 (the rate of secondary necrosis) varies, other parameter va lue h ld 
fixed (see Table 6.2). 55] is represented by the red line and SSII by the blue. Stable steady stat s 
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Figure 6.27: Time-dependent solutions of equations (6.2.6) illustrating damped oscillations. Pa-
rameter values taken from Table 6.2 except 'Yn2 = 0.022 day- l (near to HBl). Initial conditions 
are slightly perturbed from 55! (n1 = n2 = m1 = m2 = 0 cell mm- 3, (J' = g = 0, C = 0.1 pg 
mm - 3, h = I, W = 0,). Assuming a macrophage volume of 10- 6 mm3 (Poulter & Turk, 1975), 
1000 macrophages per mm3 equates to a volume fraction of 10- 3. Similarly, assuming a typical 
neutrophil volume of 10- 7 mm3 (Ting-Beall et al., 1993), 100 neutrophils per mm3 converts to a 
volume fraction of to- 5. 
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Figure 6.28: Time-dependent solutions of equations (6.2.6) illustrating damped oscillations. Pa-
rameter values taken from Table 6.2 except 'Yn2 = 0.05 day- 1 (near to HB2). Initial conditions 
are slightly perturbed from SSI (n1 = n2 = m1 = m2 = 0 cell mm- 3, (T = g = 0, C = 0.1 pg 
mm- 3, h = I, W = 0,). Assuming a macrophage volume of 10- 6 mm3 (Poulter & Turk, 1975), 
1000 macrophages per mm3 equates to a volume fraction of 10- 3. Similarly, assuming a typical 
neutrophil volume of 10- 7 mm3 (Ting-Beall et al., 1993), 100 neutrophils per mm3 converts to a 
volume fraction of 10- 5. 
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including bronchial asthma, Alzeihemer's, cystic fibrosis and chronic obstructive pulmonary 
disease (Madema & Godson, 2003; Haslett, 1999). The resolution of inflammation is crucial 
if tissue is to be repaired and was thought to be a passive process but is now recognised as 
an active process with dysregulation of key features of resolution contributing to inflammatory 
diseases (Rossi et al., 2007). Previous mathematical models concentrate on single populations of 
white blood cells and the mechanisms that drive inflammation (Lauffenburger & Keller, 1979; 
Lauffenburger & Kennedy, 1981, 1983; Alt & Lauffenburger, 1985). We incorporate recent bio-
logical evidence that the resolution of inflammation is dependent on active anti-inflammatory 
processes centering around the interaction between separate populations of white blood cells 
(namely neutrophils and macrophages) and the interactions between them. Our model incor-
porates damage being caused in the functional form !(t) and this can be modified to model 
different disease scenarios. 
Neutrophils can playa dual role in inflammation, being essential, in a dirty environment, for 
the removal and killing of bacteria but, via the same mechanisms, they can cause damage 
to healthy tissue (Whyte et al., 2008). They have a short life dying naturally via apoptosis. 
Apoptotic neutrophils can further break down (a process called secondary necrosis) spilling 
their toxic content and causing further damage to tissue (Serhan et al., 2(08). Macrophages are 
thought to be central to anti-inflammatory pathways safely removing apoptotic neutrophils 
and releasing anti-inflammatory mediators that actively dampen pro-inflammatory processes 
(Sampson, 2000; Gordon & Taylor, 2(05). In sterile environments, such as tendon ruptures 
or wounds inflicted during surgery, the role of neutrophils is controversial. Within the con-
text of muscle loading neutrophils are thought to be helpful for muscle hypertrophy with 
non-steroidal anti-inflammatory drugs that target neutrophil pathways being shown to impair 
muscle growth (Koh & Pizza, 2009; Toumi et a1., 2006; Tidball, 2(05). In a surgical environment 
neutrophils are thought to be at odds with rapid healing (Szpaderska & DiPietro, 2(05). Neu-
trophils, and the damage they cause, are of increasing interest and our model tries to capture 
some of their characteristics by incorporating them as a seperate species from macrophages. 
We find that its dynamics of our model can be classified into four regimes: monostability, bista-
bility, excitability and oscillations. Our model demonstrates that bistability and hysteresis ex-
ists in a wide range of parameter space and we relate the outcome of the stable steady states 
to either the healthy resolution of inflammation or a chronic, self-perpetuating state. We focus 
on a small subset of parameters that are central to the many feedback mechanisms within our 
model. These parameters characterise key features of the interactions between neutrophils and 
macrophages corresponding to: the rate of neutrophil apoptosis, the rate that apoptotic neu-
trophils undergo necrosis and the rate that macrophages produce growth factors. We explore 
the effects of perturbing these parameters via bifurcation diagrams and use the model to iden-
tify how these parameters govern the behaviour of the system toward the different outcomes. 
While we believe that we have identified the key large time outcomes we have not attempted 
to capture all the unstable branches or dependence on all of the parameters. 
There is much interest in finding new therapeutic drugs to limit inflammation with the hope 
that, where the persistence of inflammation has become divorced from the inciting agent, tar-
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geting pro-resolution pathways will offer some success (Serhan et al., 2007; Pizza et al., 2005). 
Particular targets under investigation are the rate that neutrophils undergo apoptosis and the 
ability of macrophages to remove them, both processes thought to be controllable by mediators 
(Rossi et al., 2007; Henson, 2005; Maderna & Godson, 2003; Haslett, 1999). We have investigated 
the effect of perturbing the rate that neutrophils undergo necrosis in our model. We found that 
incresing neutrophil apoptosis is not necessarily anti-inflammatory, its effects being dependent 
on the ability of macrophages to remove neutrophils before they can cause further damage. 
The model helps us to represent current knowledge about the mechanisms of inflammation, 
particularly its resolution and how neutrophils and macrophages might effect this. It has lim-
itations imposed by the incomplete knowledge of the biology and a more sophisticated model 
may be possible as the parameter values and biological mechanisms are better described. Our 
model provides a good starting place in the modelling of inflammation that can be modi-
fied to incorporate further biological mechanisms as they are better understood. It demon-
strates the damage that neutrophils can cause to healthy tissue leading to progression to a 
self-perpetuating inflammatory condition that is no longer reliant on the initial stimulus. The 
model demonstrates that therapeutic mechanisms that target the rate of neutrophil apoptosis, 
accelerating it with the aim of dampening inflammation may need to up-regulate the removal 
of apoptotic neutrophils. 
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CHAPTER 7 
A spatial model of inflammation 
7.1 Introduction 
In the previous chapters we treated the problem as spatially homogeneous, with populations 
of cells and mediators in a well-mixed environment. While this provides useful insight, it is de-
sirable to extend the model to investigate damage to tissue in a spatial form and, in particular, 
how the diffusion of mediators affect the outcome of the inflammatory phase. First, however, 
it is desirable to simplify the existing model, since adding this extra dimension will compound 
further its already uninviting complexity. We wish to retain the bistable outcome of the model, 
allowing us to relate the two stable steady states to subsidence of the inflammatory response 
or to progression to a self-perpetuating condition that is no longer reliant on the initial stimu-
lus. We will concentrate on the central biological mechanisms of neutrophil apoptosis, necrosis 
and the removal of apoptotic neutrophils by macrophages allowing the bifurcation analysis of 
the previous chapter to guide us. As will become clear in what fol\ows, the results here are 
preliminary ones and numerous other directions would be interesting to explore. 
7.2 Simplifying the existing model 
Let us remind ourselves of the system of dimensional ODEs 
(7.2.1 a) 
(7.2.1 b) 
(7.2.1 c) 
(7.2.1d) 
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~ ~ ~ = khggh(1- h - w) - khd(t}h - khh ( 2 CT2 2) CT, f3cr + CT 
~ ~ ~ = khd(t)h + khh ( 2 CT2 2) CT + kwl'Ynt/(t)nl + kw2'Yn2 n2 f3cr + CT 
- kwmlmlW - kwm2m2W - kwnnlW, 
~ ~ ~ = kcrlnl + kcr2'Ynt/(t)nl + kcr3'Yn2n2 - 'Ycrh h ( f 3 ~ : : CT2) - "YcrCT, 
: ~ ~ = kewf(t)h + kehh ( f 3 ~ : :CT2) + ken1'Ynt/(t)nl + kcn2'Yn2n2 
- ('Yennl + 'Ycmmt} C - 'YeC, 
dg 
dt = kgm2 - 'Ygnnlg - "Ygg. 
(7.2.1 e) 
(7.2.1£) 
(7.2.1 g) 
(7.2.1h) 
(7.2.li) 
We simplify these by adopting the following assumptions. We shall assume that (almost) all 
the tissue is healthy (h = 1) and in so doing remove the equation for its evolution and the 
downstream equation for damaged tissue (equations (7.2.1e), (7.2.1£). We then combine both 
macrophage phenotypes (ml and m2) into one equation. We assume that macrophage removal 
of apoptotic neutrophils occurs at a constant rate (knml), removing knm2 from the third term in 
equation (7.2.1b) and that macrophage production of growth factors occurs upon macrophage 
engulfment of apoptotic neutrophils introducing the new parameter kgm : this allows us to re-
move equation (7.2.1d). We assume the uptake of all mediators is negligible (removing terms 
from equations (7.2.1g), (7.2.1h), (7.2.li». We then simplify the positive feedback loops by con-
centrating on the release of necrotic contents by apoptotic neutrophils when they undergo sec-
ondary necrosis. Assuming that kcrl < < 1 allows us to remove the first term in equation (7.2.1g) 
representing the release of toxic contents by active neutrophils. We then assume that necrosis 
of apoptotic neutrophils causes a stronger chemotactic response through damage to tissue (k,,3, 
keh ), rather than as a direct release of chemoattractants (ken2) allowing us to neglect the sec-
ond (removing the fourth term in equation (7.2.1h». We simplify the terms for the influx of 
neutrophils and macrophages by removing saturable kinetics (equations (7.2.1a), (7.2.1c». We 
remove the terms associated with neutrophil necrosis in response to external damage ('Yn], k"l' 
kenl) instead focusing solely on the release of chemoattractants from general damaged tissue 
(kew ). Under these assumptions we arrive at the following simplified model which comprises 
six ODEs and, as we show below, retains much of the behaviour of equations (7.2.1): 
dnI 
= kxc-
knnI (f3ng + g) (7.2.2a) dt (f3e+ C) , 
dn2 knnl ({3ng + g) 
- 'Yn2n2 - knm1 mln2, (7.2.2b) dt = (f3c + c) 
dmI kxmc - 'Ymlml, (7.2.2c) = dt 
dCT 
k,,3'Yn2n2 - 'YI7CT, (7.2.2d) = dt 
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de 
dt 
~ ~ ~ = kgkgmmln2 - "Igg. 
(7.2.2e) 
(7.2.2f) 
Equations (7.2.2) define our simplified model (Figure 7.1 is a schematic of the model). It has 
sixteen parameters in common with the model presented in Chapter 6 (equations 6.2.6) and one 
newly introduced parameter (kgm ). The parameter values used are identical to Chapter 6 except 
kgm, kx' kxm and kcw (see Table 7.1 for values of these and the other parameters included in this 
model). We obtain the value for the parameter kgm based on the values of macrophage and 
apoptotic neutrophil populations at 5511 for the model of the previous chapter (m2 = kgmml n2 
on the basis of quasi-equilibrium) and therefore set kgm = 1. The rates of influx of white blood 
cells (kx and kxm ) have different units to those of Chapter 6 and are modified accordingly to 
incorporate f3 x and f3xm respectively. The rate that the function /(t) produces chemoattractants 
is estimated to produce sufficient chemoattractants to initiate damage. 
7.2.1 N ondimensionalisation 
We begin by nondimensionalising (7.2.2) in a manner similar to that used in Chapter 6. TIme is 
scaled with the decay rate of the chemoattractant so that 1 = "let. The chemoattractant is then 
rescaled balancing production of the chemoattractant (from u) with its decay such that 
e = ckeh , 
"Ie 
(7.2.3a) 
On comparison of equations (7.2.2a), (7.2.2c) to (7.2.1a), (7.2.1c) we observe that the influx of 
neutrophils and macrophages due to chemotaxis has been simplified to remove saturable ki-
netics such that 
active neutrophils: (7.2.3b) 
apoptotic neutrophils: (7.2.3c) 
macrophages: (7.2.3d) 
For the remaining variables we follow Chapter 6, balancing production and decay, so that 
u=iJkU3"1c (kXkCh) , 
"10' "In2"1e 
neutrophil contents: (7.2.3e) 
g = gkgkgm (kxmkCh) (kXkCh) , 
"Ig "Iml "Ie "Int "Ie 
growth factors: (7.2.3f) 
where tildes denote nondimensionless variables. When we use the above scalings in equations 
(7.2.2) the following dimensionless groups emerge (listed in order of equation): 
k
n 
= kn, ~ n g g = f3ng"lg "Imt "Ie "Int "Ie 
"Ie kgkgm kxm kch kx kCh' 
(7.2.4a) 
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Figure 7.1: A schematic depicting the variables (blue) and reactions (solid lines) that de-
fine our simplified model of the inflammatory response. When compared to the schematic 
presented in the previous chapter (Figure 6.8) we can see that the model has be n signif-
icantly simplified. The positive feedback loops present in the full model (se Figure 6.1 3) 
have been simplified to the release of neutrophil contents by apoptotic neutrophils under-
going secondary necrosis (red lines) . Negative feedback loops (blue lines) c ntr around 
the macrophages, their consumption of apoptotic neutrophils and subsequ nt reI a of 
growth factors that enhance neutrophil apoptosis. 
$C = f3c'Yc, _ 'Yn2 kllml = knmlkxmkCh 
_ 'Yml (7.2.4b) 
'Y1I2 = -, 
'Ymllt 
, 'Y",l = --, 
kch I C 'Yc 
$er = f f u ~ ~ 1112 I C , _ 'Yu (7.2.4 ) 'Yer = - , 
ku3/c kx kch 'Yc 
k _ kCUi _ 'Yg (7.2.4d) CUi - -, 'Yg = - . 
kch 'Yc 
Under the above rescalings and dropping the tildes equations (7.2.2) transform to give th fol-
lowing dimensionless system of six ordinary differential equations with el v n dirnen ionl 
parameters: 
(7.2.5a) 
(7.2.5b) 
(7.2.5c) 
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Paramo Definition Unit Value 
kch c from CT pg mm -3 day-1 10 
kg g from macrophages pg cell-1 day-1 0.07 
kn nl apoptosis day-1 2.77 
knml n2 removal by m1 cell-1 mm3 day-1 1 x 10-3 
kcr3 CT from secondary necrosis pg cell-1 1 x 10-2 
f3c c damping n1 apoptosis pgmm-3 3 x 10-1 
f3ng g enhancing n1 apoptosis pgmm-3 0.8 
f3cr CTdamage pgmm-3 0.1 
'Yc natural decay of c day-l 4 
'Yg natural decay of g day-1 9 
'Yml rate of removal of m1 day-1 0.0495 
'Yn2 secondary necrosis day-1 2.77 
'Ycr natural decay of CT day-l 4 
kcw c from damage to tissue pg mm-3 day-1 7 x 10-3 
kx neutrophil influx cell pg-l day-l 1083 
kxm macrophage influx cell pg-1 day-1 250 
kgm g from macrophages ceU-1 mm3 1 
Table 7.1: Definitions, units and values of the parameters that appear in equations (7.2.2). Pa-
rameters that appear in the model presented in Chapter 6 are shown in the top sixteen rows. 
Note that kx and kxm have different units to the parameters for neutrophil and macrophage in-
flux defined in Chapter 6 due to the removal of saturable kinetics. The parameters kx' kxm and 
kcw appear in the ODE model defined by equations (7.2.2) but not in the related spatial model 
(see equations (7.3.2». The last parameter kgm is new to this model. 
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d(1 (7.2.5d) = 1'O'1'n2n2 - 1'0'(1, dt 
dc 
kcw/(t) + ( t > ~ ~: (12) - c, (7.2.5e) = dt 
dg 
= 1'gmln2 - 1'gg. (7.2.5f) dt 
As in Chapter 6 we assume that at t = 0 there are no white blood cells (nl = 0, n2 = 0, 
ml = 0) or mediators «(1 = 0, C = 0, g = 0) present. Tissue damage takes the same form with 
/(t) = H(An: - t) sin2(t) where 
H(Arr- f) ~ ~ { 1 if t < An: 
o if t > An: 
(see Figure 6.9 in the previous chapter for a sketch of /(t) which is dimensionless). The steady 
states are dependent on the termination of this damage (f(t) = 0). See Table 7.1 for the param-
eter values used. 
7.2.2 Model outcome and steady states 
In Figure 7.2 we present numerical simulations of the nondimensional model (equations (7.2.5» 
showing the response to one cycle of periodic damage. We obtain a similar outcome to simu-
lations presented in the previous chapter, with all inflammatory cells and their mediators sub-
siding and the system returning to a normal steady state which we term steady state I (551), 
evidence that the model can simulate resolution of inflammation. 
Keeping the same form of /(t), but increasing the number of cycles of damage from one to 
four, with the same initial conditions and parameter values, we find that a second stable steady 
state exists (see Figure 7.3). As in Chapter 6 this steady state is characterised by all cells and 
mediators settling to positive values. We term this solution steady state II (5511). 
The above results demonstrate that the simplified system exhibits bistability. We now inves-
tigate this further by studying the effect of varying three key parameters, 1'n2, kg and knmt 
(1'n2 represents the rate that neutrophils undergo secondary necrosis (participating in the posi-
tive feedback loop), kg represents the rate of production of growth factors (participates and in a 
negative feedback loop) and knml represents the rate that macrophages consume apoptotic neu-
trophils (which participates in a further negative feedback loop». See Figure 7.1 for a schema 
depicting the various feedback loops. 
In Figure 7.4 we present a bifurcation diagram showing how the steady state concentration of 
the chemoattractant c varies with 1'n2, the rate of secondary necrosis. The bifurcation structure 
is similar to that obtained in Chapter 6 (see Figure 6.26). There are two areas of bistability, 
steady state II gains stability at LP and loses stability at a Hopf bifurcation HBl for a small area 
of parameter space. 5511 then gains stability at a further Hopf bifurcation and this is retained (in 
the simplified model) for 1'n2 > HB2. This in contrast to the unexpected bifurcation behaviour 
presented in the previous chapter where, for large values of secondary necrosis, the system was 
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Figure 7.2: Numerical simulations of equations (7.2.5) illustrating how the system evolves to 
steady state I. Inflammation subsides, with all cells and mediators settling to zero. As in Chapter 
6 it is I(t) that causes the inflammatory response. One cycle of damage results in an increase in 
chemoattractants, neutrophils and their contents: each cycle is not enough to sustain damage 
so that upon cessation of damage all cells and mediators subside. Parameter values are taken 
from Table 7.1. 
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Figure 7.3: In this case the system evolves to steady state II. This is an unhealthy response 
to injury which is consistent to chronic inflammation in which all cells and mediators evolve 
to positive values. The macrophages release significant levels of growth factors which reduce 
the number of neutrophils but not enough to prevent ongoing damage. Parameter values are 
stated in Table 7.1. In Figure 7.2 we presented results from a simulation in which all system 
parameters and initial conditions are identical, apart from the functional form of I(/} . Here 
we present results from a simulation in which all system parameters and initial conditions are 
identical to used to generate the results presented in Figure 7.3, apart from the functional form 
of I(t) which is increased from one to four cycles of damage. 
159 
monostable resolving to 55!. In the middle region between the two Hopf bifurcations again, SSI 
is stable but both branches of 5511 are unstable resulting in excitable behaviour. 
Figure 7.5 illustrates the bifurcation behaviour of the system (7.2.2) in terms of the steady state 
concentration of the chemoattractant as we vary kg, a key parameter in a negative feedback 
loop. The system is bistable for 0 < kg < HB. Steady state II loses stability via a Hopf bifurcation 
when kg = HB. For HB < kg < LP there are three steady states, but only the lower branch is 
stable and simulations in this range exhibit excitable dynamics. For kg > LP, the system settles 
to 55!. We remark, that in contrast to the behaviour reported in Chapter 6, where the system 
settled to S5I for small values of kg (see Figure 6.15), for the present model the system settles to 
5511 when kg is small. 
Figure 7.6 illustrates the bifurcation behaviour of the system (7.2.2) in terms of the steady state 
concentration of the chemoattractant as we vary k nm1 , a key parameter in another negative 
feedback loop. As we vary knml the system displays similar dynamics to varying kg. It is 
bistable for 0 < knml < HB. Steady state II loses stability via a Hopf bifurcation when knml = 
HB. Yet again simulations in the range (HB < knml < LP) exhibit excitable dynamics and for 
knml > LP, the system settles to 55!. 
We have taken our original model of inflammation, presented in the previous chapter, and 
derived a legitimate reduced model to simplify its complexity before we apply it in a more 
complicated spatial context. 
7.3 Creating a spatially structured model 
We now explain how we start to adapt the simplified ODE model (equations (7.2.5» to include 
spatial variations. For simplicity we restrict attention to one-dimensional Cartesian geometry 
and hence frame the model in terms of the independent variables t and x (the dependent vari-
ables are defined in Table 7.2). We assume there are two areas of tissue, an area of damaged 
tissue placed side by side with an area of healthy tissue on the interval 0 < x < L, so that 
damaged tissue occupies 0 < x < L/2 and healthy tissue occupies L/2 < x < L. We suppose 
that mediators (0', c, g) are free to diffuse between the two populations (with constant diffu-
sion coefficients DO', Dc, Dg) while white blood cells ("1, "2, mI) remain still in comparison. 
Cells move much slower than mediators (being larger) so this is a useful initial assumption. 
Thus only the differential equations representing the mediators require spatial derivatives. The 
damage term J(t) from the ODE model above is now replaced by a positive initial perturbation 
to the chemoattractant concentration. 
We scale displacements all with the interval length L and employ the following nondimension-
alisations for the diffusion coefficients (for all other parameters and mediators the nondimen-
sionalisations from (7.2.3)-(7.2.4) remain). 
A Dc A D(f 
Uc = -L2' Uc = -L2' 
')'C ')'0' 
A Dg 
Ug = -L2' 
')'C 
(7.3.1) 
When we incorporate the modifications outlined above into equations (7.2.5), dropping the 
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solutions change as we vary I'n2, the rate at which apoptotic neutrophils undergo condary 
necrosis (other parameter values held fixed at values stated in Table 7.1). S5! is pr s nt d by the 
green line and SSII by the blue. Stable steady states are shown as solid lines and unstabl ones 
by broken lines. As in Chapter 6, there are two intervals of bistability, LP < 1',,2 < HB2 and HBl 
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the blue. Stable steady states are shown as solid lines and unstable ones by broken lines. The 
system is bistable for kg < HB. SSII loses stability via a subcritical Hopf bifurcation (when kg = 
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steady states coalesce at knml = LP so that at knml > LP there is only one stable teady state 
(551). 
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tildes, we obtain the following system of partial differential equations: 
anI 
= /n2C -
knn} (1 + f.g) 
at (l+fc) , (7.3.2a) 
an2 knnl (1 + In;) 
-/n2n2 - knmIn2ml, = 
(1 + fc) dt (7.3.2b) 
amI 
Im1C - 1m! mI, = 
at 
(7.3.2c) 
acr a2cr 
at = DO' ax2 +Iuln2n2 - IUcr, ~ ~
(7.3.2d) 
diffusion 
aC a2c ( (T2 ) 
= Dc ax2 + ~ ~ ~ + cr2 - C, at 
~ ~
(7.3.2e) 
diffusion 
ag a2g . 
= Dg aX2 +Igm2n2 - Igg. at 
(7.3.2f) 
-....,.-
diffusion 
7.3.1 Boundary and initial conditions 
Appropriate boundary and initial conditions are needed to close equations (7.3.2). We assume 
that the mediators are contained on a closed interval imposing no flux boundary conditions at 
both ends, so that 
ae acr ag 
- = - = - = 0 (x = 0 and x = I). ax ax ax (7.3.3a) 
As we assume that white blood cells remain motionless the remaining variables do not require 
boundary conditions. 
We must choose a suitable initial spatial profile for each of the dependent variables and use 
the stability analysis presented in Section 7.2.2 as a guide. For simplicity, we assume that each 
profile is piecewise constant across the areas of damage (0 < x < 0.5) and healthy (0.5 < x < 1) 
tissue. 
To initialise the model we choose the steady state obtained for simulations of the simplified 
ODE model above with knml = 0.26 (to place us just to the left of the Hopf bifurcation HB in 
Figure 7.6). For a healthy response we use an initial perturbation of nl = n2 = ml = cr = g = 0 
and c = 0.001, for which the ODE system settled to 551 with nl = n2 = ml = 5 = g = e = O. 
In contrast, for an unhealthy response use an initial perturbation of nl = n2 = ml = cr = g = 0 
and c = 0.1. For which the ODE system settled to 5511 with nl ~ ~ 1,7, n2 ~ ~ 168, ml ~ ~ 1777, 
s ~ ~ 0.17, g ~ ~ 3.1, c ~ ~ 1.7.) The composite initial condition for each of the variables are shown 
as thick black lines in Figures 7.7, 7.8 and 7.9. 
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Variable Description Unit 
"1 active neutrophils cells mm-3 
n2 apoptotic neutrophils cells mm-3 
m1 pro-inflammatory macrophages cellsmm-3 
CT neutrophil toxic contents pgmm-3 
C chemoattractants pgmm-3 
g growth factors pgmm-3 
Table 7.2: Definitions of the model dependent variables and their units. 
Paramo Definition Unit 
Dc Chemoattractant diffusivity mm2 day-l 
Dg Growth factor diffusivity mm2 day-1 
Du CT diffusivity mm2 day-I 
Table 7.3: Definitions, units and values of the parameters newly introduced to the spatial model. 
Parameters for the nonspatial terms are common to the ODE model presented in this chapter 
are shown in Table 7.1. 
7.4 Numerical solutions 
To integrate the system (equations 7.3.2, 7.3.3) numerically we use the method of lines. Firstly 
we uniformly discretise the spatial domain using N grid points, so that Xj = j/(N - 1) 
(j = 0 ... N -1). We then semi-discretise the governing equations in space using second-order 
centred finite differences; this reduces the PDE model to a system of 6N ODEs coupling the 
spatially discretised variables Cj (Cj = c(Xj», CTj and gj, nI,j' mI,j and m2,/ (j = 0 ... N - 1). The 
no-flux boundary conditions at each end of the domain are implemented using ghost points in 
a straightforward manner. The resulting system is solved numerically using the ode15 solver 
in MATLAB. Simulations were typically conducted using N = 100 grid points, but the results 
have been checked by varying N to ensure they are insensitive to the spatial resolution. 
We use the parameter values from the ODE model (Table 7.1) but we have three new parameters 
(Dc, Du and Dg) which we assume are equal since the mediators are likely to be of a similar size 
and move in a similar manner. In simulations we set Dc = Du = Dg = 0.1 mm2 day-I and use 
the initial conditions constructed in Section 7.3.1 above. 
In Figure 7.7 we illustrate the temporal evolution of the system with knmI = 0.268 where a 
damaged region (SSII) is completely healed (SSI) with all mediators and cells settling to zero. 
However, when knml = 0.26 (all other parameters and initial conditions as before) a damaged 
region overwhelms a healthy region (Figure 7.8) with all mediators and cells settling to 5511 
165 
500 
400 
300 
200 
100 
o 
1 
2500 
2000 
Active neutroph ils (n ,) 
o 0 
Macrophage (m ,) 
o 0 
Chemoattractant (c) 
o 0 
40 
40 
40 
200 
150 
1.5 
5 
4 
Apoptotic neutrophils (172) 
40 
o 0 
eutroph it conten ts a) 
40 
o 0 
Growth fac tors (g) 
40 
o 0 
Figure 7.7: When knml = 0.268 the system resolves to 55!. Solutions of are of the system (7.3.2), 
(7.3.3) with initial conditions of 55II imposed on 0 < x < 1/2 and 55l imposed on 1/ 2 < x < l. 
Parameter values are taken from Table 7.1 except Dc = DO' = Dg = 0.1 and k nml = 0.268. 
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with an intermediary period of damped oscillation. 
Finally, Figure 7.9 shows the temporal evolution for knml = 0.23 (all other parameters and initial 
conditions as before), where we are now further from the Hopf bifurcation and the system 
quickly saturates to 5511 overwhelming the region of healthy tissue. 
Figures 7.10 and 7.11 providing indications of travelling wave behaviour connect the two stable 
steady states. Travelling wave solutions in bistable systems in mathematical biology have been 
well studied, as described Keener (1998), for example. At early time points (Figure 7.10) a 
wave of mediators (e, g and u) move from steady state II (the left hand side) into the healthy 
region (right hand side). Neutrophils respond to the chemoattractant and, via the positive 
feedback from neutrophils through neutrophil necrosis, produce a rise in chemoattractants, 
neutrophils and neutrophil contents. Macrophages follow later and produce a rise in growth 
factors. Macrophages remove neutrophils and subsequently the system settles to steady state I 
(the healthy steady state) over the entire region (Figure 7.11). 
These solutions demonstrate that, with the introduction of diffusion, damaged tissue can ei-
ther resolve to a healthy outcome or spread into a healthy region with the two stable steady 
states being connected by travelling waves; the sign of the wave velocity determines which of 
these possibilities is realised and a full analysis would take us well beyond the goals of the pre-
liminary investigation undertaken here. An interesting study, which we have not undertaken, 
would be to vary the size of the initial ratio of damaged to undamaged tissue. 
7.5 Discussion 
In this chapter we first presented a simplification of our model for inflammation so that we 
can reduce the models complexity before we apply it in a spatial context. The model retains 
the key physiological mechanisms of the model presented in Chapter 6 and this Simpler model 
still displays bistability that we relate to resolution of inflammation or progression to a self-
perpetuating inflammatory condition. We have explored how key parameters affect the out-
come of our model comparing this to the results of Chapter 6. 
We have also presented some initial discussion on how spatial variations can be incorporated 
into this simpler model and examined how they may influence the qualitative behaviour of the 
system; by demonstrating that two adjacent areas of tissue, one damaged and one healthy, can 
interact we have shown that it is desirable to progress beyond an ODE analysis to fully char-
acterise the outcome of inflammation. Physiologically, medical intervention may be possible to 
partially heal an area of damaged tissue. This might be the case in cartilage, for example, where 
replacement tissue is not necessarily large enough to replace the whole damaged area. Our 
toy model indicates that such an intervention may sometimes be sufficient to push the neigh-
bouring damaged area into a healthy state. However, more detailed modelling is required to 
characterise accurately the circumstances where this is a possibility. 
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Figure 7.10: Evolution of the system (7.3.2), (7.3.3) at early time points. We plot the variables as 
a function of length x at equally spaced times. Red arrows indicate the way in which the cells 
and mediators change as t increases. Initial conditions of 55II are imposed on 0 < x < 1/2 
and 551 imposed on 1/2 < x < 1. Parameter values are taken from Table 7.1 except Dc = 
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chemoattractants and neutrophil contents subsequently are produced as a result. 
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rise before they settle to SSI. The whole region resolving to a healthy steady state. 
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CHAPTER 8 
Discussion 
Soft tissue repair is thought to involve the same inter-related and overlapping phases for a wide 
range of stimuli and across different soft tissues. These phases include: coagulation (the stop-
ping of bleeding), inflammation (where bacteria are killed and cell and tissue damage removed) 
and the final phases of remodelling and repair (where damaged tissue is replaced). In this thesis 
we have confined our modelling attempts to the early phases of repair, namely coagulation and 
inflammation, using a variety of techniques to develop and analyse new mathematical models 
of these processes. While the work was motivated by an interest in soft tissue repair in response 
to musculoskeletal disorders, coagulation and inflammation are of interest in their own right, 
playing roles in many diverse disease states such as Alzheimer's disease, cardiovascular dis-
ease, Parkinson's disease, rheumatoid arthritis and inflammatory bowel disease (Serhan et ai., 
2008; Perretti & Flower, 2008; Danese et ai., 2007; Libby, 2008). 
This thesis is divided into two parts, one focused on coagulation (Chapters 2, 3 and 4) and one 
focused on inflammation (Chapters 5, 6 and 7). The work on coagulation began (in Chapter 2) 
with an overview of the biological processes involved in coagulation and a review of the rel-
evant mathematical literature. Coagulation is governed by the enzyme thrombin which is the 
end product of the coagulation cascade and it is here that we focused our modelling attempts. 
The coagulation cascade is a complicated network and we began by considering a reduced set 
of reactions which have previously been shown to reproduce the characteristic thrombin gen-
eration curve (Willems et ai., 1991). From these reactions we formulated a model comprising 
fourteen ordinary differential equations which we analysed using asymptotic techniques in or-
der to elucidate its underlying mechanisms. Having identified a small parameter E (the ratio of 
the rate of activation of the slowly acting protein C inhibitory system to the fast acting rate at 
which antithrombin III inhibits thrombin) we rescaled the system parameters and dependent 
variables in order to bring the appropriate reactions into leading-order balance. To determine 
the variable scalings reqUired for each subsequent timescale we manipulated the long term be-
haviour of the leading-order system on the preceding timescale. The resulting analysis exhibits 
seven distinct timescales, each covering an individual step required for the formation of the 
enzyme thrombin. This type of asymptotic analysis is particularly useful for complex biologi-
cal networks such as this. It enables us to distinguish the timescales on which such a network 
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operates and also provides means to derive simplified models. We have demonstrated this by 
providing a series of network diagrams that highlight the dominant reactions on each timescale 
and identify two of the reduced models that capture the major interactions in thrombin's explo-
sive growth and subsequent inhibition. We were able to identify the physiological mechanisms, 
such as the initial concentrations of factor V and prothrombin, responsible for the rate of throm-
bin growth. We obtained an equation that approximates the characteristic time-lag for thrombin 
that occurs before explosive growth. Two possible bifurcation points exist within the asymp-
totic analysis and these require a more detailed biological investigation before it is possible to 
determine if they are physiological. 
In chapter 4 we extended the model presented in chapter 3 to include the extrinsic and intrin-
sic pathways associated with the coagulation cascade, generating a model that encompasses 
(if in a somewhat simplified form) the complete coagulation cascade relevant to haemostasis. 
Where possible the parameter values were taken from literature and we solved the resulting 
system of twenty-nine ordinary equations numerically. By performing a series of simulations 
of subsystems of this model we were able to highlight the contribution of the extrinsic and 
intrinsic pathway to coagulation. Subsystem one comprises the reactions of the extrinsic and 
common pathways and simulations with a low level of tissue factor revealed a peak thrombin 
concentration of 4 nM after 25 minutes. Subsystem two extends subsystem one by incorporat-
ing factors associated with the intrinsic pathway but neglects thrombin activation of factor XI. 
We found that the inclusion of the intrinsic pathway substantially increases the peak thrombin 
concentration (from 4 to 750 nM) and reduces the time taken to reach the peak from 25 to 21 
minutes. We conclude that the contribution of the intrinsic pathway makes a significant con-
tribution to thrombin formation. By running successive simulations of subsystem two with 
decreasing initial concentration of the procoagulants VIII and IX, we were able to compare our 
model to experiments of thrombin formation in plasma deficient in factor VIII and IX which 
can be related to haemophilia A and B respectively. Haemophilia A and B are characterised by 
a prolonged time to clot and a reduction in peak thrombin concentrations (Salvagno et al., 2009; 
Dargaud et al., 2005). Simulations of haemophilia A were in close agreement to experimental 
results (Salvagno et al., 2009) and once the model presented was modified to remove competi-
tion for the various factors simulation results for haemophilia B also showed close correlation 
to experimental data (Dargaud et al., 2005). The mechanisms of competition and how these are 
captured are an area for further investigation. 
The motivation for Chapter 4 was recently published experimental data which indicate that 
thrombin can activate factor XI (Kravtsov et al., 2009). There is interest in factor XI as a thera-
peutic target since it is thought to playa key role in thrombosis but a lesser role in haemostasis 
(Gailani & Renne, 2007b). Simulations of the full model, under activation by factor XIa, are 
qualitatively similar to experiments designed to assess the sensitivity of thrombin production 
to factor XIa activation (Kravtsov et al., 2009). They do, however, show a marked increase in 
peak thrombin formation. Simulations of the full model and of subsystem two assessed against 
data from experiments in which levels of thrombin formation in plasma deficient in factor XI 
were compared with those performed in plasma containing factor XI (Kravtsov et al., 2009). 
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These showed good qualitative agreement, with detection of thrombin activation of factor XI 
possible at low levels of tissue factor activation although there were discrepancies in the total 
amount of thrombin formed. There are several possible explanations for these discrepancies. 
We have had to rely on established estimates for the parameters representing the rate of in-
trinsic tenase formation and the rates at which protein C and ATIII degrade intrinsic tenase. 
There could also be missing some biological complexity such as the interaction of cell surfaces 
and an extended model may produce better results. To date the only mathematical model to 
specifically assess the contribution of thrombin activation of factor XI to thrombin generation 
(Kramoroff & Nigretto, 2001) failed to detect any such contribution. Their model was based on 
a reduced subset of the coagulation cascade reflecting the APPT screening test which uses high 
levels of activation via FXlIa which our results suggest would mask the effects of thrombin's 
activation of factor XI. 
The asymptotic analysis presented in Chapter 3 is based on a subset of reactions. An extension 
of this to the whole cascade would be interesting particularly in determining the parameters 
and initial conditions from the full cascade that contribute to thrombin's time lag and explosive 
growth. Before this could be achieved the parameters related to protein C activation and its role 
in factors V and VIII would need better data as there are at present deficiencies in their values 
and the asymptotic analysis of the reduced pathway leads us to suspect that these would be 
important. 
There is evidence to suggest that there are very strong interactions between platelets, other cell 
types and the formation of thrombin (Hoffman, 2004) and investigation of these interactions 
represents an interesting extension to our models on coagulation. The cellular processes regu-
lating thrombin formation occur on different length and timescales, indicating that a spatially 
structured model of clot formation could provide useful new insight into the ways in which 
these processes interact. 
In part I we used mathematical methods to investigate an area of biology (coagulation) which 
has been well-studied and tested in-vitro for which a comprehenSive and reliable set of pa-
rameter values is available. In part two we focused on the less well understood process of 
coagulation which now is attracting increasing interest, as it has been implicated in many 
diverse diseases (Serhan et al., 2008; Perretti & Flower, 2008). We began in Chapter 5, with a 
biological description of inflammation and a review of the relevant mathematical literature. 
Whereas most existing mathematical models concentrate on the processes that drive inflamma-
tion (Lauffenburger & Kennedy, 1981, 1983; Alt & Lauffenburger, 1985; Kumar et al., 2004), we 
focused on the mechanisms that promote its resolution (Lawrence & Gilroy, 2007; Haslett, 1999; 
Nathan, 2002; Maderna & Godson, 2003). 
In chapter 6 we presented our model of inflammation. Where previous mathematical mod-
els have tended to concentrate on a generic white blood cell (Lauffenburger & Keller, 1979; 
Lauffenburger & Kennedy, 1981, 1983; Alt & Lauffenburger, 1985; Reynolds et al., 2006) we ac-
counted for two distinct cell types (namely neutrophils and macrophages) their interactions and 
their involvement in promoting and resolving inflammation. Neutrophils, while being essen-
tial for the removal of pathogens, can cause damage to healthy tissue by releasing of their toxic 
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factors while macrophages promote resolution of inflammation by removing neutrophils before 
they can cause damage and by releasing anti-inflammatory growth factors (Lawrence & Gilroy, 
2007; Giles & Lawrence, 2008; Haslett, 1999; Ward et al., 1999). Using numerical simulations 
and bifurcation analysis we found that our model exhibits bistability and hysteresis over a 
wide range of parameter space. We related the outcome of the stable steady states to either 
the healthy resolution of inflammation or a chronic, self-perpetuating state. We performed a 
limited parameter sensitivity analysis in which we focused on parameters associated with the 
many feedback mechanisms within our model. These correspond to: the rate of neutrophil 
apoptosis, the rate that apoptotic neutrophils undergo necrosis and the rate that macrophages 
produce growth factors. We explored the effects of perturbing these parameters via bifurcation 
diagrams and discussed how these parameters govern the behaviour of the system towards the 
different outcomes. 
In Chapter 7 we simplified our model of inflammation concentrating on the key biological in-
teractions of neutrophils and macrophages retaining neutrophils ability to cause damage to 
healthy tissue. We demonstrated that this simplified model retains the key outcomes of the 
model presented in Chapter 6. We had, thus far, only considered the model under the assump-
tion that the cells and mediators could be treated as representing a spatially homogeneous envi-
ronment. While this is a useful assumption we presented some preliminary work on extending 
our model spatially. 
There is much interest in finding new therapeutic drugs to limit inflammation. It is hoped that 
where the persistence of inflammation has become divorced from the inciting agent targeting 
pro-resolution pathways will offer some success (Serhan et al., 2007; Pizza et al., 2005). Partic-
ular targets under investigation are the rate at which neutrophils undergo apoptosis and the 
ability of macrophages to remove them, both processes thought to be controllable by mediators 
(Rossi et a1., 2007; Henson, 2005; Maderna & Godson, 2003; Haslett, 1999). We used our model, 
via a bifurcation analYSiS, to investigate the effects of perturbing these parameters on the out-
come of the system. We found that increasing the rate of neutrophil apoptosis alone may not be 
sufficient to obtain a healthy outcome. It is essential that macrophages are capable of removing 
apoptotic neutrophils safely preventing the spilling of toxic contents and the perpetuation of 
inflammation. The model helps us to represent current knowledge about the mechanisms of 
inflammation, particularly its resolution and how neutrophils and macrophages might effect 
this. It has limitations imposed by the incomplete knowledge of the biology and a more sophis-
ticated model may be possible as the parameter values and biological mechanisms are better 
described. We hope the model does, however, provide a good starting place in the modelling 
of inflammation, and can be modified to incorporate further biological mechanisms as they 
become understood. 
If therapeutic targets are to be identified for inflammation and coagulation it is crucial that 
the mechanisms controlling the resolution of inflammation and the formation of thrombin are 
understood as fully as possible. As we have stated, inflammation and coagulation participate 
in many disease conditions and so the importance of understanding has relevance not only to 
musculoskeletal disorders but many other diseases. In this work we have developed and anal-
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ysed models which, when combined with experimental results, provide new insight into the 
physical mechanisms regulating inflammation and its resolution, coagulation and the forma-
tion of thrombin. 
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ApPENDIX A 
Supplementary Material for Chapter 
Three 
A.1 Calculation of A and f3 for the third timescale 
Substituting the solution for factor Xa <f: = klalla t) into equations (3.5.9a)-(3.5.9b) we have 
the system 
Ivo F ~ ~ + k2b klalla Ivo t _ k 'If t Fa lvO + k2am II lvO + 1 + IuD la Ila v' (A.LIa) 
q3a k 1a Ilatt:, (A.l.lb) 
k4a Q4bliio i'txa 
( ) Dva· Q4a IuD + k4bm (A.I.Ic) 
Sequentially differentiating for Fg results in 
(A.L2a) 
(A.L2b) 
(A.I.2c) 
(A.I.2d) 
We then assume Va to be of the form tg f'V 1] Iv eAt where Iv = t13 where Iv is to be determined 
and the constant 1'], f3 and A need to be calculated. This differentiates to 
dFa 1] eAt ( it eAt + 1]Alv) , v f'V df 
d2F.a 
1] eAt (d
2
[v + 2A d / ~ ~ + A2fi ) v f'V df2 dT2 dT v, 
d3f.a 
1] eAt (d3lv +3A d2fv +3A2dlv + A3fi) v f'V (A.l.3) dt3 dt3 dt2 dt v, 
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which, when substituted into A.1.2d results in 
Balancing terms we can see that 
Ivo k4a Q4bliio k t ~ ~ k tA2 ( - 0 
U + k ) ( ~ . . . + k ) Q3a la rIa J v - la rIa J v -
V vO 2am q4a J 110 4bm 
and therefore 
A= 
Also 
and therefore 
Since this is equivalent to Iv = 1Jffl, we can see that 
f3 = _ (A2 + 2kla rIa) • 
2k1a /la 
If we now assume Bxa I'V A t.B+1eAt then va 
substituting this into equation A.1.1b results in 
from which, at leading order, we can see that 
and therefore 
resulting in 
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(A.1.4a) 
(A.l.S) 
(A.l.6) 
(A. 1.7) 
We now assume;!/; '" Bff3+1eAt then II 
which, when substituted into equation A.t.te, results in 
At leading order this implies 
resulting in 
B = 1Jk1a 'Yla k4a q4b Q3a!iio 
q4a (fiiQ + k4bm ) j\2 
t79 
(A. 1.8) 
ApPENDIX B 
Summary of figures from Chapter 
Four 
Table 8.1 summarises the figures from Chapter 4 providing a reference to the various simula-
tions presented in the chapter and the systems of equations used to produce them. Subsystem 
one (One) comprises the reactions of the extrinsic and common pathway. Subsystem two (Two) 
additionally includes the reactions of the intrinsic pathway. Simulations of the full model (Full) 
include thrombin activation of factor XI. Modifications of the model remove competition for 
thrombin (between fibrinogen and factors V, VIII and XI) for the intrinsic tenase (between fac-
tor IX and X) and for factor Xa (between factor V and prothrombin). Simulation of this full 
modified model are run (Modified full) and for subsystem two (Modified two). 
I Figure I Model Desciption 
4.1 
-
Model schema illustrating the procoagulants, activated 
factors and inactivated factors position within the cascade. 
4.2 
-
Model schema illustrating which factors comprise the 
intrinsic, extrinsic and common pathway. 
4.3 
-
TF:VIIa profile, from Drfeo et al. (2005). 
4.5 
-
Schema of TFPI inhibition. 
4.4 One Profiles of the major component factors of subsystem one. 
4.6 One Simulations illustrating activation levels that cause 
complete prothrombin conversion to thrombin. 
4.7,4.8 Two Profiles of the major component factors of subsystem two. 
4.9 One, Two Simulations illustrating the contribution of the 
intrinsic pathway to thrombin generation. 
4.10 Two Simulations with various levels of the procoagulant VIII 
Continued on next page 
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Figure Model Desciption 
relevant to the clinical condition Haemophilia A. 
4.11 Two Simulations with various levels of the procoagulant IX 
relevant to the clinical condition Haemophilia B. 
4.12 Full A series of profiles showing how factor IXa influences 
thrombin generation in factor XI deficient plasma. 
4.13 Two, Full Simulations demonstrating the contribution of 
thrombin activation of factor XI to thrombin formation. 
4.14 Modified Full Simulations illustrating the contribution of thrombin activation 
Modified Two of factor XI to the generation of thrombin. 
4.15 Modified two Simulations with various levels of the procoagulant IX 
relevant to the clinical condition Haemophilia B. 
Table B.l: Summary of Figures from Chapter 4. 
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